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Summary  
Although mounting evidence suggests that Tamoxifen exerts cardioprotective effects 
against atherosclerosis, the findings that associate Tamoxifen and atherosclerosis at a 
molecular level are inconsistent and unclear.  
Tamoxifen is a potent autophagy inducer and we believe that the cardioprotective 
effect of Tamoxifen may be arisen from this autophagy inducing ability. This is 
because recent studies have shown that enhanced autophagy may be beneficial at 
both early and advanced stages of atherosclerosis.  
However, the estrogenic activity of Tamoxifen in the endometrium cells increases 
the risk of endometrial cancer in the patients treated with Tamoxifen. We, therefore, 
would like to minimize this risk by developing derivatives of Tamoxifen which 
induce autophagy, but with no apparent estrogenic activities.  
We started our project based on the syntheses of dichlorocyclopropyl analogues of 
Tamoxifen as Magarian et al. reported that the introduction of a dichlorocyclopropyl 
moiety in place of the olefinic link in Tamoxifen can significantly reduce the 
estrogen agonist activity. We found that, however, those dichlorocyclopropanes were 
not particularly stable and degraded easily through dichlorocyclopropyl ring 
openings. Thus, we moved to synthesize the difluorocyclopropyl and other classes of 
derivatives of Tamoxifen. 
 A wide range of structurally different analogous of Tamoxifen have been 
synthesized and biologically tested for induction of autophagy, of which some 
display the desired autophagic activity in a dose-dependent manner but lower than 
that of Tamoxifen. Tamoxifen was observed to be cytotoxic to cells at high doses 
iii 
 
(>5  M), but this toxicity is not observed with our drug molecules. We ascertained 
that the presence of an amioethoxy basic side chain in conjunction with a diaryl 
backbone were essential pharmacophores for the induction of autophagy. 
Additionally, neither the antiestrogenic nor estrogenic activity is responsible for the 
autophagic effect of our drug candidates as they did not bind to estrogen receptor. 
Based on the results of ours and others in the literature, we propose that our novel 
aminoethoxy difluorocyclopropanes may be AEBS inhibitors. Selected compounds 
are in the process of being patented.  
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Chapter 1 Tamoxifen and Atherosclerosis 
1.1 Tamoxifen 
1.1.1 Breast cancer  
Breast cancer is the most frequently diagnosed cancer in women.
1, 2
 More than half 
million women died of breast cancer throughout the world in 2012, making breast 
cancer one of the most common cancer deaths among females.
2
 In the UK, 
approximately 46,000 new cases of breast cancer were reported in 2010 which is one 
person every 10 minutes and an estimated 12,000 deaths as a result of the disease 
every year.
3
  
 
Breast cancer can be broadly classified into four classes by receptors types:
4
  
 Human epidermal growth receptor (HER2) positive 
 Endocrine receptor (estrogen or progesterone receptors) positive  
 Triple negative  
 Triple positive  
 
Breast cancer cells may or may not have receptors for chemical messengers, such as 
hormones, to bind and activate.
5
 HER2-positive occurs when a patient tests positive 
for a protein called human epidermal growth factor receptor 2 (HER2).
1
 The cancer 
cells produce surplus levels of HER2 as a result of gene mutation which in turn 
promotes the growth of cancer cells.
4
 Similarly, endocrine receptor positive means 
that breast cancer cells grow in response to hormones estrogen and progesterone.
4
 
Cells that do not have any of these three receptor types are called triple-negative or 
conversely, triple positive if all these three receptors are present.
1, 6
  
2 
 
About 80% of all breast cancer cells are estrogen receptor (ER) and/or progesterone 
receptor (PR) positive.
7
 These cells require estrogens to bind and activate the 
estrogen receptors in order to grow. The inhibition of estrogen receptors provides 
effective control of uterine growth and the growth of estrogen-dependent mammary 
tumours.
8
 Tamoxifen (Tam) was one of the first antiestrogens discovered and 
approved for the treatment of breast cancer (Figure 1).
9
 
 
 
Figure 1: The structure of Tamoxifen. 
 
Discovery of Nonsteroidal Antiestrogens and Tam 
In the 1950s/1960s, coronary heart disease was a major target for drug development 
and Triparanol (Figure 2) was a potent lipid-lowering compound developed by 
Merrell.
10
  
 
 
Figure 2: The structures of Triparanol and its analogues. 
 
3 
 
However, Triparanol was withdrawn from the clinical trials due to its toxicity.  It 
was believed to inhibit the biosynthesis of cholesterol, leading to the accumulation of 
desmosterol and caused acute cataract formation in patients treated with the drug 
(Figure 3).
11, 12
   
 
 
Figure 3: The inhibition of cholesterol biosynthesis pathway by Triparanol and its analogues.
13
 
 
Triparanol and its analogues, MER 25 and clomiphene (Figure 2) had also been 
tested as a treatment for breast cancers since a lot of triphenylethylenes were known 
to be estrogenic and a correlation between estrogen and breast cancer had long been 
established.
14,15,13
 Although MER 25 and clomiphene were found to be effective, the 
drugs were considered to be too toxic for long-term use.  
 
Tamoxifen was first discovered by Dr. Arthur L. Walpole and his research team in 
the early 1960s at Imperial Chemical Industries (ICI) Pharmaceuticals.
13
 He was 
leading a project conducting research into alternative compounds to Triparanol and 
its analogues as contraceptive pills owing to their apparent antiestrogen properties, 
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but with potentially less side effects. They found that while Tamoxifen was indeed 
an effective postcoital contraceptive in rats,
16
 it was not useful in human 
contraception due to the distinct difference in pharmacology and physiology of 
ovulation between women and rats. In their clinical studies, Tamoxifen was found to 
promote ovulation rather than acting as an antifertility agent.
17
  
 
It was not until 197l that Tamoxifen was redeveloped from a failed contraceptive 
agent and entered preliminary clinical studies as a treatment for breast cancers at the 
Christie Hospital in Manchester.
18
 The studies showed a promising effect in 
advanced breast cancer in postmenopausal women. A further clinical trial was 
conducted by Harold W.C. Ward at the Queen Elizabeth Hospital, Birmingham in 
1972. Ward showed that at a dose, 10 mg twice daily, of Tamoxifen gave a response 
rate of 77% with minor side effects such as hot flushes, gastro-intestinal intolerance 
and tumour pain.
18
 By 1973, Tamoxifen was approved for the treatment of breast 
cancer by the Committee on the Safety of Medicines in the United Kingdom and 
sold under the trade name Nolvadex.
13
 
 
Estrogen and Estrogen Receptors: How do they signal  
Tamoxifen is a synthetic, non-steroidal, potent antagonist of ER in breast tissues. 
The natural ligands of ERs are steroidal estrogens.  The sex hormone estrogens are a 
group of compounds which act as signaling molecules and are important for 
numerous physiologic processes.  They play a key role in growth, differentiation, 
and function of various tissues,
19
  which include the testes, epididymis and prostate 
in men, and the glands, uterus, vagina, and ovaries in women.
19
  Estrogens are 
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present in both men and women, but women produce these hormones at much higher 
levels.  
The three major naturally occurring estrogens in women are estrone (E1), 17b-
estradiol (E2) and estriol (E3), and are steroids derived from cholesterol (Figure 4). 
The most potent and dominant estrogen found in women of reproductive ages is E2. 
E1 is most commonly found in postmenopausal women, while E3 is abundant 
primarily during pregnancy. Although E3 and E1 also have high affinities for ERs, 
E2 is a much stronger agonist.
20
  Their levels in the body fluctuate with life stage, 
suggesting that they may have unique functions in biological and disease 
progression.21  
 
 
Figure 4: The structures of the estrogens. 
 
Many studies suggest that estrogens inhibit bone resorption and help to protect 
against osteoporosis,
22
 reduce the incidence of cardiovascular disease through 
regulation on blood lipids,
23
 and it may also help to protect against cognitive decline 
and delay the onset of Alzheimer’s disease.24 However, prolonged estrogen exposure 
also contributes to increased risk of breast cancer, invasive carcinoma and uterine 
sarcoma.
19, 25
  
 
The biological actions of estrogen are facilitated through their binding to ERs which 
are transcription factors that modulate the activity of different genes.
26
  When an 
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estrogen molecule enters the cell, it binds to the estrogen receptor and causes a 
conformational change. Once activated, the estrogen receptor will dimerize to form 
an estrogen-receptor-ligand complex which then interacts with the estrogen response 
elements (EREs) in DNA.
27
 After it becomes attached to the EREs, the dimer 
complex binds to various coregulators. These coregulators act as linker molecules 
between DNA binding proteins and protein transforming enzymes.
28
  It has now 
been established that estrogen facilitates the interaction of the ER with coactivators 
which leads to activation of DNA transcription (Figure 5).
27
   
 
 
Figure 5: The binding mechanism of an estrogen to an estrogen receptor. 
 
Emerging evidence suggests that the estrogen receptor’s signaling pathway is much 
more complicated than the one just described. The estrogen receptors may regulate 
the physiological process through several distinct pathways. They could either 
activate the gene expression or repression through both genomic and non-genomic 
pathways, and with or without estrogen.
20
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The Antiestrogenic Effect of Tamoxifen in Breast Tissue 
Tamoxifen is an antiestrogen of ERs in breast tissues. Instead of activating the ERs 
like estrogen does, it competitively binds to the ERs and blocks the estrogen-
stimulated tumour growth. After binding and triggering the ER to form an 
antagonist-activated-dimer-complex, it selectively interacts with corepressors and 
exerts antiestrogenic effects, e.g. suppressing the DNA transcription (Figure 6).
27
 
 
 
Figure 6: The binding of an antiestrogen to an estrogen receptor as compared to an estrogen. 
 
Tamoxifen is widely used for the treatment of hormone-dependent breast tumours in 
pre- and post-menopausal women
29
 and as a preventative therapy in woman at high 
risks of developing the diseases.
30
 It is also the common treatment for male breast 
cancers.
31
 In addition, Tamoxifen has been shown to be effective in treating other 
conditions such as infertility in women resulted from anovulatory disorders
32
 and 
gynaecomastia related to high estrogenic level.
33
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Tamoxifen is a Selective Estrogen Receptor Modulator  
Tamoxifen is a ligand for the ER with an affinity in the nanomolar range.
34
  
Tamoxifen belongs to a class of molecules called Selective Estrogen Receptor 
Modulators (SERMs). The characteristic of SERM compounds is that their 
mechanisms of action on estrogen receptors are different depending on the targeting 
tissues and genes. For example, Tamoxifen is a potent antagonist of estrogen 
receptor in breast tissue, however, in other tissues such as the endometrium, it 
behaves as an agonist.
19
 The  mixed agonist and antagonist activities of Tamoxifen 
are tissue- and cell-specific and may vary from one species to another.
19
  In addition 
to its well-known anti-breast cancer properties, previous studies by others also 
reported that treatment with Tamoxifen may help prevention of osteoporosis
22, 35
 and 
protection against atherosclerosis.
23
 However, the estrogenic activity of Tamoxifen 
in the endometrium cells is also linked to increased risk of deep vein thrombosis
36
 
and uterus cancers
19
 (Figure 7), and better SERMs are needed as a result.  
 
In theory, it is possible to synthesize multiple-targeting SERMs displaying pure 
estrogenic agonist activity on one type of tissue and complete estrogenic antagonist 
activity on the other for the treatment of multiple diseases in women.  Nevertheless, 
the exact molecular targets associated with the beneficial effects of Tamoxifen or 
other SERMs in many tissues remains unclear. The cardioprotective effect of 
Tamoxifen against atherosclerosis, in particular, has attracted much interest in the 
past decades. With atherosclerosis being the primary cause of heart disease and 
strokes, accounting for approximately 50% of deaths in the Western world,
37
 perhaps 
it is not surprising that tackling heart disease remains one of the top priorities in drug 
research and developments.  
9 
 
 
Figure 7: The potential beneficial and harmful effects of Tam. 
 
1.1 Tamoxifen and Atherosclerosis  
1.2.1 The Pathological Progression of Atherosclerosis 
Atherosclerosis is a progressive disease resulting from the accumulation of lipids and 
fibrous elements in large arteries. Atherosclerotic lesions are broadly categorized 
into two types: stable and unstable plaques. The stable atherosclerotic plaques are 
generally rich in extracellular matrices and smooth muscle cells. They tend to be 
asymptomatic, while the unstable plaques are rich in macrophages and foam cells.
38
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The development of unstable atherosclerotic plaques is thought to be initiated by the 
accumulation of oxidatively modified low density lipoprotein (LDL) in the intima 
(the innermost layer of an artery or vien). The modified LDL stimulates the 
endothelial cells to produce a number of pro-inflammatory molecules,  leading to the 
adhesion of monocytes to the vessel wall.
37
 The monocytes then transmigrate into 
the intima where they proliferate, differentiate into macrophages and absorb the 
lipoproteins to form the foam cells.
37
 After these foam cells die, they leave behind 
lipid-rich debris that can accumulate at the site of the developing lesion (Figure 8).  
 
Figure 8: The development of fatty lesion and unstable plaques.  
 
Over time the unstable plaques gradually increase in size and encroach on the lumen. 
These unstable plaques are weak and prone to rupture, leading to thrombus 
formation that can prevent or restrict blood flow in the arteries, causing myocardial 
infarction or stroke. The pathological process in which a stable, matrix-rich plaque 
phenotype transforms into an unstable pro-inflammatory phenotype is highly 
complicated, and the balance between inflammation and fibrosis is believed to be 
11 
 
mediated by transforming growth factor beta (TGF-β),39 although the exact 
mechanism is not yet fully understood. 
 
1.2.2 TGF-β and its possible anti-inflammatory role in atherosclerosis 
TGF-β is a multifunctional cytokine that belongs to the transforming growth factor 
beta superfamily. It has been known to have roles in cell proliferation,
40
 
differentiation,
41
 and other functions in many cell types. There are three structurally 
closely related isoforms of TGF-β in mammals, termed TGF-β1, TGF-β2, and TGF-
β3 (Figure 9); all of which are known to bind to the same receptors and appear to 
exert similar functions.
42
 Increasing evidence suggests that misregulation of the 
TGF-β concentration in plasma leads to the development of cancer,43, 44 fibrotic 
disease,
45, 46
 atherosclerosis,
39, 47-50
 and many other diseases.
51
 
 
 
 
Figure 9: The structure 3 isoforms of TGF-β. 
Image from www.rcsb.org PDB ID: 1KLA, 2TGI, 1TGK 
 
Among the three TGF-β isoforms, TGF-β1 has been studied most extensively, 
particularly with its link to atherosclerosis, although the studies do not specify which 
ligand is accounted for the reported effects.
42
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TGF-β1 was first identified as an anti-inflammatory cytokine52 and due to its anti- 
inflammatory properties. It has been proposed that TGF-β1 may function as an 
inhibitor of atherosclerosis.
47
 In agreement of this hypothesis, it has been reported 
that expression of apolipoprotein A 1 in mice inhibited the activation of TGF-β, thus 
promoting smooth-muscle cell proliferation and the subsequent development of fatty 
lesions.
50
 Consistent with this result are two independent but similar studies by 
Mallat et al.
47
 and Lutgens et al.
39
 In their studies, they employed neutralisation 
approaches to show that inhibition of TGF-β signalling in apolipoprotein E-deficient 
mice favours the formation of inflammatory cell-rich and collagen-poor lesions.  
 
It has been demonstrated that Tamoxifen stimulates TGF-β production both in cancer 
cells and vascular smooth-muscle cells in vitro.
53
 Grainger et al. postulated that 
Tamoxifen would inhibit atherosclerosis in mice
54
 and their hypothesis has been 
shown to be correct. In various mice models, Grainger et al. were able to 
demonstrate that treatment with Tamoxifen triggered an increase in serum TGF-β1 
levels and suppressed the diet-induced formation of lipid lesions in the aorta.
48, 55
 
 
1.2.3 TGF-β and autophagy in atherosclerosis  
Recent studies have, however, also shown that TGF-β is able to induce autophagy in 
certain human cancer cells.
56
 Autophagy is a highly conserved homeostatic 
mechanism that involves lysosomal degradation of damaged and unwanted cellular 
components.
56
 It is believed to play an important role in atherosclerosis and plaque 
progression, although the exact mechanism is still poorly understood.
57
 The most 
convincing evidence for the beneficial effects of autophagy in atherosclerosis so far 
is probably an in vivo study conducted by Verheye and his co-workers. They 
13 
 
demonstrated that treatment with cholesterol-fed rabbits with everolimus, a 
derivative of rapamycin, led to a significant reduction (90%) of marcophage content 
via autophagic cell deaths without affecting the smooth muscle cells.
58
 This finding 
is very significant since it is a common believe that presence of macrophages causes 
destabilization of atherosclerotic plaques.
58
 Autophagy may exert its beneficial effect 
in atherosclerosis by degrading damaged intracellular organelles, thereby preventing 
oxidative injuries and cellular distresses.
59
  
 
1.2.4 Other molecular targets of Tamoxifen  
There is ample evidence of cardioprotective effects of Tam,
55, 60, 61
  however, the 
findings that associate Tamoxifen and atherosclerosis at a molecular level are 
inconsistent and unclear. Some believe that Tamoxifen may mediate its cardio-
protective effects by up-regulating serum TGF-β level which is, in turn, believed to 
stem from its antiestrogen ability.
62
 The up-regulation of TGF-β may activate 
autophagy and/or have anti-inflammatory effects against atherosclerosis. On the 
other hand, others propose that it is the estrogenic activities that helps to reduce the 
incidence of coronary heart disease through down regulating the blood lipids.
23
 It is 
also possible that the cardioprotective effects of Tamoxifen are through other 
mechanisms which are independent to its binding to the ERs. This is because 
Tamoxifen has also been demonstrated to inhibit cholesterol biosynthesis,
63-65
  to act 
on P-glycoprotein and possibly cause interruption to the intracellular transport of 
cholesterol,
66, 67
 to inhibit cholesterol acyltransferase (acyl-CoA) and the 
esterification of cholesterol,
68
  and to prevent the apoprotein B of low-density 
lipoprotein (LDL) from being oxidative damaged.
69, 70
 All these actions of 
14 
 
Tamoxifen could account for its cardioprotective effects and the exact underlying 
mechanisms are highly complex and have yet to be further confirmed or identified.  
 
Tamoxifen is a potent inducer of autophagy.
71, 72
  We and our collaborator, Grainger 
et al. believe that the cardioprotective effect of Tamoxifen may be arisen from this 
autophagy inducing ability. This is because studies by others recently have shown 
that enhanced autophagy may be beneficial at both early and advanced stages of 
atherosclerosis.
59, 73, 74
 However, an increased incidence of endometrial cancer has 
also been reported in breast cancer patients treated with Tamoxifen and we would 
like to minimize this risk by developing derivatives of Tamoxifen with no apparent 
estrogenic activities, or at least, no intrinsic estrogenic activity in the endometrium 
cells.
19
  
 
cis-1,1-Dichloro-2,3-diphenylcyclopropane 1 and its 4-methoxylated analogue 2 
(Figure 10) were first synthesized and tested as pure antiestrogens by Magarian et 
al.
75
 This class of derivatives of Tamoxifen may be of medicinal interest as the 
antiestrogenic activity of Tamoxifen was reported to up-regulate serum TGF-β level; 
and the up-regulation of TGF-β level has been shown to induce autophagy56 which 
has been associated with the cardioprotective effects of Tamoxifen.
62
  
 
 
Figure 10: Magarian’s dichlorocyclopropyl analogues of Tamoxifen 
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Additionally, the replacement of a dichlorocyclopropyl moiety in place of the 
olefinic link in these derivatives of Tamoxifen can lead to a significant reduction or 
elimination of their estrogenic activity,
76-83
 thus minimizing the risk of developing 
endometrial cancer. Therefore, we started our project based on Magarian’s finding 
on dichlorocyclopropanes and aim to take a step-wise approach by first identifying 
the class or classes of derivatives of Tamoxifen with essential pharmacophores that 
could lead to induction of autophagy. 
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Chapter 2 Diaryldichlorocyclopropanes  
2.1 Structure activity relationship studies and Magarian compounds 
In the last few decades, Tamoxifen and its analogues have been extensively studied 
and the structure-activity relationship studies of these compounds reveal that the Z- 
arrangement of the α and β rings are crucial for the antiestrogenic activity (Figure 
11).
78
 In addition, it has been shown that the introduction of a dichlorocyclopropyl 
moiety in place of the olefinic link in these compounds can significantly reduce or 
eliminate their estrogen agonist activity.
76-83
 
 
 
Figure 11:  The structures of Tamoxifen and its dichlorocyclopropyl analogues 
 
cis-1,1-Dichloro-2,3-diphenylcyclopropane (1) was first synthesized and tested for 
its biological activity as an antiestrogenic agent by Magarian et al. in 1975 in an                                                                                                                                                                                                                                                                                                                                                             
attempt to reduce the undesirable estrogenic effects.
80
 The compound displays 
antiestrogenic activity comparable to that of Tamoxifen against the hormone-
dependent 7,12-dimethylbenz[a]anthracene (DMBA) induced rat mammary tumour 
model,
81
 and is also found to be active against the hormone-independent DMBA-4 
transplantable metastatic rat mammary tumour model,
82
 although it produces no 
intrinsic uterotrophic effects. Magarian and his co-workers went on to synthesize 
some more derivatives of 1 and tested them for their anti-tubulin ability. 
Methoxylated analogue 2 was shown to have a five-fold increase in potency than 1, 
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having an IC50 less than 1 µM for the MCF-7 cell line and less than 5 µM for the 
MDA-MB231 cell line.
77
 In addition to the anti-proliferative ability against both the 
hormone-dependent and independent breast cancer cells demonstrated by Magarian 
et al.
77, 81, 82
 and others,
84
  1 and 2 have also been shown to inhibit the growth of 
human prostate cancer cells in three transgenic adenocarcinoma of mouse  prostate 
(TRAMP) models.
85
 Again the 4-methoxylated analogue gives a higher potency with 
an IC50 less than 5 µM in all three cell lines. 
 
Magarian’s compounds 1 and 2 demonstrated that it is possible to synthesize 
dichlorocyclopropyl analogues of Tamoxifen which may have some desirable 
therapeutical effects, but without the estrogenic activities. Dichlorocyclopropyl 
stilbene derivatives have been tested for their antiestrogenic activity and anti-
tumours properties, however, to the best of our knowledge, this class of compounds 
has not been tested for their ability to induce autophagy or in any atherosclerosis 
model. Thus, the focus of this project is to synthesize some dihalocyclopropyl 
Tamoxifen analogues and test their biological activities for autophagy in vitro, since 
it is believed that the cardioprotective effect of Tamoxifen may be arisen from its 
autophagy inducing ability.  
 
2.2 Synthetic routes for the preparation of dichlorocyclopropanes 
2.2.1 Common methods for the synthesis of dichlorocyclopropanes  
While there are numerous routes for the synthesis of cyclopropanes, methods for 
gem-dichlorocyclopropanes are very limited, with the great majority of the reactions 
reported involving the [2+1] cycloaddition of dichlorocarbenes to the olefins.
86
 The 
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most important and widespread used methods for generating the dichlorocarbenes to 
date are the following: 
 
1. α-elimination of hydrogen chloride from chloroform under concentrated aqueous 
solution of a base, often NaOH or tert-BuOK, in the presence of a lipophilic 
tetraalkyammonium salt as the phase transfer catalyst  (Scheme 1).
86
  
 
 
Scheme 1: α-elimination of hydrogen chloride from chloroform. 
 
2. Thermal decomposition of a metal complex carbene precursor: trichloro- or 
bromodichloromethyl (phenyl) mercury (Scheme 2).
87
 This method is very effective 
and allows transformation of alkenes with sensitive functional groups or alkenes of 
low reactivity to the desired gem-dichlorocyclopropane in good yields.
87
 
Unfortunately, in spite of their excellent reactivity, their high toxicity and subsequent 
lack of commercial availability have severely limited their use as a dichlorocarbene 
source. Their preparation is also both difficult and hazardous.  
 
 
Scheme 2: Thermal decomposition of phenyl-(trichloro) or (bromodichloromethyl) mercury. 
 
3.  Decarboxylation of an alkali metal carbene precursor: e.g. sodium trichloroacetate 
(Scheme 3).
86
 With unreactive alkenes (either due to electronic or steric reasons), a 
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large excess of the carbene precursor is often required, meaning the process 
inevitably becomes more expensive.  
 
 
Scheme 3: Decarboxylation of sodium trichloroacetate. 
 
There are certainly numerous ways of generating the dichlorocarbene, such as 
photolysis of dichlorocarbene complexes using visible or UV light,
88
 lithiation of 
diethyl trichloromethyl phosphonate
89
 and reaction of carbon tetrachloride with 
magnesium
90
 or butyllithium
90
 in the presence of alkenes, etc. They do not, however, 
offer any advantages over the methods presented earlier.
86
 
     
Among all the methods that have been mentioned, phase transfer catalytic (PTC) 
dichlorocyclopropanation is probably the simplest and most favoured way of 
preparing the gem-dichlorocyclopropanes as it is easy to perform, has a low energy 
requirement and uses inexpensive, relatively non-toxic and commercially available 
reagents and solvent. Thus, for this particular project, PTC has been chosen as the 
primary method for the dichlorocyclopropanation step.   
 
2.2.2 Mechanism of formation of dichlorocyclopropanes in PTC: 
Although the term phase-transfer catalysis was introduced by Starks in 1971,
91
 when 
he first demonstrated that reactions between two substances located in two 
immiscible phases could be accelerated by a phase transfer agent, the first interfacial 
mechanism for the generation of dichlorocarbene in a biphasic system was proposed 
by Maükosza
92
 in 1975. According to his proposal (Figure 12), in the biphasic 
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system composed of an organic phase containing chloroform with alkene and an 
inorganic aqueous base, deprotonation of chloroform happens at the interface. 
Trichloromethyl anions generated form salts with sodium cations undergo ion 
exchange with quaternary ammonium salts to give organic soluble ion-pairs. These 
ion-pairs are extracted to the organic phase, where they dissociate reversibly to form 
dichlorocarbenes that are trapped by alkenes to afford the gem-
dichlorocyclopropanes and the quaternary ammonium salts are re-generated.  
 
 
Figure 12: The interfacial mechanism proposed for the generation of dichlorocarbene in PTC.
33 
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2.3 Research and development   
2.3.1 Non asymmetric synthesis of dichlorocyclopropyl stilbenes  
All the dichlorocyclopropyl compounds Magarian et al. synthesized and biologically 
tested were racemic, yet those compounds still displayed excellent therapeutic 
properties. Thus, this project began with the syntheses of some of those known, 
racemic dichlorocyclopropyl analogues of Tamoxifen.  
 
The synthesis of 1, 3 and 4 are straightforward and can be achieved in one step with 
moderate to good yields by the PTC dichlorocyclopropanation method since the 
starting material triphenylethylene, cis- and trans-stilbenes are all commercially 
available (Scheme 4).  
 
 
Scheme 4: The dichlorocyclopropyl analogues of Tamoxifen synthesized using PTC method 
 
For a functionalized rac-1,1-dichloro-2,3-diarylcyclopropane such as 2, an improved 
synthetic route from Magarian was adopted which involved the preparation of cis-β-
bromosytrene that was then coupled with 4-methoxybenzeneboronic acid via Suzuki 
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coupling to give mainly the cis-isomer of 4-methoxy stilbene, followed by the PTC 
dichlorocyclopropanation (Scheme 5). 
 
 
Scheme 5: An improved synthesis of cis-1,1-dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane (2) 
 
However, the synthesis of enantiomerically pure or enriched dichlorocyclopropanes 
is a topic of great importance if they are ever to become medicinally useful. 
Therefore, we intended to synthesize this class of compounds asymmetrically.   
 
2.3.2 Asymmetric synthesis of dichlorocyclopropanes   
2.3.2.1 Previous studies on asymmetric synthesis of dichlorocyclopropanes   
Still et al.
93
 has demonstrated that dichlorocarbene reacts stereoselectively with 
secondary allylic alcohols to give the syn - dichlorocyclopropanes (the 
dichlorocyclopropyl and the hydroxyl groups being on the same face) preferentially. 
Additionally, the cis-isomer is more diastereoselective than the corresponding trans-
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isomer in giving the syn- products. Some of his findings are summarized in Scheme 
6.  
 
Scheme 6: Still’s asymmetric synthesis of dichlorocyclopropanes 
 
The diastereoselectivity of the dichlorocyclopropanation for trans- and cis-pent-3-
en-2-ols (9 and 10 respectively) may be explained by the alkene conformations of 
the starting materials using Houk’s model shown in Figure 13. In both cases, the 
lowest energy conformations are the ones on the left hand side, in which the 
hydrogen eclipses the double bonds, reducing the 1,3-allaylic strain by having the 
alcohol group being away from the cis substituents (H and Me).  
 
 
Figure 13: Houk's model 
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The dichlorocarbene then is more likely to attack the conformations with lowest 
energy from the less hindered face, giving the diastereomers as observed (Figure 14). 
The cis-alkene gives higher selectivity than its corresponding trans-alkene is because 
the 1,3-allylic strain in the higher energy conformation is greater for 10 (H and OH 
group) than 9 (Me and OH group) and therefore the reaction is more selective for the 
former than the latter.  
 
 
Figure 14: The stereoselective reactions of cis- and trans-pent-3-en-2-ols with dichlorocarbenes. 
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Based on the findings, we believed that if the stereochemistry of the directing 
groups, in this particular example, the hydroxyl group in the olefins can be 
controlled, then an asymmetric synthesis of dichlorocyclopropanes may be possible. 
 
2.3.2.2. Diastereoselective synthesis of dichlorocyclopropanes using OH as a 
directing group and the challenges encountered 
Still’s finding has been tested on a few carefully selected aryl containing substrates 
and showed very positive results. For example, a mixture of diastereoisomers with a 
high diastereomeric ratio of about 83:17 was obtained when trans-ketone 11 was 
reduced with NaBH4 to give the trans-alcohol 12 before being treated with 
dichlorocarbene derived from CHCl3/NaOH to offer the dichlorocyclopropyl alcohol 
13 (Scheme 7). A marked increase in the diastereomeric ratio was observed under 
the same reaction condition when a geometric isomer cis-15 (synthesized via 
reduction of alkyne 14 using Lindlar’s catalyst) was used as the substrate instead of 
the trans-11. It seems that only one diastereoisomer can be seen in the spectrum of 
the crude reaction product, suggesting the diastereomeric excess (de) is ≥ 95%.  
 
Similarly, the diastereoselectivity of the dichlorocyclopropanation for 11 and 12 
could be explained by using Houk’s model shown in Figure 15. Again, the carbene is 
more likely to attack the lowest conformations which are the ones on the top left 
hand side for both substrates. The cycloaddition of carbenes to the alkenes are 
achieved from the less hindered faces, giving syn-dichlorocyclopropanes 
preferentially.  
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Scheme 7: The asymmetric synthesis of dichlorocyclopropanes from alcohol. 
 
To confirm only one of two diastereoisomers was preferentially formed, we had 
synthesized both diastereoisomers by a slightly different route with the same starting 
alcohol 15.  The OH group of 15 was protected with 3,4-dihydro-2H-pyran (THP) 
and subsequent dichlorocyclopropanation of 17 gave a mixture of the THP-protected 
diastereoisomeric alcohols. The protected-dichlorocyclopropyl alcohols were not 
isolated and were directly used for the next deprotection step by simply stirring the 
reaction mixture in methanol with a few gains of (±)-camphorsulfonic acid to offer 
18. The two diastereoisomers of 18 were subsequently separated by standard silica 
chromatography and the 
1
H NMR spectra of both diastereoisomers were then 
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compared with the 
1
H NMR spectrum of the crude product of 16 which, indeed, 
showed that only one diastereoisomer was present.  
 
 
Figure 15: Diastereoselective dichlorocyclopropanation  on allylic alcohols. 
 
It is worthy to mention that for all the substrates tested the dichlorocyclopropyl 
products and the alkenes tend to be very similar in polarity. Indeed, they often come 
as a single spot in TLC plates under a wide range of solvent systems, making 
monitoring the progress of reactions by TLC very difficult or sometimes impossible. 
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Isolation of the products also proved to be problematic as all of the gem-
dichlorocyclopropanes synthesized are essentially oils; the easiest and cheapest way 
of purifying those products in milligrams scale is probably by standard silica 
chromatography, which again relies greatly on the TLC analysis. Although it is not 
ideal and can be quite time-consuming and resource-wasting, a solution to this 
problem would be to collect different fractions and analyse each fraction by 
1
H NMR 
spectroscopy. 
 
Furthermore, for substrates like stilbenes and triphenylethylene, in which there are 
no other functional groups or activated C-H bonds apart from the alkenes that can 
react with the dichlorocarbene (for example, the synthesis of 1-4), the reactions 
normally proceed quite cleanly with high conversion. The main side reactions are the 
carbene oligomerisation or hydrolysis of the dichlorocarbene whose by-products can 
be easily separated from the products during work up or by column chromatography. 
On the other hand, for substrates bearing an alcohol group and a C-H bond that has 
been activated by the presence of an adjacent hetroatom, oxygen and nitrogen for 
example, then insertion of carbene into both the O-H
94
 and the C-H
95
 bonds can 
occur. 20 was a by-product that was successfully identified from the reaction of 19 
with CHCl3/NaOH in the presence of benzyltrimethyl ammonium bromide as the 
phase transfer catalyst. From 20, it is discovered that the dichlorocarbene insertion 
by-products can react further in the presence of other appropriate species, leading to 
a lot of side products being formed. The formation of 20 is possible via the 
mechanism shown in Figure 16.  
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Figure 16: The possible mechanism for the formation of compound 18. 
 
To minimise the side reactions, we had tried to protect the alcohols 12, 19 and 27 
with THP before the dichlorocyclopropanation step (Scheme 8). Although the 
protection and deprotection using THP did limit the amount of undesired molecules 
being formed in the preparation of 23 and 26, an extra stereocentre was introduced 
into the molecules which may potentially affect the diastereoselectivity. In fact, 
when 12 was protected with THP, the diastereomeric ratio of the cyclopropane 
product 26 reduced from ~83:17 to ~65:35. The reason for the decrease in selectivity 
is not certain, but the protection of an alcohol group with a THP resulted in creation 
of a new stereogenic centre which may have hindered or even altered which face the 
dichlorocarbene was attacking the alkenes.  
 
Unsurprisingly, as the alpha position to the hydroxyl group becomes more sterically 
hindered, it becomes harder to protect the hydroxyl group. Attempts to protect the O-
H group in 27 failed to give a reasonable amount of the protected alcohol 29, but 
unexpectedly direct dichlorocyclopropanation of 27 proceeded smoothly to give 28 
without too many side reactions. 
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Scheme 8: The asymmetric synthesis of dichlorocyclopropanes from alcohol. 
 
In comparison to the direct synthesis of 12 and 27, the yields of the 
dichlorocyclopropanes did not seem to benefit greatly from the protection of OH 
since it involves two more steps in the synthesis. Not only did the protection and 
deprotection steps rarely go to completion, but also some of the desired product may 
have been lost in the additional work up procedure. As a result, the use of THP as a 
protecting group was eliminated for this range of substrates. 
 
2.3.2.3. Product formation vs reaction time studies using 1H NMR spectroscopy 
The difficulties in monitoring the progress of the dichlorocyclopropanations using 
TLC had prompted us to use 
1
H NMR spectroscopy as an alternative method to 
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briefly examine the reaction rates. In our time study using substrate 12, a small 
amount of the reaction mixture was taken out from the reaction flasks in 30 min 
intervals and submitted for 
1
H NMR analysis.  
 
When monitoring the reaction, we found that alkenes bearing a free O-H group 
reacted much faster with dichlorocarbene than alkenes with a protected hydroxyl 
group (2 days), diaryl (6 hours) or triarylethylene (3 days). Within two hours, the 
majority of the starting material had converted to the desired dichlorocyclopropanes 
along with a small amount of side products that presumably resulted from carbene 
insertions into OH. Based on this observation, it is believed that 
dichlorocyclopropanation of the olefins is in competition with carbene insertion side 
reactions. The relative rate of dichlorocyclopropanation and carbene insertions 
depends on many factors, but mainly nucleophilicity and steric hindrance of the 
alkenes involved, electrophilicity of the dichlorocarbene generated in that particular 
environment and the types of bonds that are present to allow carbene insertion to 
take place.  
 
Alkenes with an OH group are particularly susceptible to carbene insertions, 
although the dichloropropanation of such an alkene appears to happen at a faster rate 
than carbene insertion. Hence, at the beginning of the reaction when the 
concentration of the alkene is high, the dichlorocarbene reacts primarily with the 
alkene to offer the dichlorocyclopropane and the carbene insertion side reactions are 
less prominent. As the reaction proceeds towards to completion, the alkene still 
competes for the dichlorocarbene, but insertion of carbene into both the O-H and C-
H bonds in the product becomes dominant since the concentration of 
32 
 
dichlorocyclopropyl product is now much higher than the alkene. This finding is 
very useful as it tells us that the reaction time is very crucial in determining the 
yields and the dichlorocyclopropanation has to be stopped as soon as it is completed, 
otherwise the products generated will start to degrade rapidly. 
 
2.3.2.3 Synthetic routes proposed for asymmetric synthesis of 1, 1-dichloro-2, 3-
diaryl cyclopropanes  
Encouraged by Still’s finding and the results of our own, we started to design a 
synthetic route for asymmetric synthesis of the dichlorocyclopropyl analogues of 
Tamoxifen (Scheme 9). Starting with inexpensive D-mannitol (30), 1,2-5,6-terminal 
diols were selectively protected with 2,2-dimethoxypropane using catalytic amount 
of p-toluene sulfonic acid. Subsequent oxidative cleavage of 31 with NaIO4 gave 
aldehyde 32 which was not isolated and was used directly for the Wittig reaction in 
the next step. Reaction of 32 with benzyltriphenylphosphonium bromide and n-
butyllithium provided the alkene 33 with cis and trans ratio of ~70:30. The two 
geometric isomers of 33 were subsequently separated by standard silica 
chromatography. Treatment of 33 with CCl2 derived from CHCl3/NaOH offered the 
diastereoisomeric dichlorocyclopropanes 34 with a ratio of ~88:12 that were also 
separable using column chromatography. Deprotection and oxidative cleavage of 34 
should afford the target molecules 35 which would then be treated with butenyl 
magnesium bromide to give the secondary alcohol 36. Oxidation of 36 would 
generate the ketone 37 which could be treated again with an appropriate Grignard 
reagent to give 38. The tertiary alcohol 38 may undergo ring-closing metathesis to 
give 39, and finally dehydration and dehydrogenation of 39 should give the 
enantiomerically pure/enriched dichlorocyclopropyl compound 40.  
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Scheme 9: The proposed asymmetric syntheses of diaryldichlorocyclopropanes 
 
However, only up to the synthesis 34 had been accomplished as we then realized that 
compound 2 and 4 were not particularly stable. Upon being stored in sealed vials at 
room temperature for a week, compound 2 decomposed, and so did compound 1 
after a few weeks.  
The decomposition of diaryl- or triaryldichlorocyclopropanes is not unknown. In 
fact, Magarian and his colleagues had reported that the attempts to purify trans-
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diphenyldichlorocylclopropane 3 by sublimation
96
 and 41 by standard silica 
chromatography
97
 both resulted in the thermal loss of HCl with rearrangement to 
give the 2-chloro-1-phenylindene 42 and  the 2-chlorodiarylindene 43 respectively 
(Figure 17).  
 
 
Figure 17: 40 and 41 were the degradation products from 3 and 39 identified by Magarian et al. 
 
The thermal loss of HCl and rearrangement of 41 is believed to proceed via a 
concerted cleavage of the C
2
-C
3
 cyclopropyl bond with one of the chlorides as a 
leaving group to form an allyl cation.
97
 The   electrons from one of the aromatic 
rings then attacks the allyl cation giving an indenyl cation, which subsequently loses 
a proton to complete the aromatization and afford 43,
97
 Figure 18.  
 
The proposed mechanism of cyclopropyl ring opening postulated by Magarian et al. 
seems to be consistent with our finding. While the stability of unfunctionalized 
diphenyldichlorocyclopropanes 1 and 3 was found to be satisfactory and no 
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degradation was detected, compound 2 was quite unstable and decomposed at room 
temperature over a few weeks under the same handling conditions. This may be due 
to the fact that the electron donating methoxy group helps to stabilize the allyl cation 
formed upon ring opening, thus accelerating the degradation of 2.   
 
 
Figure 18: The proposed mechanism for the thermal loss of HCl and rearrangement of 41 to 43. 
 
The unstable nature of these dichlorocyclopropanes has not only led us to abandon 
the plan for their asymmetric synthesis, but has also prompted us to expand our 
range of desired compounds to include its difluorocyclopropyl analogues. The 
difluorocyclopropanes may offer higher stability due to the relatively stronger C-F 
bond.   
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Chapter 3 The Syntheses of Difluorocyclopropanes 
3.1 Difluorocyclopropanes 
3.1.1 The nature of fluorine as a substituent  
Introduction of fluorine substituents into organic molecules often has a profound 
change in their physical, chemical and biological activities.
98
 Fluorine atoms are very 
electronegative and fairly small in size which means that the C-F bond is very polar 
and has a relatively high ionic character. The 2s and 2p orbitals of fluorine also 
match more closely in size with those of carbon than any other of the halogens since 
they are elements of the same period and hence the orbital overlap of carbon with 
fluorine is much larger than with any other halides. All these reasons have 
contributed to the fact that C-F is one of the strongest single bonds in chemistry.  
 
There are a number structural and thermochemical effects present in fluorinated 
organic compounds that result from the unique properties of fluorine. For example, 
there is a strong energetic preference for multiple fluorine substitutions at a carbon 
atom due to the increasing Coulombic interaction between the negatively charged 
fluorine atoms and the positively charged carbon.
99
 These increased Coulombic 
interactions result in the strengthening of all carbon-carbon bonds neighbouring the 
fluorine substituents and lead to the inherent thermal stability of fluorinated organic 
compounds. In addition, fluorine has a strong tendency to be attached to a carbon 
bearing other carbons rather than hydrogens.
100
 This is because tertiary carbons are 
more able to bear the positive charge that occurs when bonded to a highly 
electronegative atom.  
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3.1.2 Fluorinated cyclopropane 
In the special case of geminally difluorinated cyclopropanes, the effect is one of 
destabilization. The presence of two fluorine atoms on a cyclopropyl cabon is known 
to facilitate the cleavage of the C
2
-C
3 
bond. Fluorine is very electronegative and its 
strong σ-acceptor nature means that it withdraws significant electron density from 
the molecular orbital of the three-membered ring. However, as Durmaz et al. 
suggested that neither the π donation of the lone pair nor the σ-acceptor character is 
responsible for the shortening of vicinal (C
1
-C
3 
and C
1
-C
2
) bonds and the 
lengthening and thus, weakening of the distal (C
2
-C
3
) bond.
101
 Of importance is the 
effect of fluorine substituents on the change of hybridization of the carbon molecular 
orbitals and steric interaction.
101
 Due to fluorine’s high electronegativity, it very 
much prefers to bond to carbon orbitals with high p-characters. As a considerable 
excess of p-character has already been utilized for the formation of the strained C-C 
bonds in cyclopropane, when one or more of the hydrogens are replaced by fluorine, 
the fluorine will “steal” p-character from the C-C bonds.98 This re-distribution of s- 
and p-character on fluorine-bearing carbons results in the weakening of the C-C 
bonds, especially the C
2
-C
3
 bond and leads to a bond differentiation in the 
substituted cyclopropanes. The C
2
-C
1
-C
3
 bond angle is also increased which 
intensifies the “strain” in the system.98  
 
3.1.3 Synthesis of difluorocyclopropanes 
While the syntheses of fluorinated cyclopropanes are numerous, methods for gem-
difluorocyclopropane synthesis are very limited and the majority can be categorized 
into 3 types (Figure 19). The most common used is a [2+1] cycloaddition of a 
difluorocarbene or metal carbenoid to an alkene (A). Alternative routes for 
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synthesizing gem-difluorocyclopropanes that do not involve carbene include: a 
Michael addition of an anion to a double bond that is stabilized by an electron-
withdrawing group followed by Michael initiated ring closure (B) and finally, 
consecutive elimination of hydrogen chloride and subsequent addition of fluoride 
ions and protonation to replace the chloride atoms in the dichlorocyclopropane (C).  
 
 
Figure 19: Common synthetic routes to difluorocyclopropanes 
 
While examples for method A are various, the others are less well-known and 
utilized. In fact, not many successful examples have been reported using methods B 
and C. Perhaps it is worthwhile to give at least an example of each of those methods, 
but the main focus of this introduction will be on the carbene route since it is the 
most extensively studied and probably the most effective way of making the 
difluorocyclopropanes.  
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Method B: Taguchi reported an remarkable Michael addition followed by 
subsequent cyclisation process to synthesize functionalized difluorocyclopropanes 
through the reaction of 2,4,6-trimethylphenyl (TMP) ester of 4-bromo-4,4-
difluorocarotonate (44)  with the lithium enolate of an ester or amide (uiiScheme 
10).
102
 It was found that addition of triethylborane is necessary to initiate the 
cleavage of CF2-Br bond after the Michael addition step, which then underwent an 
intramolecular substitution reaction.  
 
 
uiiScheme 10: Michael addition of a lithium enolate followed by triethylborane promoted cyclisation 
 
Interestingly, when 44 reacts with carbanions derived from active methylene 
compounds, such as malonate anion, only direct SN2 displacement is observed at the 
malonate carbon and no triethylborane is needed (Scheme 11).
102
  
 
 
Scheme 11: Michael addition of a maloate anion followed by cyclisation. 
 
Method C: gem-difluorocyclopropanes could also be conveniently synthesized from 
the corresponding gem-dichlorocyclopropanes via a series of elimination-addition 
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processes (Scheme 12).
103
 Although this reaction is very easy to perform, it can only 
be applied to substrates bearing a strong electron-withdrawing group and an α 
hydrogen atom must also be present. Yields of the products are usually quite low. 
Most importantly, the stereochemical outcome is very likely to be under 
thermodynamic control, meaning that trans-products will always be preferentially 
formed even when a cis-substrate is used.  
 
 
Scheme 12: Displacement of chloride by fluoride atoms on the gem-dichlorocyclopropyl ring 
 
3.2 Difluorocarbene 
3.2.1 Structure of carbene in general 
Carbenes are a family of neutral, two-coordinate carbon compounds with an 
oxidation state of II whose valence shells contain only six electrons, of those two are 
non-bonding electrons.
104, 105
 The structure of carbene can either be bent or linear, 
depending on their degree of hybridization. Most singlet carbenes adopt a bent 
geometry with a sp
2  
hybridization, because the two non-bonding electrons share the 
same px orbital (also known as σ orbital) while leaving the py orbital (or pπ) almost 
unchanged (Figure 20).
105
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Figure 20: The general structure of a singlet carbene and triplet carbene.  
This figure is reproduced from Bourissou et al.
105
  
 
On the other hand, triplet carbenes have a linear sp hybridized structure with each of 
the two non-bonding electrons occupying one of the two degenerate orbitals  (px and 
py) respectively.
105
  
 
There are four possible electron configurations for carbenes as illustrated in Figure 
21. The two nonbonding electrons can either be in the same σ or pπ orbitals, giving 
rise to two different 
1
A1 states, though σ
2
 is generally more stable than pπ
2
.
105
 When 
the two nonbonding electrons are placed in two different orbitals with parallel spin, 
the configuration is depicted as σ1pπ
1 
with a 
3
B1 state. Finally, an excited singlet state 
with a σ1pπ
1 
configuration has a 
1
B1 state.  
 
 
Figure 21:  The four electronic configuration of carbenes 
This figure is reproduced from Bourissou et al.
105
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As the two nonbonding electrons in the singlet carbene are spin-paired, it has a total 
spin of zero while that of triplet is one since there are two singly occupied orbitals 
and can be considered as diradicals. The group-state spin multiplicity of carbene is 
an important aspect, since it determines their reactivities.
105
  If the energy gap 
between σ – pπ orbital is large, typically above 2 eV, the singlet ground state is 
favoured, whereas a separation of less than 1.5 eV will most likely favour the triplet 
ground state.
106
 The energy separation of σ – pπ is, in turn, greatly influenced by the 
electronic and steric effects of substituents on the carbene.
105
 
 
The electronic effects of substituents on a carbene can be divided into two parts: 
inductive effects and resonance effects. The inductive effects arise due to the 
electronegativity difference between the substituents and the carbon atom forming a 
σ bond. It has been demonstrated that electronegative substituents (e.g. F) favour a 
singlet ground state while electropositive substituents (e.g. Li) favour the triplet state 
(Figure 22),
107
 although resonance effects also play an important factor on their 
ground state multiplicity.  
 
Figure 22: The effect of substituents' electronegativity on the ground state carbene spin multiplicity 
This figure is reproduced from Bourissou et al.
105
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Figure 23 illustrates the effect of a) electronegative and b) electropositive 
substituents on the perturbation orbital diagram of carbenes. As shown, 
electronegative substituents lower the energy of the σ nonbonding orbital by 
inductively withdrawing electron density while leaving the pπ orbital unchanged. 
This results in an increase of σ – pπ separation and thus favours the singlet ground 
state.  Conversely, electropositive substituents donate their electron density to the 
carbon atom, pushing the energy of the non-bonding σ orbital closer to the empty pπ 
orbital.  The σ – pπ energy gap is reduced and therefore a triplet state is more 
favourable.  
 
 
Figure 23: Pertubation orbital diagrams showing the influence of the inductive effects. 
This figure is reproduced from Bourissou et al.
105
 
 
Compared to inductive effects, however, resonance effects are in general of more 
importance.
105
 Resonance effects involve the interaction of the carbon orbitals (px, 
py)  with suitable p or π orbitals of the two subsitutents on carbene.
105
 There are two 
classes of substituents that can induce these interactions, π electron-donating groups 
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Y (e.g. -F, -Cl, -Br, -I, -NR2, -PR2, -OR, -SR, -SR3...) and π electron-withdrawing 
groups Z (e.g. -COR, -CN, CF3, -BR2, -SiR3, -PR3
+……). Thus, carbenes can have 3 
different arrangements of substituents: the highly bent Y-C-Y carbene, the linear Z-
C-Z carbene or quasi-linear Y-C-Z carbene.
105
 Again, the effects of Y or Z groups on 
the σ – pπ energy separation can be easily illustrated using a perturbation orbital 
diagram (Figure 24).  
 
 
Figure 24: Pertubation orbital diagrams showing the influence of the resonance effects. 
This figure is reproduced from Bourissou et al.
105
 
 
When both of the substituents are Y groups, the lone pairs of the Y substituents 
interact with the empty pπ orbital of carbene, creating a polarized four-electron three-
centre π system (Figure 24a). The energy of pπ orbital is increased as a result of this 
interaction, but the energy of the σ orbital remains unchanged.105 Therefore, the σ – 
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pπ energy gap increases, favouring the singlet ground state. (Y,Y)-carbenes usually 
have a bent geometry which can be depicted as a superposition of two zwitterionic 
structures with C-Y bonds acquiring some double bond character and the carbene 
centre bearing the negative charge.
105
 The most common carbenes of this type are the 
dimethoxy and diaminocarbenes as well as the main focus of this introduction, 
dihalocarbenes.  
 
According to Bourissou et al.
105
, most (Z,Z)-carbenes would be singlet with linear 
structures. An example of this type is the diborylcarbenes (Figure 24b). As it is 
illustrated, the py orbital of carbon interacts with the vacant orbital of the Z 
substituents to form a polarized two-electron three-centre π system, whilst leaving 
the pπ orbital of the carbon unaffected,
105
 thus, the (px, and py) orbitals are no longer 
degenerate. The C-Z bonds also have some double bond characters and are best 
represented by the superposition of two zwitterionic atom with the carbene centre 
now bearing a positive charge.
105
  
 
The (Y,Z)-carbenes possess both types of electronic interactions discussed above 
(Figure 24c). The lone pair of the Y substituents interacts with the pπ orbital while 
the empty orbital of the Z substituent interacts with the px orbital of the carbon 
atom.
105
 Consequently, both of the substituents are stabilized and both favour a 
singlet state.
105
 The C-Y and C-Z bonds in this type of carbene also have double 
bond character and are described as examples of a “ polarized allene-type system” by 
Bourissou et al. 
105
 
 
49 
 
In conclusion, most CX2 carbenes are predicted to be singlet with a highly bent 
geometry if X are elements or groups more electronegative than the central carbon 
atom
108
 (e,g N to F) , and are triplet with either a linear or slightly bent geometry if X 
are elements or groups more electropostivie than the central carbon atom 
108
 (e,g Li 
or H). (Z,Z)- and (Y, Z) types of carbene are the exception in which the singlet 
carbenes also adopt a linear or quasi-linear structure.   
 
3.2.2 Properties of difluorocarbene  
As has been mentioned previously, difluorocarbene is bent with a singlet electronic 
state. This is consistent with the stereospecific outcome of its addition reaction. 
Relative to other dihalocarbenes,:CF2 is much more stable and less reactive. This is 
because among all halo substituents, fluorine atom provides the strongest electron 
donation via resonance to the empty p orbital of carbene and the strongest inductive 
stabilization of the two carbene’s non-bonding electrons.109    
 
The relatively unreactive nature of difluorocarbene means that only electron-rich 
olefins may react readily with difluorocarbene under mild condition to give the 
difluorocyclopropanes. For less nucleophilic alkenes, the reaction is much more 
difficult and challenging. This often requires :CF2 to be generated at high 
temperature (>80 °C) to overcome the substantial energy barrier for addition.
98, 110
 In 
most cases, the reactive intermediate is believed to involve a “free” difluorocarbene. 
This naked difluorocarbene is very electrophilic and can react with any substrates 
that can serve as stronger nucleophiles than the alkenes, e.g. water, in the reaction 
mixture. Thus, it is not surprising to know that a rigorously dry reaction conditions is 
often crucial for the successful addition of difluorocarbene to alkenes.  
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3.2.3 Methods for generating difluorocarbene  
Over the last few decades, many methods have been developed for the generation of 
difluorocarbene. All except a few involve thermal fragmentation of a suitable 
difluorocarbene precursor with or without a catalyst. The first published and 
probably still the most frequently employed method is the pyrolysis of sodium 
chlorodifluoroacetate in refluxing diglyme at 190 °C (Scheme 13).
111
  
 
 
Scheme 13: ClCF2COO
-
Na
+ 
is a thermal precursor of :CF2 
 
Since then, a few closely related reagents such as sodium trifluoroacetate
112
 and 
bromodifluoroacetate
113
 and other metal salts of chlorodifluoroacetate (Scheme 
14)
114
 have also been reported. 
 
For this class of reactions, a large excess of reagents, in some cases more than 
tenfold equivalents, are usually required to drive the reaction to favour the 
difluorocyclopropanation. Useful to good yields can be obtained even for relatively 
unreactive alkenes and the reactions are performed under neutral reaction condition 
which means any acid or base sensitive functional groups are tolerated. 
Unfortunately, these methods are only limited to substrates with high thermal 
stability due to the rather harsh reaction conditions. 
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Scheme 14: Metal salts of halodifluoroacetate as thermal precursors of :CF2 
 
Another effective thermal source of :CF2  is 11, 11- difluoro-l,6-methano-
[l0]annulene (45) (Scheme 15)
115
 which undergoes thermolysis upon being heated at 
250 ºC; In the presence of an excess of cyclohexane, 7,7-difluoronorcarane was 
obtained in excellent 95% yield. Although effective, the very high temperature 
required has precluded its widespread application.  
 
 
Scheme 15: Thermolysis of 11, 11- difluoro-l,6-methano-[l0]annulene to give :CF2. 
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Some highly strained and polyfluorinated three membered rings, for example, 
perfluorocyclopropane (46) (Scheme 16)
116
 and hexafluoropropylene oxide (47) 
(Scheme 17)
117
 may also be decomposed thermally to extrude difluorocarbene at 
slightly lower temperature (>180 ºC). Yields are generally modest for reactive 
alkenes, but poor with unreactive ones. 
 
 
Scheme 16: Pyrolysis of perfluorocyclopropane to give :CF2 
 
 
Scheme 17: Photochemical precursor of :CF2 
 
Difluorodiazirine (48) (Scheme 18)
118
 is another early difluorocarbene precursor 
developed. When photochemically heated at 180 ºC or above, it decomposes to give 
:CF2 and N2 gas. The reaction is very clean and the addition reactions with 
nucleophilic alkenes generally give good yields. The main drawback for this reagent 
is that it is potentially explosive and both its preparation and usage are hazardous.  
 
Attempts to generate the difluorocarbene at low temperature have also been 
explored. Balcerzak et al. (Scheme 19)
119
 reported the first practical example of  
difluorocyclopropanation in a PTC system at room temperature by reaction of 
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CH2Br2 and CBr2F2 in the presence of alkenes and tetrabutylammonium 
hydrogensulphate (TBAHS) as a PTC catalyst.  
 
 
Scheme 18: Thermal decomposition of difluorodiazirine to give :CF2 
 
 
Scheme 19: Difluorocyclopropanation in a phase-transfer catalysed (PTC) system 
 
The reaction works by deprotonation of CH2Br2 with 60% aqueous solution of KOH 
and subsequent ion exchange with the TBAHS offers the lipophilic ion pair CHBr2
-
Q
+
 (Figure 25). In the organic phase, it is possible that 
-
CHBr2Q
+
 reacts with CBr2F2 
to give HCBr3 and the reactive intermediate CBrF2Q
+
 which further dissociates into 
:CF2 and tetrabutylammonium bromide. The :CF2 generated under this environment 
can give difluorocyclopropanes with  modest to good yields from electron rich 
alkenes, but fails to react with electron poor olefins. The conventional PTC method, 
e.g. dehydrohalogenation of a difluorohalomethane, does not work for 
difluoropropanation due to rapid base hydrolysis of difluorocarbene formed at the 
interfacial region by a concerted loss of proton and halide ion.
7, 25
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Figure 25: Possible reaction mechanism of CH2Br2 and CBr2F2 in the presence of KOH and TBAHS 
 
Another noteworthy room temperature difluorocyclopropanation method is the use 
of an appropriate phosphine with difluorodihalomethane reported by Burton and 
Naae (Scheme 20).
120
 They discovered that the treatment of 
bromodifluoromethylphosphonium bromide salt, formed from PPh3 and CBr2F2, 
with either KF or CsF would  generate  :CF2 which is able to covert nucleophilic 
alkenes to difluorocyclopropanes in good yield. Mechanistic study suggest that a 
CF2Br
-
 anion is directly generated from bromodifluoromethylphosphonium bromide, 
followed by decomposition of this anion to :CF2.  
 
 
Scheme 20: Generation of :CF2 via the reaction of PPh3 and CBr2F2. 
 
CBr2F2 is also used with zinc by Dolbier et al. (Scheme 21)
121
 in a reaction similar to 
the Simmons-Smith reaction at ambient temperature. With a catalytic amount of I2, 
the reactive species, thought to be a “free” carbene rather than a zinc 
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difluorocarbenoid, can transform alkenes to their corresponding 
difluorocyclopropanes in up to 96% yield.
121
 Although this method only works well 
with electron-rich unsaturated systems, it is very mild and easy to perform and needs 
no special anhydrous conditions, thus it may be considered as a method of choice for 
reactive olefins. 
 
 
Scheme 21: Simmons-Smith like difluorocyclopropanation using CBr2F2, zinc and I2. 
 
The use of organometallic reagents as :CF2 sources has also been widely reported.  
This class includes organomercury, organotin, organocadmium and organosilicon 
compounds.
102
 One of the earliest organometallic :CF2 precusors developed was 
PhHgCF3 which was prepared by Seyferth et al.
122
. When PhHgCF3 is treated with 
stoichiometric amount of sodium iodide, the nucleophilic iodide ion attacks on Hg 
and displaces the 
-
CF3 anion. Subsequent loss of a fluoride ion from the 
trifluoromethyl anion gives difluorocarbene (Scheme 22).
122
 Under these neutral 
reaction conditions, electron rich olefins give excellent yield of 
difluorocyclopropanes and even for relatively unreactive alkenes, 
difluorocyclopropanes can be obtained in modest yields.  
 
 
Scheme 22: Seyferth’s reagent, PhHgCF3, generates relatively reactive: CF2 species 
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Me3SnCF3 is another example of an organometallic :CF2 transferring agent. This 
reagent can give difluorocyclopropanes from their corresponding alkenes in good 
yield with or without the use of sodium iodide. In the presence of sodium iodide, a 
trifluoromethyl anion is thought to serve as an intermediate in the difluorocarbene 
formation and the mechanism of reaction may be similar to that of PhHgCF3 
(Scheme 23).
123
  
 
 
Scheme 23: NaI catalyzed thermal decomposition of Me3SnCF3 to give :CF2 
 
In the absence of sodium iodide, Me3SnCF3 undergoes thermolysis at a temperature 
of 150 ºC or above to liberate the difluorocarbene (Scheme 24).
124
  
 
 
Scheme 24: Direct thermolysis of Me3SnCF3 to give :CF2 
 
Another milder, purely thermal source of :CF2 of this class is Cd(CF3)2 (Scheme 
25)
125
 which is highly unstable in low coordinating solvents and decomposes easily 
even at -5 ºC to evolve :CF2. The reactivity of the carbene species produced in this 
environment is probably the most reactive one to date. This is because the carbenes 
generated can be trapped by highly unreactive olefins at low temperature, e.g. cis- 
and trans-stilbene, to give difluorocyclopropanes in quantitative yields >95%. With 
all the reported examples given so far, the cis-diphenyldifluorocyclopropane is 
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particularly challenging to prepare due to possible isomerisation of both the substrate 
and the product (at sufficiently high temperatures) and the very unreactive nature of 
a highly conjugated, non electron rich system toward a difluorocarbene.  
 
 
Scheme 25: Thermal decomposition of (CF3)2Cd to give :CF2 
 
Despite the excellent reactivity of these organometallic :CF2 transfering reagents, 
their toxicity and subsequent lack of commercial availability has limited their use in 
modern synthetic chemistry.
126
 Their preparation is also both difficult and 
hazardous.
110, 126
  
 
In comparison to other organometallic :CF2 sources, organosilicon reagents are 
relatively non-toxic and easy to prepare. An effective reagent of this category is the 
recently reported trimethylsilyl fluorosulfonyldifluoroacetate (TFDA), which 
undergoes thermolysis in the presence of catalytic fluoride ion to extrude :CF2 
(Scheme 26Scheme 26).
126, 127
  The difluorocarbene generated under these conditions 
can even add efficiently to relatively unreactive alkenes, such as acrylate esters, to 
give the corresponding difluorocyclopropanes in modest to good yields.  
 
Scheme 26: NaF catalyzed thermal decomposition of TFDA to give :CF2 
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The main drawback of TFDA is that there is no single “recipe” that can offer optimal 
results for all alkene substrates and this highly complicates the screening process for 
suitable reagents. In the first instance, 2.0 equiv. of TFDA in toluene at 115 ºC gave 
the desired difluorocyclopropane from ethyl cinnamate (49) in 67% yield, whilst 
trans-1-phenylpropene (50) did not react under the same reaction conditions 
(Scheme 27). The best reaction conditions found for 50 was 2.0 equiv. of TFDA in 
methyl benzoate at 120 ºC and an excellent yield of 91% was achieved (Scheme 27). 
 
 
Scheme 27: Different substrates require different reaction conditions when using TFDA 
 
In respect to the reactivity of carbenes formed under these conditions, they may still 
be quite reactive, but are not as superior as that of (CF3)2Cd, since a rather 
unsatisfactory yield of 36% was obtained compared to a quantitative yield of >95% 
when trans-stilbene (51) was used as the substrate (Scheme 28). 
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Scheme 28: TFDA only gave low yield of difluorocyclopropane from trans-stilbene. 
 
Recently, Hu and his co-workers reported the use of Me3SiCF2Cl as a 
difluoromethylenation reagent which starts to decompose at temperatures above 80 
ºC under the influence of catalytic amount of chloride ions to emit :CF2. This method 
is very useful and not only allows the effective formation of difluorocyclopropane 
from alkenes (Scheme 29), but is also able to turn a range of alkynes to their 
difluorocyclopropene analogues in good yields (Scheme 30). 
 
 
Scheme 29: Ddifluorocyclopropanation using Me3SiCF2Cl 
 
 
Scheme 30: Difluorocyclopropenation using Me3SiCF2X 
 
Interestingly, the authors found that while Me3SiCF2Br may also serve as a 
difluorocarbene precursor with similar yields, Me3SiCF3 was inert under the same 
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reaction conditions (Scheme 30).
128
 However, both Me3SiCF2Br and Me3SiCF2Cl are 
not commercially available and its preparation involves the use of ozone-depleting 
CBr2F2 and CBrClF2
129
 which are currently banned in many countries, thus limiting 
its practical synthetic potential.  
 
Me3SiCF3, also commonly referred to as the Ruppert–Prakash reagent, has been 
employed extensively as a trifluoromethylating agent, yet its use as a :CF2 source has 
not been explored until very recently.
129
 With an appropriate halide initiator, the 
Ruppert–Prakash reagent can give trifluoromethyl anion at low temperatures, yet this 
anion is susceptible to decomposition to :CF2 and F
-
 anion and was recognized as a 
serious side reaction in trifluoromethylation.
130
 Hu et al. exploited this side reaction 
and went on to demonstrate that the difluorocarbene generated can be trapped 
cleanly and conveniently by various alkenes and alkynes at low or elevated 
temperature to give their corresponding difluorocyclopropanes (Scheme 31) and 
difluorocyclopropenes in good to excellent yields (Scheme 32).
129
  
 
 
Scheme 31: Difluorocyclopropanation of an alkene using Me3SiCF3 
 
Of the three halodifluorotrimethylsilane reagents, Me3SiCF3 is probably the most 
useful since it is commercially available and inexpensive. This method also has 
many advantages over the others, either because the others are not commercially 
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available or their preparations are difficult or their thermolysis required harsh 
reaction conditions, and/or gave low product yields.  
 
 
Scheme 32: Difluorocyclopropenation of an alkyne using Me3SiCF3 
 
3.3 Research and development  
3.3.1 Synthesis of 1,2-diaryl-difluorocyclopropanes and its challenges. 
Numerous methods were investigated for the synthesis of difluorocyclopropyl 
stilbene analogues 52 and 53 (Figure 26). These include reaction of CH2Br2 and 
CBr2F2 with a strong aqueous base in the presence of tetrabutylammonium 
hydrogensulphate as a PTC catalyst,
119
 thermal decomposition of sodium 
trifluoroacetate, chlorodifluoroacetate and bromodifluoroacetate,
112, 18, 19
 and NaF 
induced thermal decomposition of TFDA.
131
 All attempts failed to affect the 
difluorocyclopropanation on the relatively electron-deficient stilbenes.  
 
 
Figure 26: Structure of cis-  and trans-1,1-difluoro-2,3-diphenylcyclopropanes 
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Initially, it was believed that the energy barrier for addition of difluorocarbene to the 
relatively unreactive stilbenes may be too high for the low temperature PTC method 
and the thermal fragmenatation of sodium halodifluoroacetates to take effect. Thus, 
the temperatures of the pyrolysis reactions were gradually increased from 150 ºC up 
to 190 ºC; Still, no difluorocyclopropyl stilbenes were detected. Dolbier et al.
131
 
reported to have made the trans-difluorocyclopropyl stilbenes using TFDA in low 
yield (36%), yet when their procedure was followed exactly, their result could not be 
reproduced in our laboratory. The reaction temperature for NaF induced thermal 
decomposition of TFDA was also raised from 105 ºC to 190 ºC progressively, 
though it too failed to give any difluorocyclopropane.   
 
It is known that slow rate of addition of reagents would increase the immediate ratio 
of difluorocarbene to available alkenes and hence favours product formation.
114
  
Nevertheless, attempts to improve the reaction conditions by adding the reagents 
over longer periods and with a greater excess of reagents than reported were all in 
vain and did not seem to afford the difluorocyclopropanes at all.  
 
It was discovered from the literature that cis- and trans-difluorocyclopropyl stilbenes 
could interconvert via the cleavage of C
2
-C
3 
bond at temperature >150 °C, with 
irreversible formation of 2,2-difluoro-1-phenylindane (54) which further undergoes 
HF elimination to give a mixture of 1- and 3-phenyl-2-fluoroindene (55 and 56), 
Figure 27.
132
 Based on this finding, we concluded that the very high temperature 
needed for pyrolysis reactions will not work on our substrates. 
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Figure 27: Thermal decomposition of diphenyldifluorocyclopropanes.
132
 
 
Apart from TFDA, synthesis of cis-difluorocyclopropyl stilbene has only been 
reported using a few other methods, which  include  F3CHgPh
133
 and (CF3)2Cd.
125
  
Due to their high toxicities, these methods were not considered and other methods 
for effective difluorocyclopropanation of stilbenes were sought.  
 
 The use of Me3SiCF3 as a difluorocarbene source in the presence of an appropriate 
initiator both at low and elevated temperature published by Hu
36
 was also attempted. 
Again, it failed to react with the electron poor stilbenes while reported examples, 
such as the preparation of 57 and 58 were easily repeated (Scheme 33). 
 
It was concluded at this point that the stilbenes are extremely unreactive toward the 
difluorocarbene, probably because of the presence of an extended π-conjugated 
system rather than being electron poor. This may as well explain why in the 
literature, examples of difluorocyclopropanation on 1,1-diarylethenes are plentiful, 
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while only a few involve 1,2-diarylethenes in spite of them being structurally very 
similar.  
 
 
Scheme 33: No difluorocyclopropanation of stilbene was observed using Hu’s methods. 
 
3.3.2 Microwave assisted difluorocyclopropanation (MAD) 
We then tried to facilitate the difluorocyclopropanation of stilbenes with Me3SiCF3 
using a microwave reactor since microwave irradiation can be more effective than 
conventional heating.
134
  To our delight, some of the stilbenes did transform into 
difluorocyclopropanes after heating the reaction mixture in a sealed microwave tube 
for just 20 minutes at 80 ºC (Scheme 34), although the conversion was only ~22%.  
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Scheme 34: MAD of stilbenes using Me3SiCF3 
 
Despite much of our effort to optimize the reactions, however, the conversion never 
exceeded 30%. Replacement of NaI with a different salt: NaF, NaCl, NaBr, KF, KCl, 
KBr, KI and CsF resulted in no or only trace amounts of product being formed. 
When THF, toluene, diglyme, DMF and DMSO were used as solvents instead of 
CH3CN, only a trace amount of difluorocyclopropanes was detected. If the reaction 
temperature was below 80 ºC, only small quantities of difluorocyclopropane were 
formed in the 20 minutes timescale, indicating that a sustainable high temperature 
(>80 ºC) is required to overcome the energy barrier for the addition of :CF2  to the 
olefins. Conversion of trans-stilbene to the desired trans-difluorocyclopropane 
increased with increasing reaction temperature, but only up to ~30% at 130 ºC; At 
140 ºC, isomerisation of trans-difluorocyclopropane to cis-difluorocyclopropane was 
observed in a small percentage (~2%) which was in strong agreement with Roth’s 
finding.
132
   
 
With cis-stilbene, the situation is a little bit more complicated. Table 1 shows a short 
summary of selected reactions when cis-stilbene was used as the model substrate. At 
80 ºC, about 22% of cis-stilbene was converted to difluorocyclopropane, while a 
hefty amount of starting material (~41%) was isomerized into the trans-stilbene 
which was also accompanied by the formation of trans-difluorocyclopropane (~1%, 
Entry 5). Interestingly, at temperature ≥ 120 ºC, trans-difluorocyclopropane (16%) 
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was detected as the major cyclopropane product (Entry 7). The cis- and trans-
isomerisation was increased from 41% to 57%, whereas the overall formation of 
difluorocyclopropane was reduced from 23% to a mere 17%. 
 
 
Entry Solvent 
Catalyst 
(equiv.) 
ºC Min 
% of crude reaction  mixture 
59 51 52 53 
1 THF NaI (2.5) 80 20 ~99 Trace 0 0 
2 Toluene NaI (2.5) 80 20 ~99 Trace 0 0 
3 Diglyme NaI (2.5) 80 20 ~99 Trace 0 0 
4 CH3CN NaI (2.5) 60 20 ~99 Trace 0 0 
5 CH3CN NaI (2.5) 80 20 ~36 ~41 ~22 ~1 
6 CH3CN NaI (2.5) 100 20 ~34 ~50 ~15 ~1 
7 CH3CN NaI (2.5) 120 20 ~26 ~57 ~1 ~16 
8 CH3CN NaI (2.5) 80 10 ~63 ~20 ~17 0 
9 CH3CN KF  (2.5) 80 20 ~99 Trace 0 0 
10 CH3CN CsF (0.2) 60 20 ~99 Trace Trace 0 
11 THF CsF (0.2) 60 20 ~99 Trace Trace 0 
12 Toluene CsF (0.2) 60 20 ~95 Trace ~5 0 
13 Toluene CsF (0.5) 60 20 ~98 Trace ~2 0 
 
Table 1: Difluorocyclopropanation using cis-stilbene as a model substrate; the conversions were 
measured by 
1
H NMR spectroscopy. 
 
There are two possible pathways by which trans-difluorocyclopropane may be 
formed from cis-stilbene, Figure 28: 
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Figure 28: Possible pathways for the formation of trans-diphenyldifluorocyclopropane from cis-
stilbene 
 
From the isomerization and conversion of cis-stilbene to trans-stilbene and 
difluorocyclopropanes (41% vs. 23% at 80 °C), we can conclude that the energy 
barrier for isomerization is much lower than difluorocyclopropanation, implying 
selective preparation of cis-difluorocyclopropanes is very difficult to achieve. 
 
To the best of our knowledge, difluorocyclopropanation using microwave irradiation 
had not been explored before and this method provides a fast and convenient way to 
the syntheses of difluorocycloproapanes in just 20 minutes.  The conversion shown 
in Entry 5 may seem trivial in the first instance, however, when the method is 
applied for more reactive alkenes, the conversion is remarkable, Scheme 35 and 
Table 2: 
 
 
Scheme 35: Typical reaction condition for MAD method. 
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Substrate Product %  of Conversion de 
 
  
 
>98 
 
- 
  
 
>98 
 
>99 
  
 
>98 
 
>93 
 
Table 2 shows conversions of more reactive olefins using MAD method 
 
The very high conversion obtained with other alkenes further provides evidence that 
stilbenes are, indeed, very unreactive towards difluorocarbene. 
 
3.3.3 Room temperature difluorocyclopropanation (RTD) 
Apart from the MAD, we also serendipitously discovered that the :CF2 generated 
from TMSCF3 using the same catalyst and the same solvent can react with the 
stilbenes very slowly at room temperature. Upon being sealed in a pressure tube and 
stirred at room temperature for two weeks, both cis- and trans-difluorocyclopropanes 
can be obtained in a more stereoselective manner from their corresponding stilbenes 
(Scheme 36).  
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Scheme 36: Conversion of cis- and trans-stilbenes to difluorocyclopropanes using RTD method. 
 
It is worth noting that the formation of both trans-stilbene and trans-
difluorocyclopropane were still observed even when the difluorocyclopropanation of 
cis-stilbene was conducted at room temperature. However, unlike MAD method 
where the trans-stilbene was the main product, the RTD method actually gave the 
desired cis-difluorocyclopropane from its corresponding cis-stilbene as the major 
product. This further illustrates that the synthesis of cis-1,2-diaryl-2,3-
difluorocyclopropanes is extremely difficult to accomplish and this may be the 
reason why successful synthesis of the named compound has only ever reported with 
the use of highly toxic but also extremely effective Cd(CF3)2 as the carbene 
precursor.  
 
The only drawback of the RTD is the very long reaction time required for good 
conversion; with 5 equivalent of TMSCF3 and NaI, stilbenes required at least 2 
weeks to get ~50% conversion. For reactive olefins such as styrene, only 2.5 
equivalent of reagents were needed to achieve a conversion of >98% in 4 days. The 
reaction time may be reduced by using more equivalents of reagents, although by 
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doing that this will decrease the cost efficiency. This method is, however, more 
selective with fewer limitations than the MAD and is more suited to sensitive 
substrates.  
 
3.3.4 Isolation of difluorocyclopropanes 
It was impossible to isolate the diaryldifluorocyclopropanes from the mixture by 
standard silica chromatography since the stilbenes and the difluorocyclopropanes 
have very similar polarities on silica in many different solvent systems. To isolate 
the products, the reaction mixture was treated with osmium tetroxide and oxone and 
the stilbenes were oxidatively cleaved, whereas the difluorocyclopropanes were left 
unchanged which could then be easily separated from the carboxylic acids (Scheme 
37). 
 
 
Scheme 37: Typical reaction conditions for oxidative cleavage of unreacted stilbenes 
 
3.3.5 Mechanism of NaI with TMSCF3 in CH3CN 
Hu et al. recently examined the reaction between Cl
- 
anion produced from n-Bu4NCl 
and TMSCF2Cl using the density functional theory (DFT) model to evaluate the 
possible reaction pathways of difluorocarbene with alkenes.
128
 They proposed that a 
pentacovalent silicate transition state 60 was formed after Cl
- 
attacked on the silicon 
centre, a process well established by others.
135, 136
 A chlorodifluoro-methyl anion 
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was then released from 60 which readily underwent α-elimination of a chloride ion 
to give difluorocarbene (Figure 29). 
 
 
Figure 29: Hu's proposed mechanism for the reaction of TMSCF2Cl and n-Bu4NCl 
 
Mechanistically, it is not unreasonable to assume that NaI and TMSCF3 in CH3CN 
may react in a similar fashion to n-Bu4NCl and TMSCF2Cl, in which a five-
coordinated silicate complex 61 may also be involved. Upon decomposition of the 
ate complex, Me3SiI (iodide may undergo rapid halide exchange with the fluoride 
ion in the solution media to give Me3SiF and re-generate NaI) and 
-
CF3 are formed 
which subsequently loses a fluoride ion to generate :CF2 (Figure 30).  
 
 
Figure 30: The possible mechanism of reaction between NaI and TMSCF3 
 
The mechanism above, however, may be a little over-simplified as it cannot give a 
plausible explanation for a phenomenon that we had observed in our preliminary 
experiments. We found that the reaction tubes had to be securely sealed, otherwise 
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little or no difluorocyclopropanes would be formed even if the reactions were carried 
out at room temperature and it is the reason why pressure tubes were used in our 
experiments instead of normal reaction flasks. In addition, we observed that a large 
amount of gas was produced during the reactions.  
 
Although we did not try to identify the gaseous product, the formation of HCF3, 
which is a gas, from the reaction of 
–
CF3 with residual water was well documented 
by Prakash, who introduced TMSCF3 to a vocabulary of organic chemistry over the 
last few decades.
129
 By assuming 
–
CF3 must have abstracted a proton from water 
residue only, the reactions were subsequently carried out under vigorously dried 
conditions with the use of anhydrous CH3CN as well as ultra dried NaI. 
Nevertheless, it did not seem to reduce the amount of gas being produced.  
 
CH3CN is frequently used as a solvent in fluorine chemistry,
137
 but we realized that 
it is not chemically inert. In fact, the strongly basic 
-
CF3 (pKa of HCF3 = 31)
135
 
released from TMSCF3 upon addition of a 
–
F anion from tetramethylammonium 
fluoride is known to deprotonate a neighbouring CH3CN (pKa = 25)
138
 molecule to 
give gaseous CF3H and a 
-
CH2CN anion.
135
 According to Prakash, Me3SiF would be 
formed as the end product, presumably along with Me4N
+
CH2CN
- 
(Figure 31).  
 
 
 
Figure 31: Prakash et al.’s proposed formation of Me3SiF and Me4N
+
CH2CN
-
 
 
73 
 
Adams et al., on the other hand, suggested that the 
-
CH2CN anion then re-attacks the 
silicon centre to form a pentacoordinate silicate complex 62, which is stable in 
acetonitrile for at least a day in the absence of fluoride or moisture (Figure 32).
135
 
 
Figure 32: Adams et al. suggested formation of a pentacoordinate silicate complex 
 
When the five-coordinated complex collapses back to a four coordinated silicate, it 
could either be an active source of fluoride or 
-
CH2CN, depending on the reaction 
conditions.
135
 Undoubtedly, their mechanistic models may not be directly applicable 
to our reactions, since NaI is used as the initiator rather than tetramethylammonium 
fluoride. What can be drawn from their findings is that the whole reaction 
mechanism is probably under equilibrium, and all the reactions may be reversible, 
except the difluorocyclopropanation where the energy difference between alkenes 
and difluorocyclopropanes is probably too high (Figure 33).  
 
 
Figure 33: Our proposed mechanism between TMSCF3 and NaI in CH3CN 
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As we can see from Figure 33 above, 
–
CF3   can be lost by proton abstraction from 
CH3CN to give HCF3 as a gas, so if the pressure tubes are tightly sealed, then the 
loss of gaseous HCF3 from the reaction is diminished. This, in turns, favours the 
decomposition of 
-
CF3 to :CF2, thus favouring the formation of 
difluorocyclopropanes.  
 
3.3.6 Synthesis of functionalized cis- and trans-stilbenes 
As none of the non-difluorocarbene methods investigated had worked, we decided to 
focus on the [2+1] cycloaddition of difluorocarbene to the diarylethene in the 
meantime.  To synthesize the diaryldifluorocyclopropanes, we first had to prepare 
the functionalized cis- and trans-stilbenes since they are not usually commercially 
available.  
 
Different methoxylated analogues of stilbene were investigated for this project 
mainly due to two reasons. First and foremost, 2 was one of the most active 
antiestrogenic and anti-tumour compounds Magarian et al. discovered and was 
shown to have a five-fold increase in potency than the non-functionalised 
diphenyldichlorocyclopropanes 1.
77
 This indicates the methoxy group on the phenyl 
ring is an important pharmacophore for the significant increase of antiestrogenic and 
anti-tumour activities of these analogues. Therefore, we would like to determine 
whether the position of the substituents has any pronounced effect on its biological 
activities.  
 
Secondly, the methylated analogues of stilbene resembles Resveratrol structurally, a 
natural polyphenol found in grapes, berries, peanuts and other plants. Resveratrol 
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was found to be effective against a wide range of age-associated diseases including 
cancer, diabetes and cardiovascular diseases
139
 and has been demonstrated to induce 
autophagy by others. 
140-143
  
 
Many routes can lead to functionalized stilbenes, yet only few provide the alkenes in 
a selective manner. Not only Wittig reactions typically give a mixture of both cis- 
and trans-isomers, but the formation of a large amount of triphenylphosphine oxide 
as a by-product also make the purification of products very challenging and time-
consuming (Scheme 38). 
  
 
Scheme 38: Wittig reaction to give alkenes and triphenylphosphine oxide 
 
As a result, the utilisation of Wittig reaction for alkene synthesis was abandoned and 
the stereoselective syntheses of trans-stilbenes (63 – 66) were achieved via Horner-
Wadsworth-Emmons (a modified Wittig reaction using phosphonate-stabilized 
carbanions) reactions instead. Briefly, mono- or di-methoxy substituted 
benzaldehydes were reduced to give primary alcohols which were followed by 
conversion to the benzyl bromide using PBr3 (Scheme 39). Treatment of the benzyl 
bromide with triethyl phosphite afforded benzylphosphonic acid diethyl esters and 
subsequent reaction with a benzaldehyde offered predominately the trans-stilbenes 
as solids, which were easily purified by re-crystallisation. Although quite a few steps 
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were involved, the overall yields of the products were good and no chromatographic 
purification was needed at any stage.  
 
  
Scheme 39: Typical reaction conditions for Horner-Wadsworth-Emmons reactions 
 
Preparations of substituted cis-stilbenes, on the other hand, are much harder to 
perform in a selective manner since they are thermodynamically less table than their 
trans-counterparts and hence their formations are not favoured. Their isolation from 
a mixture of both cis- and trans-isomers is also very difficult, but generally 
achievable with slow and careful standard silica chromatographic techniques.  
 
Perkin condensation of phenylacetic acid and aryl aldehyde to give aryl cinnamic 
acid has been extensively studied both for its mechanism and synthetic applications. 
Synthetically, it is very useful as it allows a fast and convenient access to a range of 
α,β-unsaturated aromatic acids, which could subsequently be transformed to their 
corresponding stilbenes. Mechanistically, it is interesting because cis-diarylethenes 
are preferentially formed as the major products after the decarboxylation of the 
adducts.  
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Scheme 40: Typical reaction conditions for Perkin condensations. 
 
A wide series of aryl cinnamic acids have been successfully prepared using the 
method shown in Scheme 40, with yields ranging from 39 – 71%. Although the 
yields in general were not that impressive, the syntheses were really easy to perform 
and the starting materials were readily accessible and inexpensive. After 
decarboxylation of the aryl cinnamic acids with copper chromite and quinoline at 
180 ºC (Scheme 41), a mixture of cis-  and trans-stilbenes were obtained in good to 
excellent yields, with a combined yields of cis-  and trans-isomers ranging between 
68 - 98%. 
 
 
Scheme 41: Typical reaction conditions for copper chromite assisted decarboxylation 
 
Careful separation of the two stereoisomers on silica chromatography permitted, at 
least, a fraction of the total cis-stilbenes to be isolated cleanly in most cases except 4-
chloro and 4-fluoro stilbenes. These stilbene analogues were the only cases in which 
separation of the two geometric isomers on standard silica chromatography were 
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found impossible to achieve as they were very non-polar in nature and both isomers 
of these two compounds were eluted out quickly at the same time. The remaining 
isomeric stilbene mixtures were conveniently turned to predominately trans-stilbenes 
using a catalytic amount of iodide in refluxing hexane for two days (Scheme 42).  
The crude reaction mixtures were then purified by recrystallization to offer the trans-
diarylethenes. This iodine catalyzed isomerisation of cis-stilbene allows a rapid 
expansion of the trans-stilbenes library.   
 
 
Scheme 42: Typical reaction conditions for cis- and trans- stilbene isomerisation 
 
3.3.7 Synthesis of difluorocyclopropanes  
After the required stilbene substrates were prepared, we used both MAD and RTD 
developed in our laboratory for the syntheses of diarylfluorocyclopropanes. The 
MAD is very fast and convenient and was used for the syntheses of 
diphenyldifluorocyclopropanes 52 and 53, Scheme 43. However, it is not as 
stereoselective as the RTD method. Thus, all other functionalized 
diaryldifluorocyclopropanes (86 - 93)were achieved using the RTD method, Scheme 
43.  
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Scheme 43: Microwave-assisted difluorocyclopropanation (MAD) of cis- and trans-stilbene 
 
 
Scheme 44: Typical reaction conditions for RTD of stilbene and its analogues 
 
Although slow, the RTD method is very easy to perform and is very suitable for 
stereoselective syntheses of difluorocyclopropanes derived from alkenes, such as cis-
stilbene, in which the energy barrier for isomerisation is lower than that for 
difluorocyclopropanation. 
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Chapter 4 Structure and Activity Relationship Studies 
of Tamoxifen and Its Analogues for Autophagy.  
4.1 Biological testing of functionalized cis- and trans-stilbenes and 
their dihalocyclopropyl derivatives  
As discussed earlier, Tamoxifen is a well-known multi-target drug. In addition to its 
high affinity to the ERs, Tamoxifen binds with relatively high affinity to an 
intercellular site called the antiestrogen binding site (AEBS). Additionally, it has 
been shown to have affinities to a number of other molecular targets which include 
protein kinase C (PKC), calmodulin (CaM)-dependent enzymes and Acyl 
CoenzymeA: Cholesterol Acyl Transferase (ACAT).
34
 Any one or more of these 
targets could account for its cardioprotective effects and therefore it is very difficult 
to study the mechanism of action at a molecular level.  
 
It is known that, however, Tamoxifen is a potent autophagy inducer and there is a 
strong correlation between enhancing autophagy and cardioprotection
34
 and common 
age-related diseases.
144
  Consequently, in our project we focused on finding novel 
molecules which could induce autophagy and were structurally similar to 
Tamoxifen. This chapter reports data obtained from our collaborators at E3Bio by 
Kate Willetts and Dr. Jill Reckless in various biological assays. Tamoxifen had been 
used as a positive control in all of our assays, whereas for the negative control 
dimethyl sulfoxide (DMSO) vehicles were used. Monodansylcadaverine (MCD) is 
an autofluorescent dye developed as a specific in vivo marker for 
lysosomal/autophagic vacuoles.
145
 MCD accumulates in autophagic vacuoles 
possibly due to a combination of ion trapping in acidic compartments and specific 
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interactions of this molecule with autophagic vacuole membrane lipids.
146
 However, 
it is known to produce a high background and weak fluorescent signal. AB139484 is 
an optimized autophagy detection assay which uses a novel 488 nm-excitable green 
fluorescent dye that selectively labels autophagic vacuoles while minimizing the 
staining of lysosomes. The assay allows for a convenient, specific and quantitative 
measure of the autophagic vacuoles and monitoring autophagic flux by the 
fluorescence intensity using fluorescence microscopy, flow cytometry and 
fluorescence microplate assay. 
 
In our first structural activity relationship study, we tested compounds which 
predominantly only contain cis- (part A) and trans- (part B) stilbene backbone 
moieties as well as the dichlorocyclopropyl and acrylic acid derivatives of 
Tamoxifen (Figure 34) without the amino side chains.   
 
 
Figure 34: Part A and B moieties of Tamoxifen 
 
The compounds tested could be categorized into three different classes of 
compounds which include 1,2-diarylethenes, diaryl-2-propenoic acids and di- and 
tri-aryldichlorocyclopropanes. Our decision to test 1,2-diarylethenes is based on the 
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fact that resveratrol and other stilbene analogues have been reported to induce 
autophagy.
140-143
 
 
Resveratrol (Figure 35), in particular, has attracted a lot of interest in the past 
decade.  It is a natural polyphenol which is found in grapes, berries, peanuts and 
other plants. Many preclinical and clinical studies have demonstrated that resveratrol 
is effective against a wide range of age-associated diseases including cancer, 
diabetes, and neurodegenerative, cardiovascular and pulmonary diseases through 
modulation of multiple cell signalling pathways.
139
 In addition to Resveratrol, all 
other 1,2-diarylethenes and their derivatives synthesized and biologically tested are 
shown in Figure 35.  
 
Figure 35: The structures of functionalized stilbenes synthesized and biologically tested. 
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As can be seen clearly seen from Graph 1, none of the compounds of these classes 
shown in Figure 35 induced a significant difference in the autophagic assays 
compared to the controls. In fact, the 1,2-diarylethenyl or triphenylethylene derivates 
of Tamoxifen did not seem to stimulate autophagy at all except resveratrol.  
 
 
Graph 1: Measure induction of autophagy of stilbene and its analogues shown in Figure 35 using 
Tamoxifen (Tam) and DMSO as positive and negative controls respectively.  
 
Resveratrol was reported to be a potent autophagy inducer by others,
147
 but it had 
only had a marginal effect in our biological assays. Interestingly, the cis-isomers 
(cis-stilbene and compound 76 to 79) appeared to give consistently and slightly 
better results than their trans-counterparts (trans-stilbene and compound 63 to 66), 
although the DMSO control also appeared to have higher autophagic flux on the 
fluorescence microscopy than the trans-diarylethenes. This could be a result of 
experimental errors as the standard error bar of the control was much higher than the 
other compounds tested. In order to draw a less ambiguous conclusion about whether 
cis-stilbene and its derivatives are any better than their trans-isomers, further 
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investigation is needed. However, even if there was an experimental error in the 
control and the cis-isomers were in fact better than the trans-isomers, the statistical 
difference between those compounds would not be insignificant.  
 
The stilbene precursors, 2,3-diaryl-2-propenoic acids (Figure 36), were also tested 
because some of these compounds have been found to be biologically active by other 
researchers.
148
  
 
 
Figure 36: The structures of 2,3-diaryl-2-propenoic acids synthesized and biologically tested. 
 
Graph 2 illustrates the results of the autophagic assays for the diarylpropenoic 
derivative of Tamoxifen shown in Figure 36. Treatment of THP-1 cells with these 
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compounds did not result in induction of autophagy. On the other hand, autophagy 
was potently induced by Tamoxifen at a concentration half that of the tested 
compounds. 
 
 
Graph 2: Measure induction of autophagy of 2,3-diaryl-2-propenoic acids shown in Figure 36 using 
Tamoxifen (Tam) and  DMSO as positive and negative controls respectively. 
 
The di- and tri-arydichlorocyclopropanes are derivatives of stilbene and Tamoxifen, 
in which the olefinic link is replaced by a dichlorocyclopropyl moiety. The presence 
of a cyclopropyl ring is thought to reduce or eliminate their estrogenic activity. This 
class of compounds and its derivatives (Figure 37) may be of medicinal interest as 
Magarian and others have demonstrated that they have antiestrogenic and anti-
tumour activities.
76-83, 149
   
 
Graph 3 illustrates the test results for the dichlorocyclopropyl analogous of 
Tamoxifen shown in Figure 37. Again, none of the compounds of this class induced 
autophagy in the biological assays.  
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Figure 37: The structures of di- and triaryl-dichlorocyclopropanes synthesized and biologically tested. 
 
 
Graph 3: Measure induction of autophagy of dichlorocyclopropanes shown in Figure 37 using 
Tamoxifen (Tam) and DMSO as positive and negative controls respectively. 
 
The first biological testing results were certainly very disappointing. However, from 
our earlier experience we knew that di- and tri-aryldichlorocyclopropanes were not 
particularly stable and degraded easily at room temperature, thus it may be possible 
that the inactivity of these compounds in our biological assays were attributed to 
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their instability. Consequently, we aimed to synthesize some more dihalocyclopropyl 
analogues of Tamoxifen which were more stable for our second biological testing.  
 
4.2 Biological testing result for the difluorocyclopropyl stilbenes and 
aminoethoxy derivative of Tamoxifen  
4.2.1 Difluorocyclopropyl analogues of Tamoxifen 
In comparison to dichlorocyclopropanes, the syntheses of difluorocyclopropyl 
compounds were much more difficult to achieve due to the highly unreactive nature 
of difluorocarbene toward electron poor olefins.  A lot of effort had been made to try 
to find good practical methods for the synthesis of gem-difluorocyclopropanes. 
However, none of the methods we tried giving the desired 
diaryldifluorocyclopropanes. The use of highly toxic Cadmium complex Cd(CF3)2 is 
the only example ever reported for the successful difluococyclopropanation of cis-
stilbene. However, its use had not been considered in our laboratory due to its high 
toxicity. Although the RTD we developed generally requires long reaction times for 
unreactive alkenes, it is particularly suitable for unstable substrates such as cis-
stilbene, in which the energy barrier for isomerization is much lower than the 
cycloaddition of difluorocarbene, making the selective synthesis of their products 
very challenging. Consequently, the difluorocyclopropyl compounds illustrated in 
Figure 38, all except 52, 53 and 58 were synthesized using the RTD method.  
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Figure 38:  The structures of diaryldifluorocyclo- propanes and propene synthesized and tested. 
 
As can be seen from Graph 4, when differentiated THP-1 cells were treated with 
0.3, 1.0, 3.0, and 10.0 µM of Tamoxifen as positive controls, Tamoxifen potently 
induced autophagy in a dose-dependent manner from a concentration as low as 0.3 
µM. In contrast, treatment with those 1,2-diaryldifluorocyclopropanes gave similar 
results as their corresponding dichlorocyclopropyl analogues and no sign of any 
autophagy was observed at a concentration as high as 10 µM (Graph 4), despite 
those difluorocyclopropyl derivatives of Tamoxifen being more stable than its 
dichlorocyclopropyl counterparts and did not degrade under normal handling 
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condition. This result, although disappointing, helped to eliminate the possibility that 
the inactivity of diaryldichlorocyclopropanes was due to their instability. 
 
 
Graph 4: Measure induction of autophagy of 1,2-diaryldifluorocyclopropanes shown in Figure 38 
using Tamoxifen (Tam) and DMSO as positive and negative  control respectively. 
 
As all the compounds tested in the first biological assays were without the amino 
side chain, we also tried to synthesize some difluorocyclopropyl analogues with part 
C and part D moieties to test for activity (Figure 39). 
 
 
Figure 39: Part C and D moieties of Tamoxifen 
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4.2.2 The syntheses of aminoethoxy derivatives of Tamoxifen 
Introducing an amino side chain to the 1,1-diaryl and 1,2-diaryl analogues was found 
to be quite challenging and a number of methods were attempted for the synthesis of 
compounds 97 and 98.  
 
 
Figure 40: The structures of difluorocyclopropyl analogues of Tamoxifen 
 
From our experience, 
-
CF3 is able to attack an electrophilic center or abstract a 
proton from other reagents and solvent before decomposing into :CF2. In addition to 
reacting with nucleophiles such as alkenes in the cycloaddition, the difluorocarbene 
has also been reported to insert into C-H,
150
 C-Br,
150
 Si-H,
151
 O-H
152
 and also other 
bonds.
153
 All these possible side reactions led us to decide to protect the OH group 
with a methyl ether and attempt to synthesize 97 via Scheme 45. 
 
As it is illustrated in Scheme 45, the reaction of 4-methoxyacetophenone (99) with 
Grignard reagent PhMgBr would provide a tertiary alcohol, which was not isolated 
but was directly used for the next dehydration step. The dehydration of alcohol was 
achieved by adding a few gains of p-toluenesulfonic acid in refluxing toluene to give 
the intermediate 100. Reaction of 100 with TMSCF3 in the presence of NaI offered 
101 smoothly. However, 100 was found to be degraded when the demethylating 
agent BBr3 was used to cleave the methyl ether in the deprotection step. 
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Scheme 45: Proposed route for synthesis of 97 
 
Subsequently, we tried to introduce the aminoethoxy functional group before the 
difluorocyclopropanation step and without protection of the alcohol group. 104 was 
synthesized by the coupling of 4-hydroxyacetophenone 103 with the Grignard 
reagent PhMgBr followed by dehydration as previously described. The alkylation of 
104 with 2-chloro-N,N-dimethyl ethylamine  in the presence of a weak base 
potassium carbonate in refluxing acetone gave 105 as expected, Scheme 46. 
However, the difluorocyclopropanation step failed to afford the desired product 97. 
Instead, a complex mixture was formed which could not be purified using standard 
silica chromatography.  
 
Scheme 46: Proposed route for synthesis of 97 
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It was considered that the difluorocarbene may have attacked the nucleophilic 
nitrogen atom of the tertiary amine.  Although nothing in the literature specifically 
documents the reaction between difluorocarbene and a tertiary amine, the 
electrophilic attack of dichlorocarbene
154
 or other type of carbenes
155
 by amines 
giving rise to N-ylides are well recognized. The N-ylides are not stable which may 
undergo further rearrangement (Figure 41:)
154
 to give a complex mixture containing 
many side products. 
 
 
Figure 41: Rearrangements of N-ylides 
 
Upon knowing that TMS-protected trifluoromethylated alcohols could be prepared 
from both aldehyde and ketone using TMSCF3 in one step (Scheme 47),
156
 it was 
realized that the phenol may not need to be protected at all.  
 
 
Scheme 47: One pot syntheses of TMS-protected trifluoromethylated alcohols using TMSCF3 
 
It was postulated that the (CH3)3SiCF3 or (CH3)3SiI generated in situ may be able to 
form a trimethylsilyl-protected phenol with the phenolic ion (Figure 42).  
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Figure 42: One pot synthesis of TMS-protected difluorocyclopropanel from 4-(1-phenylvinyl)phenol.  
 
To test this hypothesis, 104, prepared from coupling of 4-hydroxyacetophenone 
(103) with the Grignard reagent followed by dehydration as previously described, 
was subjected to difluorocyclopropanation directly without any phenol protection. It 
was found that compound 105 was, indeed, formed cleanly and smoothly as 
expected. The trimethylsilyl-protected phenol was not isolated and was subsequently 
deprotected cleanly and easily by stirring it directly with 0.2 equiv. of N-
bromosuccinimide in MeOH. Alkylating 102 with 2-chloro-N,N-dimethyl 
ethylamine hydrochloride under mild basic conditions offered the target compound 
97 in good yields (>75%), Scheme 48.  
 
  
Scheme 48: The successful synthetic route for 97 
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It was noteworthy that 1-(4-hydroxyphenyl)-1-phenylethene (104) was very unstable 
and was oxidized within hours if it was not stored under nitrogen and at low 
temperature, whilst its analogue 1-(4-methoxyphenyl)-1-phenylethene (100) was 
found to be chemically quite inert under ambient  and normal handling conditions. 
 
Following the successful synthesis of 97, a similar method was utilized for the 
synthesis of its regioisomer, 1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-3,3-    
difluorocyclopropane 98 (Scheme 49). Although the trimethylsilyl-protected phenol 
109 was observed in the crude reaction mixture, 110 was not obtainable as the 
cyclopropyl ring was destroyed during the TMS deprotection step. 
 
 
 Scheme 49: The proposed synthetic routes for the preparation of 97 
 
During the attempted syntheses of 97 and 98, we came across 1,1-diarylmethanes as 
another class of derivatives of Tamoxifen reported in the literatures.  This class of 
compounds was reported to bind selectively to AEBS which is the second highest 
affinity binding site for Tamoxifen after ERs.
34
 Tamoxifen is known to induce two 
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different types of effects against tumour cells depending on the dosage. At low doses 
(< 0.1 µM), it is anti-proliferative to ER-positive cell lines and the anti-proliferation 
is reversible by adding estrogen E2 which acts as an agonist to ERs and stimulates 
the growth of cancer cells. At high doses (>1 µM), Tamoxifen is cytotoxic to the 
tumour cells and its cytotoxicity cannot be reversed by addition of estrogen E2, 
implying Tamoxifen may mediate this effect through other cellular targets which is 
independent of ERs.
34, 157
 Interestingly, selective ligands of AEBS also display anti-
tumour activities and antiviral properties.
68
  
 
4.2.3 Tamoxifen and ligands of AEBS inhibit biosynthesis of cholesterol 
4.2.3.1 Molecular identity of AEBS and its biological actions  
Two decades ago, Sutherland et al. noticed that Tamoxifen bound to another binding 
site with high affinity in addition to the estrogen receptors.
158
 The site was termed 
microsomal antiestrogen binding site (AEBS) since it is located within the 
microsomes of cells.
159
 Previous studies reported that Tamoxifen and its derivatives 
resulted in the accumulation of zymosterol in the blood of patients.
63
 This coupled 
with the fact that oxysterols such as 7-ketocholesterol, 6-ketocholestanol and 7-
ketocholestanol (Figure 43), are another class of ligands that bind to AEBS with high 
affinities, led Poirot et al. to hypothesize that there may be a possible link between 
the AEBS and lipid and sterol metabolism.
160
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Figure 43: The structures of cholesterol precursors. 
 
Poirot et al. went on to confirm the hypothesis by showing that AEBS is involved in 
the post-lanosterol intermediates of cholesterol biosynthesis and inhibition of AEBS 
leads to an accumulation of cholesterol precursors.  
 
Poirot et al. also reported that the treatment of PBPE (Figure 44), a selective AEBS 
ligand, and Tamoxifen at low dosages (both 0.5 µm) to the human breast 
adenocarcinoma cell line MCF-7 led to a massive intracellular accumulation of 
sterols. For Tamoxifen treatments, 5α-cholest-8-en-3β-ol (zymostenol) was detected 
as the major metabolite.
159
 When treated with PBPE, two major sterols were isolated 
and identified which were 5a-cholest-8-en-3β-ol, and cholesta-5,7-dien-3β-ol (7-
dehydrocholesterol), suggesting the selective AEBS ligand, PBPE,  affected at least 
two enzymatic  steps.
159
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Figure 44: The structures of known AEBS ligands 
 
Zymostenol and 7-dehydrocholesterol are substrates of 3β-hydroxysterol-∆(8)-∆(7)-
isomerase (D8D7I) and 3β-hydroxysterol-∆(7)-reductase (DHCR-7) respectively and 
accumulation was due to a noncompetitive inhibition of these two enzymes (Figure 
45).
161
 This finding led Poirot et al. to identify AEBS as a hetero-oligomeric enzyme 
complex which consists of D8D7I and DHCR-7 as subunits.
159
  Additionally, Poirot 
et al. showed that the coexpression of D8D7I and DHCR-7 is essential and sufficient 
to reconstruct the AEBS in mammalian cells.
159
 
 
 
Figure 45: The proposed biosynthesis pathway of cholesterol 
This figure is reproduced from Kedjouar et al.
159
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At high dosage (PBPE = 40 µM, Tamoxifen = 10 µM),  Tamoxifen and PBPE were 
reported to trigger active cell death and induction of autophagy,
161
  indicating that 
binding to AEBS could result in both apoptosis and autophagy depending on the 
concentration of ligands. Other diphenylmethyl compounds, such as DPPE, were 
also potent inhibitors of AEBS and produced similar sterol accumulation profiles, 
active cell death and autophagy in MCF-7 cells, but PBPE was found to have the 
highest affinity for AEBS in the series.
159, 161
  
 
During the last decade, research has shown that apoptosis (self-killing) and 
autophagy (self-eating) are two very closely related, coordinately regulated 
biological processes. In general, autophagy is a cellular stress adaption which 
promotes cell survival and suppresses apoptosis. However, in some certain cases, 
autophagy may lead to induction of apoptosis or autophagic cell death resulting from 
excessive cytoplasm degradation.
162
 The underlying mechanisms which control the 
decision of autophagy to act as a cell survival or cell death are still poorly 
understood.
162
 
 
4.2.3.2 Different classes of AEBS ligands inhibit different enzymes or steps in the 
cholesterol biosynthesis 
The binding of the microsomal antiestrogen binding site by Tamoxifen and other 
selective AEBS ligands such as PBPE and DPPE leads to a significant concentra-
tion- and time-dependent accumulation of cholesterol precursors.
161
 Interestingly, 
different classes of AEBS ligands have been shown to inhibit different enzymes or 
steps in the cholesterol biosynthesis pathway, leading to different sterol 
accumulation profiles. Selective Estrogen Receptor Modulators bearing a hydroxyl 
102 
 
group on their aromatic backbone such as 4-OH-Tamoxifen and triparanol, inhibit 
the 3β-hydroxysterol-∆24-reductase (DHCR24) and give rise to the accumulation of 
cholest-5,24-diene-3β-ol (desmosterol). Ring B oxysterols such as 7-ketocholesterol, 
6-ketocholestanol and 7-ketocholestanol are inhibitors of D8D7I, leading to 
accumulation of zymostenol, while Raloxifene is able to inhibit both cholesterogenic 
enzymes D8D7I and DHCR24, causing an accumulation of zymosterol (Figure 
46).
163
  
 
An interesting observation was made by Poirot et al. that the accumulation of 
zymostenol in MCF-7 cell reached a plateau 24 h after treatment with Tamoxifen 
and other selective AEBS ligands and decreased significantly in favour of oxysterols 
after 48 h, indicating a reactive oxygen species producing system may be present.
159
 
Indeed, Tamoxifen and 7-ketocholesterol have been shown to produce reactive 
oxygen species,
164-166
 which lead to these cholesterol precursors being further 
oxidized into different oxysterol species that might have different pharmacological 
properties.
159
 
 
It was established that the accumulation of cholesterol precursors and the stimulation 
of reactive oxygen species contribute to the autophagic effects, cell differentiation 
and apoptotic properties of Tamoxifen, other SERMs and selective AEBS ligands in 
breast cancer cells.
71, 160, 161
 Interestingly, it was found that co-treating MCF-7 cells 
with high doses of vitamin E reversed the effect of  diminishing zymostenols.
160
 
Moreover, treatment with vitamin E inhibited the cell differentiation and active cell 
death induced by PBPE, Tamoxifen, and 7-dehydrocholesterol, but not 
autophagy.
160, 161
 Together, these data suggest that zymostenol was transformed by 
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oxidation and  the accumulation of sterols alone is enough for induction of 
macroautophagy, whereas apoptosis requires both the sterols accumulation and 
production of reactive oxygen species.
71
  
 
 
Figure 46: Inhibition of cholesterol biosynthesis by different classes of AEBS ligands 
This figure is reproduced from Kedjouar et al.
159
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4.2.3.2  Different classes of AEBS ligands and their link to ChEH 
Several structurally different classes of ligands of AEBS have been identified which 
include Selective Estrogen Receptor Modulators and diphenylmethanes that contain 
an aminoethoxy basic side chain, such as Tamoxifen, 4-OH Tamoxifen and 
raloxifene for the former and DPPE and PBPE for the latter. AEBS has no affinity 
for estrogens or other non-cationic SERMs. Additionally, AEBS has been reported to 
bind to poly-unsaturated fatty acids such as arachidonic acid and docosaheaxaenoic 
acid as well as ring B-oxysterols, for example, 7-ketocholestrol, 6- and 7-
ketocholestanol.
167
 The last oxysterol is an autoxidation product of zymosterol and 
the substrate of D8D7I.
168
 Interestingly, 7-ketocholestrol and 6- and 7-
ketocholestanol are also potent inhibitors of cholesterol epoxide hydrolase 
(ChEH),
169
 a microsomal epoxide hydrolase which catalyzes the trans-hydration of 
cholesterol-5,6-epoxides (5,6-ECs) into cholestane-3β,5α,6β-triol (CT), Figure 47,  
indicating AEBS may be pharmacologically and structurally associated with ChEH. 
Indeed, according to Poirot et al. all AEBS ligands are inhibitors of ChEH and it has 
even been proposed that AEBS and ChEH could be a single entity
170
 since 
experiments indicated that the enzymes which form the AEBS also participated in 
the catalytic activity of ChEH.
171
 The knockdown of either D8D7I or DHCR7 using 
siRNA resulted in partial inhibition of the ChEH activity and the knockdown of both 
D8D7I and DHCR7 enzymes almost completely abolished the hydrolyzing actions 
of ChEH, whereas the co-expression of both D8D7I and DHCR7 fully reconstructed 
the ChEH activities.
171
 Moreover, Poirot et al. demonstrated that the substrates of 
ChEH, 5,6-CEs and its hydration product (CT) are competitive ligands of Tamoxifen 
binding to the AEBS.
171
  Conversely, every AEBS ligand tested inhibited ChEH and 
the higher affinity of these ligands for AEBS, the more potently they inhibit 
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ChEH.
171
 These results clearly show that AEBS and ChEH are very closely related if 
not a single entity.  
 
 
Figure 47: trans-Hydration of 5,6-ECs into CT 
 
It was also demonstrated in the single knockdown experiments that D8D7I and 
DHCR7 had different influences on the kinetic parameters of ChEH activity. The 
Vmax of the enzymatic activity of ChEH was observed to diminish considerably when 
only D8D7I was knocked down, whereas the single knockdown of DHCR7 led to an 
increase of the Km value.
171
  From these data, Poriot et al. suggests that D8D7I may 
have a catalytic role in the ChEH activity, whilst DHCR7 plays an important role in 
regulating and assisting substrate binding.
171
  
 
4.2.3.3 The molecular action of AEBS/ChEH  
ChEH is widely distributed in mammals. It belongs to an epoxide hydrolase family 
which catalyze the hydration of reactive epoxides with water to yield 1,2-diol 
products. Generally speaking, the hydration is energetically more favourable and 
leads to more stable products being formed, however exceptions do exist.
172
  In 
vertebrates, a number of epoxide-hydrolase enzymes have been identified so far 
which includes leukotriene-A4 hydrolase (LTA4H), hepoxilin-epoxide hydrolase 
(HXEH), microsomal epoxide hydrolase (mEH), soluble epoxide hydrolase (sEH) 
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and cholesterol 5,6-epoxide hydrolase. Both LTA4H and sEH are bifunctional 
enzymes with great structural complexity which catalyze not only the epoxide 
hydrolase activities, but also aminopeptidase and phosphate phosphatase activities 
respectively.
173
 If AEBS and ChEH were really a single entity, then it would be a tri-
functional protein complex consisting of two closely related enzymes, D8D7I and 
DHCR-7, as subunits, but is involved in three enzymatic steps in the sterols and lipid 
metabolism. All epoxide hydrolases, except ChEH, have been cloned and 
molecularly characterized. The greater complexity of ChEH probably provides the 
reason why ChEH is the only member of the epoxide hydrolase family whose 
cloning and purification has never been reported before.
173
 
 
The only known substrate of ChEH is cholesterol-5,6-epoxide (5,6-ECs) which can 
exist in two diastereoisomeric forms: cholestan-5α,6α-epoxy-3β-ol (5,6α-CE) and 
cholestan-5β,6β-epoxy-3β-ol (5,6β-CE), Figure 48. The binding of ChEH is highly 
speciﬁc for both 5,6-CEs,  yet the enzyme in liver microsomes from several species 
shows an approximate 2 to 2.5 fold preference for 5,6α-EC over 5,6β-EC under 
physiological pH conditions.
174
  
 
 
Figure 48: Structure of 5,6α-CE and 5,6β-CE 
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4.2.3.4 The stability and toxicity of 5,6-ECs  
Owing to their highly polarized C-O bond and three-membered strained ether ring, 
epoxides in general are quite unstable and react readily with electron rich 
nucleophiles. Some reactive epoxides have been reported to have mutagenic, toxic 
and carcinogenic effects.
175
 An example of these is styrene oxide which is a potent 
alkylating agent that can form a covalent adduct with critical biological targets such 
as DNA and proteins, thus contributing to its mutagenicity and carcinogenicity. Most 
epoxides produced in organisms are, however, of intermediate reactivity and are 
relatively stable at physiological conditions, hence they do not present a serious 
danger to cells and organisms.
175
   
 
Unlike zymostenol which is very sensitive to oxidants,
159
 5,6-ECs are relatively 
stable under physiological conditions
176
 and exceptionally stable under non-catalytic 
chemical conditions.
177
 It was reported that when treating 5,6α-CE and 5,6β-CE with 
2-aminoethanol in refluxing ethanol for 2 days, only 2% of the expected 
aminoethanolic compound was formed from 5,6α-CE and no reaction was observed 
with 5,6β-CE under the same reaction conditions.177 The desired product obtained 
from 5,6α-CE was subsequently increased from the extremely low yield of 2% to an 
unsatisfactory yield of 25% in the presence of a strong Lewis acid (LiClO4) and even 
in these reaction conditions, 5,6β-CE still did not react.177 In contrast to the lower 
reactivity of 5,6β-CE toward nucleophiles being observed, it was reported that at pH 
2, the rate of hydrolysis of 5,6β-EC was approximately six times faster than that of 
5,6α-EC.177 These results highlight a difference in the stability of these two 
diastereoisomers in different pH environments.  
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The hydrolysis of both diastereoisomers of 5,6-CEs by ChEH yields CT as the 
exclusive product.
174
 It was found that CT as well as its further oxidative metabolites 
are mutagenic and cytotoxic and are associated with increased lipid peroxidation. 
5,6-ECs may be derived from the photo oxidation of cholesterol in response to UV 
radiation and fears had been raised over the formation of 5,6-ECs in biological 
systems as cholesterol epoxides were suspected to associate with an increased skin 
cancer risk.
178, 179
 Although the mutagenicity of 5,6-ECs had been examined in 
numerous studies, conflicting results were reported. In vivo, the tumourigenicity of 
5,6-CEs was evaluated in the rat mammary gland  and both disastereosiomers of the 
cholesterol epoxide were demonstrated to be non-tumour promoting agents.
180
 In 
vitro, Smith et al. studied air-aged samples of cholesterol in several strains of 
Salmonella typhimurium and found that 5,6-ECs were not mutagenic, although some  
unidentified autoxidation products of cholesterol were.
181
 This finding was 
subsequently confirmed by Cheng et al. and his group found that CT was instead 
mutagenic and suggested that reactive oxygen species (ROS) might play an 
important role in this eﬀect.182 On the contrary, Sevanian et al. reported that 5,6-CEs 
were weak mutagenic agents at high concentration in Chinese hamster lung 
fibrolasts,
183-185
 with the β isomer being a more potent mutagen than the α isomer. 
The cytotoxicity of 5,6-CEs had also been investigated and compared; it was 
established that the β-cholesterol epoxide was more toxic than its α-cholesterol 
epoxide counterpart.
183, 184
   
 
5,6-ECs are the major autoxidation products of cholesterol.
186
 Interestingly, the 
inhibition of AEBS also leads to accumulation of 5,6-ECs resulting from the 
secondary oxidative metabolites of cholesterol precursors inhibiting ChEH 
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activity.
171
  This finding is in a strong agreement to Poirot et al.’s suggestion that 
AEBS and ChEH is an single entity.
170
 In their studies, they demonstrated that the 
enzymes constituting AEBS are also involved in the catalytic activity of ChEH.
171
 In 
addition, Poirot et al. suggests that it is highly unlikely that 5,6-ECs are directly 
mutagenic and carcinogenic substances themselves as some well-known drugs such 
as Tamoxifen and raloxifene are potent inhibitors of AEBS and lead to accumulation 
of 5,6-ECs.
173, 187
 In fact, several lines of evidence demonstrated that inhibition of 
AEBS and accumulation of 5,6-ECs contribute to the anticancer and 
chemopreventive activities of these compounds.
173
 Tamoxifen inhibits AEBS 
activity in a nanomolar concentration range and is widely used as a treatment or 
prevention of breast cancer, while omega-3 docosahexaenoic acid, also a potent 
inhibitor of ChEH, is a common dietary supplement which was demonstrated to 
increase survival of metastatic breast cancer patients undergoing chemotherapy.
173
 
Consistent with these results was the beneficial effect of DPPE, another potent 
AEBS inhibitor, reported in a phase III clinical trial in which a substantial 
improvement on the overall survival rate was observed in patients co-treated with 
doxorubicin.
173
  
 
The role of ChEH was initially proposed to be a detoxifying enzyme similar to that 
of microsomal epoxide hydrolase,
169
 though this possibility may be ruled out.
171
 As 
opposed to detoxification, the cytotoxicity
183, 185
 and mutagenicity
183, 185
 of CT, 
resulting from the hydrolytic action of ChEH, and its further oxidative products
182
 
were measured to be greater than both the substrates of ChEH in various studies. 
These data indicate that the inhibition of ChEH and CT production as well as its 
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mutagenic metabolites exerts a protective rather than harmful effect on biological 
systems.  
 
4.2.4 Aminoethoxy-1,1-diarylmethanes – another class of selective AEBS ligands  
Diphenylmethane derivatives of Tamoxifen are selective ligands of AEBS that do 
not bind ERs.
34, 157, 188
 DPPE, in particular, has been extensively studied and was 
reported to have a 22-fold weaker affinity than Tamoxifen for AEBS.
189
 In in vitro 
studies, DPPE has been shown to induce apoptosis and inhibit proliferation of 
tumour cells through its binding to AEBS.
160
 DPPE had been developed as far as 
phase III clinical trial testing for the treatment of metastatic/recurrent breast cancer 
before a clear understanding of the mechanism of action was established.
161
 
Although DPPE failed to show any advantage in response rate, response duration 
and progression-free survival, it significantly improved the overall survival rate in 
patients co-treated with doxorubicin.
190
  
 
111, which is the diphenylmethane homologue of Tamoxifen, has also been tested by 
Poirot et al. for its affinity to AEBS. 111 was found to have a slightly higher affinity 
than DPPE, but was still 17 times weaker than Tamoxifen.
189
  In their studies, they 
had also tested a series of other phenoxyphenol derivatives that, too, were also potent 
AEBS ligands.
191
 This class of compounds is certainly worth further investigation 
and consequently 111 and 112 were synthesized. Their syntheses were easily 
achieved by alkylating the commercially available 4-benzylphenol or 4-
phenoxyphenol with 2-chloro-N,N-dimethyl- hydrochloride ethanamine as shown in 
Scheme 50.  
111 
 
 
Scheme 50: The synthesis of analogues of DPPE 
 
Therefore, in addition to the 1,1-diaryldifluorocyclopropyl derivative of Tamoxifen 
and its precursors, the compounds listed in Figure 49 were also sent for biological 
testings.  
 
 
 
 
Figure 49: Structures of the compounds for second round of biological testing.  
 
Graph 5 shows the results for the autophagic assays of those 1,1-diarylmethenes and 
1,1-diarylethenes shown in Figure 49. To our delight, some of the compounds did 
exhibit moderate autophagic activities. Interestingly, all compounds lacking a basic 
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side chain in their structures did not induce autophagy (compound 100 to 102). On 
the other hand, compounds bearing an aminoethoxy side chain (97, 105, 111 and 
112) were potent autophagy inducers, although Tamoxifen was determined to be 
more potent under the same concentrations. The most active compound among the 
aminoethoxy derivatives of Tamoxifen tested was 105, followed by 97; 111 and 112 
were also active (Graph 5), but they were less effective as autophagy inducers and 
appeared to be as equally potent as one another.  
 
 
Graph 5: Measure induction of autophagy of the 1,1-diaryl-methenes and ethenes shown in Figure 49 
using Tamoxifen (Tam) and DMSO as positive and negative controls respectively. 
. 
4.2.5 The importance of aminoethoxy basic side chains for inducing autophagy 
In addition to ERs and AEBS, Tamoxifen  is also reported to bind to other cellular 
targets such as PKC, CaM and ACAT.
34
 However, no correlation between 
diphenylmethanes and other common molecular targets of Tamoxifen has been 
reported, except AEBS. Additionally, the diphenylmethane  derivatives of 
Tamoxifen such as DPPE and PBPE have been demonstrated to bind to AEBS with 
high affinities and specificity and do not affect CaM
192, 193
 and PKC dependent 
26 40 
71 
99 
202 
142 
31 33 33 
156 
109 108 
M
e
d
ia
n
 F
lu
o
re
sc
e
n
ce
 
Treatments 
Autophagy in differentiated THP-1 Cells 
113 
 
pathways
194
 and did not inhibit ACAT.
68
  Therefore, it is highly likely that the 
autophagic effects of both 111 and 112 in THP-1 cells and their difluorocyclopropyl 
analogues are attributed to the binding of AEBS due to the high structural 
similarities between our drug candidates and those well-known AEBS ligands.  
 
A closer inspection of the first and second biological testing data and the structures 
of compounds tested reveals that all aminoethoxy derivatives of Tamoxifen are 
potent autophagy inducers, whereas no autophagic activity was observed in the THP-
1 cell lines with compounds which lack the amino side chains. This indicates that the 
aminoethoxy moiety is a crucial pharmacophore for the induction of autophagic 
activities of Tamoxifen and its derivatives. 
 
Likewise, the presence of a protonatable amine side chain is found to be crucial for 
binding to AEBS, whereas for binding to the ERs it could be very influential to the 
binding affinity, but not essential.
34
 For instance despite 113, Metabolite X and Y of 
Tamoxifen all lacking a protonatable side chain, they still display high binding 
affinities for the ERs (Figure 50). While 113 and metabolite X are 10 times and 2 
times weaker than Tamoxifen respectively, the affinity of Metabolite Y is 
comparable to Tamoxifen for binding to the ERs.
34
 In contrast, metabolite X and 
Metabolite Y of Tamoxifen and the analogue 113 do not exhibit any binding affinity 
for the AEBS.
34
 This finding is consistent to our belief that the autophagic effects of 
our compounds are a result of interaction with the AEBS and not the ERs. 
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Figure 50: Metabolite of Tamoxifen and its analogue 
 
4.2.6 Biological testing results for their affinity to ERs.  
To confirm that that neither the antiestrogenic nor estrogenic activities through direct 
interaction with ERs is responsible for the autophagic effect of our drug molecules, 
an in vitro estrogen receptor competitive immunoassay was conducted on the 
compounds which induced autophagy. The assay works by using an ED-steroid 
hormone conjugate which could be recognized by the estrogen receptor.  The ED 
hormone is able to compete with ligands for the binding site of estrogen receptor 
binding site. In the presence of ER ligands, the binding sites are occupied by the free 
ligands and the free ED-conjugate complements with Enzyme Acceptor to form an 
active enzyme that can hydrolyze substrates to produce luminescent signals. In the 
absence of ER ligands, the ED-conjugates are bound to the ERs and are unavailable 
for complementation, leading to low luminescent signals. The strength of these 
signals is proportional to how strongly a ligand can compete for binding to the 
estrogen receptors. The signals produced are then compared with the standards with 
known concentration of 17β-estradiol.  
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Graph 6 shows the relative binding affinity of Tamoxifen and our compounds 97, 
111 and 112 in comparison to 17β-estradiol. As illustrated, Tamoxifen displays a 
binding affinity in the same order of magnitude as 17β-estradiol (100 nm of 
Tamoxifen vs S8), whereas our compounds are several orders of magnitude lower 
than that of Tamoxifen and 17β-estradiol (10 µM vs S4).  
 
Despite 1,1-diarylethylene 105 being the most active compounds among the series, it 
would not be suitable as a drug candidate and is of little medicinal interest. The 
presence of a terminal alkene moiety is susceptible to electrophilic attack by 
chemical species or oxidative metabolism by the cytochrome P450 enzyme and they 
would be chemically and enzymatically very unstable and thus, it was not tested for 
its binding affinity to ER.  
 
 
Graph 6: Estrogen receptor competitive binding assay of Tamoxifen (Tam) and compound 97, 111 
and 112 shown in Figure 49 using 17β-estradiol (S1 – S8) as positive dose dependent controls.  
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4.3 Biological testing result for other aminoethoxy diarylmethyl 
analogues of Tamoxifen synthesized for this project  
Among all the different classes of compounds tested in our previous biological 
analyses, only the derivatives of Tamoxifen with an aminoethoxy side chain are 
potent inducers of autophagic effects. Thus, we explored the structure-activity 
relationship of a few more analogues based on our previous findings. Scheme 51: 
Other phenoxyphenyl- and phenoxyphenoxyethanamines synthesized and biologically tested. and 
Scheme 52: Other 1,1-diaryldifluorocyclopropylethanamines synthesized and biologically 
tested.show other diarylaminoethoxy compounds that have been synthesized for this 
project and their preparations are similar to their related analogues reported 
previously.  
 
Scheme 51: Other phenoxyphenyl- and phenoxyphenoxyethanamines synthesized and biologically 
tested. 
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Scheme 52: Other 1,1-diaryldifluorocyclopropylethanamines synthesized and biologically tested. 
 
As illustrated in Graph 7, many of the aminoethoxy derivatives of Tamoxifen 
shown in Scheme 51 and 52 induced autophagy to various extents. These data 
confirmed our previous hypothesis that the presence of a basic aminoethoxy side 
chain is an important pharmacophore for induction of autophagy. 
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Graph 7: Measure induction of autophagy of our drug candidates shown in Scheme 51 and Scheme 52 
using Tamoxifen (Tam) and DMSO as positive control and negative controls respectively. 
 
The most active among the series were the difluorocyclopyl analogues 121 to 123 
which were found to be consistently more potent than any other phenoxyphenolic 
(113 – 116) and phenoxybenzyl (117 – 120) derivatives of Tamoxifen. 113 and 114 
are DPPE and PBPE respectively that have been extensively studied by Poirot et al. 
and others for their affinity binding to AEBS and induction of autophagic 
activities.
161
 They were once again proven to be potent inducers of autophagy in our 
independent studies. Interestingly, PBPE was the most potent AEBS ligand in the 
1,1-diphenylmethane series reported by Poirot et al. and was found to have at least a 
3-5 times higher affinity for AEBS than DPPE.
171
 However, their affinity for AEBS 
did not seem to translate directly into their induction of autophagy in our biological 
assays as DPPE was found to be a more potent inducer than PBPE. Moreover, 
analogues with a morpholine moiety attached to the aminoethoxy side chain, 116, 
120 and 124, were found to be relatively inactive, implying that the presence of an 
additional hydrogen-acceptor is probably unfavourable. This finding is in contrast to 
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Poirot et al.’s result who found 116 and 120 to be more active than DPPE, although 
they studied for their affinity to AEBS and not for their induction of autophagy.
191
   
 
If the molecular target of our compounds is AEBS, then it is perfectly sensible to 
expect a positive correlation between the binding affinity of our compounds for 
AEBS and the induced autophagic response, unless the compounds are cytotoxic to 
cells or autophagy is overdone which could lead to either apoptosis or autophagic 
cell deaths. We have tested the morpholine analogue 124 against Tamoxifen and 
DMSO vehicle again since the difluorocyclopropyl series is more potent than the 
derivatives of benzylphenol or phenoxy phenol. However, similar negative results 
were obtained for the morpholine analogues confirming that the results were not due 
to practical/experimental errors (Graph 8). 
 
 
Graph 8: Measure induction of autophagy of 125 using DMSO and Tamoxifen as controls 
 
Tamoxifen is at least equal if not more potent than any of the compounds we 
synthesized and tested. Nevertheless, its potency as an autophagic inducer is not 
reflected in our biological assay when cells were treated with high dose of 
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Tamoxifen. Tamoxifen was observed to be cytotoxic to cells at high doses (>5  M), 
but DPPE, PBPE or our novel aminoethoxy difluorocyclopropanes were not 
cytotoxic. The relatively low autophagic activity detected at 10  M treatment of 
Tamoxifen (Graph 7) was probably due the cytotoxicity of Tamoxifen on the 
differentiated THP-1 cells, making direct comparison of data rather difficult or 
unreliable as the concentrations for the treatments of Tamoxifen have to be within 
low and narrow ranges.  
 
As the difluorocyclopropyl compounds simulate the highest level of autophagy 
responses, they were further evaluated against Tamoxifen and DPPE at different 
dosages. Graph 9 demonstrates clearly that Tamoxifen, DPPE and the 
difluorocyclopropanes promoted induction of autophagy in a concentration-
dependent manner.  
 
 
Graph 9: Treatment of Tamoxifen (Tam) and its analogue induce autophagy in a concentration-
dependent manner, DMSO was used as the negative control. 
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In conclusion, we have synthesized a wide range of structurally different analogous 
of Tamoxifen and have subsequently tested them for their autophagy inducing 
abilities, of which some display the desired autophagic activity comparable to 
Tamoxifen.  We believe that the presence of an amioethoxy basic side chain in 
conjunction with a diaryl backbone were essential pharmacophores for the induction 
of autophagy as compounds lacking a basic side chain in their structures did not 
induce autophagy. Additionally, neither the antiestrogenic nor estrogenic activity is 
responsible for the autophagic effect of our drug candidates, as they did not bind to 
estrogen receptor. Tamoxifen was observed to be cytotoxic to cells at high doses 
(>5  M) and this toxicity is not observed with our drug molecules. Based on the 
results of ours and others in the literature, we propose that our novel aminoethoxy 
difluorocyclopropanes may be AEBS inhibitors.  
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Chapter 5 Summary for Recent Development on 
AEBS/ChEH and Future Work 
5.1 Recent development on AEBS/ChEH  
5.1.1 Metabolites of 5,6 ECs   
In addition to cholestane-3β,5α,6β-triol (CT), several other common metabolites of 
cholesterol-5,6-epoxides (5,6-ECs) have been identified and some display interesting 
pharmacological properties. 5,6-ECs have been reported to be sulfated into 5,6-EC-
3β-sulfate by sulfatase SULTSB1b (Figure 51), with 5,6α-EC having higher activity 
than 5,6β-EC.195 Interestingly, 5,6α-EC-3β-sulfate, but not 5,6β-EC-3β-sulfate, is an 
antagonist of alpha and beta liver receptors (LXRα and LXRβ) and was reported to 
contribute to the induced cells differentiation and apoptosis in breast cancer cells by 
Tamoxifen.
196, 197
  
 
Additionally, the 3β-hydroxyl group on ring A can be esterified by cholesterol 
acyltransferases to give 5,6-EC-3β-fatty acid ester in human sera (Figure 51). 
Besides CT and its metabolites, cholesteryl esters were also found to be associated 
with cancer development
196, 198
 and these findings may have contributed to the 
impression that the 5,6-ECs were direct-acting mutagens.
185
  
 
3β-5α-Dihydroxycholestan-6β-yl-S-glutathione (CDO-3β,5α-6β-S-GST) is another 
common metabolite of 5,6-ECs reported which is synthesized by the enzymes S-
glutathione transferases (GSTs) in the rat liver (Figure 51).
199
 It is not known 
whether the product of this addition reaction has any significant biological 
properties, but the primary role of GSTs is to detoxify electrophilic compounds by 
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catalyzing the conjugation of electrophilic substrates to glutathione,
200
 thus the 
formation of CDO-3β,5α-6β-S-GST may offer a more water soluble product which 
could be more readily eliminated than 5,6-ECs with high lipid solubility.  
 
 
Figure 51: The known metabolite of 5,6-ECs 
This figure is reproduced from Poirot et al
 168
 
 
5.1.2 The discovery of DDA and its pharmacological properties  
Recently, Poirot et al. also reported the discovery of 5α-hydroxy-6β-[2-(1H-
imidazol-4-yl)ethylamino]cholestan-3β-ol (DDA) in mammal tissues and normal 
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cells which is formed by enzyme catalysed conjugation of 5,6α-EC and histamine 
(His) (Figure 52).
170
 DDA is a highly potent selective inhibitor of AEBS/ChEH, 
although the enzyme involved in the biosynthesis of DDA has yet to be identified.  
 
 
Figure 52: The structure of DDA 
 
AEBS was earlier described by Brades et al. as having a histamine or histamine-like 
binding cavity. DPPE, a selective ligand of AEBS, was found to compete for the 
histamine binding site and its structure is very similar to the aminoethyl ether groups 
of antihistamines.
194, 201
 Histamine binds to AEBS,
170
 so do the antagonists of 
histamine receptors such as hydroxyzine and phenyltoloxamine (Figure 53), of 
which the former was demonstrated to have affinity for AEBS approximately equal 
to DPPE,
201
 and the latter is effectively a regio-isomer of DPPE.  
 
 
Figure 53: The structure of histamine antagonists: hydroxyzine and phenyltoloxamine. 
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Cholesterol epoxides are also competitive ligands of Tamoxifen binding to AEBS.
171
 
Therefore, DDA was first chemically synthesized by Poirot et al. based on the 
hypothesis that CEs and histamine may be concentrated at the AEBS binding site. 
He postulated that a ring-opening reaction of the electrophilic CEs by the 
nucleophilic histamine may be possible under proximity-induced catalysis due to the 
two substrates being spatially close to each other.
189, 202
  
 
This hypothesis was found to be correct as DDA was detected in many mammal 
tissues at a concentration ranging from approximately 50 ng per gram of tissue for 
mouse brain to 300 ng per gram of tissues for mouse liver.
170
  In addition, DDA was 
detected in human plasma and fetal bovin serum (FBS) in the several nM 
concentration ranges, implying that DDA was present in the circulation.
170
 In 
comparison however, DDA was not detectable in all of the human or mouse tumour 
cells tested by Poirot et al. who suggested a possible down regulation of DDA in 
tumour cells may occur as opposed to normal cells.
170
  
 
Poirot et al. then went on to demonstrate that DDA is synthesized through an 
unidentified enzyme which could be found in mouse brain, a tissue reported to be 
rich in AEBS.
203
 They incubated 5,6α-EC and His with brain homogenate and 
observed the transformation of 5,6α-EC and His into DDA.170 The presence of an 
active DDA synthase in the brain homogenate was crucial for the transformation and 
if the enzyme was denatured by boiling or treating the brain homogenate with 
pronase, no reaction would occur.
170
 Furthermore, the DDA synthase seems to be 
highly specific for 5,6α-EC as 5,6β-EC was found to be inactive under similar 
treatment (Scheme 53).
170
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Scheme 53: Enzyme catalyzed formation of DDA 
 
In in vitro studies, DDA was shown to induce tumour cell differentiation in P19, 
U937 and SK-Mel-28 cell lines at 1 µM, a concentration 5 to 20 fold lower than that 
of Tamoxifen, PBPE and all trans-retinoic acid (ATRA) respectively.
189
 
Additionally, DDA was demonstrated to have a high potency to kill tumour cells and 
was active against a range of different lines tested at the same micromolar 
concentration range.
189
 In in vivo studies, DDA also proved to be effective against 
cancers.  Mice crafted with melanoma (B16F10) and mammary (TS/A) cells were 
treated with DDA and such treatments led to significant prohibition of tumour 
growth and improved animal survival rates of 40% (B16F10) and 60% (TS/A) at day 
50 compared to none in the control groups.
170
 The high anti-tumour activity of DDA 
demonstrated by in vivo studies suggests that DDA may have clinical importance in 
the treatment and prevention of cancers. 
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5.1.3 Other synthetic 5,6α-epoxysteroids reported 
Along with DDA, Poirot et al. also synthesized a range of 5,6α-epoxysteroids from 
various natural amines and tested their biological activities.  The most active 
compound among the series after DDA was DDB. Interestingly, DDA is a highly 
potent inhibitor of ChEH, but the regioisomer of DDA, C17 does not inhibit ChEH 
(Figure 54).
170
 In addition, C17 was found to be only weakly cytotoxic and DDB 
was not toxic to cells up to 20 µM for 72 h, indicating the nature of the amine side 
chains play an important role in the biological properties of these cholesterol 
derivatives.
189
   
 
 
Figure 54: The structures of DDB and C17 
 
Although DDB was found not to be cytotoxic against tumour cells at low 
concentration, it was shown to induce dendrite outgrowth and cell differentiation of 
the P19 into neurons at as low as 100 nM concentration.
189
 The ability of DDB to 
induce neutrite outgrowth was also tested in SH-SY5Y and U87 human cells as well 
as mouse Neuro2A, in all of which DDB was shown to induce comparable neurite 
outgrowth at a concentration approximately 20-fold and 400-fold lower than that of 
ATRA and docosahexaenoic acid (DHA), respectively.
189
 These results demonstrate 
127 
 
the potential use of DDB as a neurotropin for the treatment of neurodegenerative 
disorders such as Alzheimer’s and Parkinson’s diseases.189  
 
5.2 Summary for our understanding of Tamoxifen and AEBS/ChEH and 
the important findings in our project.  
In various mice models, our collaborators, Grainger et al. have demonstrated that 
Tamoxifen inhibited atherosclerosis by suppressing the diet-induced formation of 
lipid lesions in the aorta.
48, 55
 Tamoxifen is a potent inducer of autophagy and 
autophagy is believed to have beneficial effects for atherosclerosis and plague 
progression, possibly by degrading damaged intracellular organelles, thereby 
preventing oxidative injuries and cellular distresses.
57
 However, Tamoxifen is a well-
known multi-targeting drug and it is not clear which molecular targets of Tamoxifen 
is/are responsible for the induction of autophagy and the cardioprotective effects of 
Tamoxifen. In addition, the estrogenic activity of Tamoxifen in the endometrium 
cells is linked to an increased risk of  ulcerous cancers.
19
 Therefore, the development 
of more selective autophagy inducers is needed if they are ever to become 
medicinally useful in the treatment or prevention of cardiovascular diseases.  
 
We started our project based on the extensive research and findings of Magarian et 
al. who had demonstrated that the dichlorocyclopropyl analogues of Tamoxifen were 
pure antiestrogens, with very interesting anti-cancer and anti-tubulin properties.
75-77, 
79, 81-83, 149, 204
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A number of those diaryldichlorocyclopropanes had been synthesized in racemical 
form and as we attempted to develop a synthetic route for their asymmetric 
synthesis, we found out the diaryldichlorocyclopropanes were not particularly stable 
and degraded easily under normal handling conditions. As a result, we abandoned 
the asymmetric synthesis of diaryldichlorocyclopropane and moved on to try to 
synthesize the difluorocyclopropyl analogues instead since it was believed that the 
relative stronger C-F bond may offer greater stability.  
 
Methods for the synthesis of gem-difluorocyclopropanes are extremely limited, with 
the vast majority of the reactions reported involving the  [2+1] cycloaddition of 
difluorocarbene to alkenes.
86
 Additionally, the difluorocarbene is the least reactive 
dihalocarbene and thus the synthesis of difluorocyclopropyl analogues of Tamoxifen 
from unreactive olefins, such as stilbenes, is particularly challenging. Having 
attempted to generate the difluorocarbene using various methods, we found that 
TMSCF3 is probably one of the most effective difluorocarbene precursors reported to 
date. Not only does TMSCF3 offer many advantages such as low toxicity, 
commercial availability and mild reaction conditions, but the catalyst NaI is also 
inexpensive, reliable and easy to handle. However, the difluorocarbene generated 
under the various reaction conditions reported by Hu et al.
205
 is only of moderate 
reactivity and does not transform the electron-deficient diarylethenes to their 
prospective difluorocyclopropanes at all. In our laboratory, we have developed two 
alternative methods based on Hu et al.’s original finding which provides the desired 
diaryldifluorocyclopropanes without the use of highly toxic Cd(CF3)2, the only 
reagent ever reported to date to convert cis-stilbene to its difluorocyclopropane 
analogue. We discovered that microwave-assisted difluorocyclopropanation can 
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enhance the reactivity of the difluorocarbene generated using TMSCF3 and allows 
rapid transformation of various olefins to their corresponding difluorocyclopropanes 
in just under 20 minutes. Although the conversion was not particularly impressive 
for stilbenes (~20%), it was very effective for more reactive and electron-rich 
olefins, such as styrene, with conversion as high as >95% (as determined by 
1
H 
NMR spectroscopy of the crude reaction mixtures). We also accidently discovered 
that the iodine ion can attack TMSCF3, giving 
-
CF3 which subsequently decomposes 
to :CF2 and reacts with alkenes slowly at room temperature. We observed that large 
amount of gases were produced, leading us to believe that 
-
CF3 can deprotonate 
CH3CN to give HCF3 as a gaseous by-product as the reactions proceeded. This belief 
is supported by the findings of other researchers who reported the extremely basic 
nature of trifluoromethyl anion and its ability to abstract a proton from CH3CN.
135
 
The loss of trifluoromethyl anions and formation of HCF3 can be limited by 
performing the difluorocyclopropanation in sealed pressure tubes. Although slow, 
the room-temperature difluorocyclopropanation method is particularly suitable for 
unstable difluorocyclopropanes such as those derived from cis-stilbene in which the 
energy barrier for isomerisation is lower than that for difluorocyclopropanation. Any 
input of energy would cause the cis-stilbene and its analogues to isomerise to their 
trans-counterpart, making the stereoselective synthesis of 
diaryldifluorocyclopropanes very difficult to achieve at elevated temperatures. Both 
microwave-assisted and room-temperature difluorocyclopropanation have their own 
advantages and disadvantages and it would be interesting to try these methods on a 
wider range of alkenes and determine their efficacies and potential applications.  
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A number of derivatives of Tamoxifen have been synthesized and tested for this 
project, yet only compounds whose structures were similar to selective ligands of 
AEBS, such as DPPE and PBPE, induced autophagic responses. DPPE and PBPE 
have been demonstrated to induce autophagy potentially through disruption in 
cholesterol biosynthesis pathway and induction of sterol accumulation.
161
 Therefore, 
it appears that our drug candidates are also selective ligands of AEBS and the 
autophagic effect of our compounds is as a result of inhibition of AEBS and 
cholesterol synthesis on the basis of high structural similarities between our 1,1-
diaryldifluorocyclopropyl and 1,1-diarylmethylene compounds with those well-
known AEBS ligands. 
 
Furthermore, we found that the presence of an aminoethoxy basic side chain is 
crucial for induction of autophagic activities and this finding is consistent with the 
fact that a basic side chain is also important for binding to AEBS.
34
 We were able to 
confirm that DPPE and PBPE were potent autophagic inducers in our independent 
study, although not analogues with a morpholine moiety attached to the aminoethoxy 
side chain. The morpholinyl derivatives MBPE should have also induced autophagic 
activity if they were high-affinity AEBS ligands as reported by Poirot et al.
191
 and 
this inconsistency in our findings deserve further investigation. Moreover, our novel 
aminoethoxy difluorocyclopropanes were found to be consistently more active than 
any of the derivatives of diarylmethane in our biological assay. Most importantly, we 
have demonstrated that our drug candidates stimulate autophagic response through 
an estrogen receptor independent pathway as they do not bind to the ERs.  
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5.3 Other molecular targets of diphenylmethanes 
In addition to cholesterol 5,6-epoxide hydrolase, a number of other mammal epoxide 
hydrolases and have also been identified and studied which includes hepoxilin 
epoxide hydrolase (HXEH), soluble epoxide hydrolase (sEH), microsomal epoxide 
hydrolase (mEH) and leukotriene-A4 hydrolase (LTA4H).  
HXEH catalyses the hydrolysis of hepoxilin A3 to trioxilin A3 (Figure 55). HXEH 
was first reported by Lee et al. who isolated the epoxide hydrolase from rat liver 
cytosol and described it as being different from other epoxide hydrolases based on its 
apparent molecular weight and specific activity for hepoxilin A3 over other epoxides 
such as leukotriene A4 and styrene oxide. However, a recent study showed that 
HXEH and sEH are actually the same enzyme.
206
  
 
 
Figure 55: The substrate and product of HXEH hydrolase 
 
sEH is a bifunctional enzyme which carries out epoxide hydrolysis activity in the C-
terminal domain and a phosphate ester hydrolysis activity in the N-terminal domain 
(Figure 56). sEH seems to play a major role in the in vivo metabolism of endogenous 
lipid epoxides. Many of these lipids are signaling molecules with various functions 
in physiological regulations such as cell proliferation, nociception, inflammation and 
control of blood pressure.
207
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Figure 56: Reactions catalyzed by soluble epoxide hydrolase 
 
sEH hydrolyzes epoxyeicosatrienoic acids (EETs) and  to dihydroxyeicosatrienoic 
acids (DHETs) which are signaling lipids derived from arachidonic acid by the 
metabolic action of the Cytochrome P450 epoxygenase (Figure 57).
208
 EETs exhibit 
vasorelaxant, anti-inflammatory and cardioprotective properties, but their hydrolytic 
metabolites, DHETs, are biologically less active.
209
 Therefore, sEH is considered a 
potential therapeutic target for cardiovascular diseases. Indeed, the inhibition of sEH 
has been demonstrated to have anti-hypertensive and anti-inflammatory and 
cardioprotective effects.
209
 In addition, sEH inhibition also leads to neuroprotection 
and pain reduction.
176
  
 
Arachidonic acid is the precursor of the leukotrienes that is released from 
membranes by Cytosolic Phospholipase A2 (cPLA2), and further transformed by 5-
lipoxygenase to give epoxide leukotriene A4 (LTA4), Figure 58. LTA4 is the 
substrate of LTA4H which is a bifunctional enzyme that catalyzes not only the 
hydrolysis of epoxide LTA4, but also aminopeptides. However, no natural peptide 
substrate has been identified yet and it is speculated that LTA4H may hydrolyze 
peptides associated to inflammatory and host defense.
211, 212
 In respect to its epoxide 
hydrolase activity, LTA4H hydrolyses LTA4 to the respective diol LTB4 (Figure 58) 
which is a powerful pro-inflammatory mediator.
213
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Figure 57: The metabolite of arachidoonic acid, EETs and DHETs 
This figure is reproduced from the work of Imig.
210
 
 
LTB4 is a potent inducer of chemotaxis that induces recruitment and activation of 
neutrophils to areas of tissue damages, mediating inflammatory responses by binding 
to BLT1 and BLT2 which are G-protein-coupled receptors.
211
 Genetic data in 
animals and humans have linked the LTB4 to cardiovascular disease and variants in 
the LTA4H gene have been associated with  vulnerability to asthma.
214
 Thus, 
compounds inhibiting LTA4H are potentially beneficial in treatment of chronic, 
autoimmune-driven inflammatory diseases. Indeed, some selective LTA4H inhibitors 
have been demonstrated to be effective in treating asthma, inflammatory bowel 
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disease and arthritis in various preclinical models, showing promising therapeutic 
effects and potential use for treating multiple inflammatory indications.
214
 
Figure 58: The formation and metabolic fate of LTA4 
 
Interestingly, many of the aminoethoxy-benzylphenols and aminoethoxy-
phenoxyphenols synthesized and tested in our biological assays have also been 
demonstrated to be potent inhibitors of LTA4H with IC50 in the micro- to nano-molar 
ranges.
213
 
 
The microsomal epoxide hydrolase (mEH) catalyses the hydrolysis of a large 
number of structurally different, highly reactive xenobiotic epoxides, such as cis-  
and trans-stilbene oxide, butadiene monoxide and benzo[a]pyrene-4,5-oxide to 
vicinal diols (Figure 59). It is generally regarded as a key detoxifying enzyme since 
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most of the corresponding diols are less toxic or mutagenic than the epoxide 
substrates and hence its inhibition is considered as not desired.
176
  
 
Interestingly, MBPE, another AEBS ligand reported by Poirot et al. (Figure 44), and 
Tamoxifen have been reported to inhibit the catalytic activity of mEH, and styrene 
oxide, a substrate of mEH, was found to be a competitive inhibitor of Tamoxifen 
binding to AEBS/ChEH.
215
 Certain series of substrates of both epoxide hydrolases 
do share striking resemblances, in particular, the aromatic moiety in the 
diphenylmethyl series of AEBS/ChEH ligands and some classes of mEH ligands 
such as stilbene, benzophenone and chalcone.
215
 Therefore, it is believed that the 
aromatic moiety of AEBS ligands may affect the catalytic activity of mEH.
215
  
 
 
Figure 59: Model substrates and products of microsomal epoxide hydrolase 
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Tamoxifen has been shown to be a carcinogen in rat tissues by inducing the 
formation of DNA and protein adducts and this carcinogenicity of Tamoxifen may 
be related to the inhibition of mEH.
215
 It has been speculated that Tamoxifen may 
inhibit the hydrolysis of its own metabolic epoxide derivatives or other toxic epoxide 
substrates of mEH.
215
 
The fact that MBPE has been demonstrated to bind to mEH,
215
 AEBS/ChEH
191
 and 
LTA4H
213
 with various affinities, implies that these EHs may have similar structural 
characteristics to one other. However, while studies of amino acid sequences of mEH 
and sEH suggest these two enzymes are distantly related enzymes that have been 
derived from a common ancestral protein, the LTA4H hydrolase is distinct.
216
 In 
addition, from the single knockdown experiments of D8D7I and DHCR7, the 
subunits of AEBS/ChEH, it is believed that AEBS/ChEH is structurally unrelated to 
the mEH and sEH.
173
  
 
5.4 Future work 
Poirot et al. are aware of the fact that selective ligands of AEBS/ChEH may also 
bind to other epoxide hydrolases
215
 and this could be the reason why DDA has been 
tested on both sEH and mEH.
217
 In their studies, DDA was found to have no affinity 
for those epoxide hydrolases.
217
 However, DDA is a derivative of 5,6-ECs and 5,6-
ECs are the only known natural substrates of cholesterol epoxide hydrolase, hence it 
is not surprising that DDA binds to AEBS/ChEH with high affinity and specificity.  
 
The aromatic moiety in diarylmethane ligands of AEBS/ChEH is thought to mimic 
the steroid backbones of 5,6-ECs,
218
 but it is also thought to affect the catalytic 
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activities of mEH.
215
 In addition, the diphenylmethane analogues of Tamoxifen have 
also been reported to bind to the LTA4H with high potency. 
 
It is not known whether our drug candidates are inhibitors of mEH or sEH or even 
AEBS/ChEH. We suggest that our drug candidates are inhibitors of AEBS/ChEH 
based on the large amount of well-performed scientific studies done on the ligands of 
AEBS/ChEH and the similarities in structures of our compounds with these ligands. 
In addition, it has been established in our project that our compounds do induce 
autophagy potently and in a dose-dependent manner. Selective ligands of 
AEBS/ChEH have also been reported to induce autophagic activities by others,
71, 161, 
219
 whereas we are not aware of any connection between inhibition of LTA4H or 
mEH/sEH/HXEH and induction of autophagy. Moreover, we found that ligands 
without a basic side chain do not induce autophagy which is consistent with the 
report that the presence of a basic side chain is also crucial for binding to 
AEBS/ChEH.
34
  
 
While the inhibition of LTA4H may offer potential benefits in treating acute and 
chronic inflammatory diseases such as asthma and cardiovascular diseases, inhibiting 
the mEH could be extremely detrimental. Thus, further research is needed to find out 
whether our compounds are potent inhibitors of any other known epoxide 
hydrolases. This could be achieved by testing the relative binding affinities of our 
compounds for each epoxide hydrolase. Additionally, high-affinity and high-
selectivity ligands of each epoxide hydrolase should also be tested for their ability to 
induce autophagic activities. Thereby, even if our compounds bind to one or more 
epoxide hydrolases, we may be able to determine which epoxide hydrolase(s) is (are) 
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responsible for the autophagic effects observed in our biological assays. If our 
compounds do bind to more than one epoxide hydrolases, further lead optimization 
is necessary for high selectivity.  
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Chapter 6 Experimental  
6.1 General Experimental  
1
H NMR and 
13
C NMR spectra were recorded on Bruker Avance DPX 300, 400 and 
500 MHz spectrometers. Chemical shifts are reported in parts per million (ppm), and 
coulpling constants (J) are given in Hertz to the nearest 0.5 Hz. Multiplicities are 
given as s = singlet, d = doublet, t = triple, q = quartet, m = multiplet, br = broad.  
Infrared spectra were measured neat using a Perkin Elmer Spectrum 100 FT-IR 
machine.  
Melting points were obtained using a Stuart STMP10 apparatus and are uncorrected.  
Optical rotations were measured on an optical activity AA 1000 polarimeter set at 
589 nm. [α]D values are expressed in units of 10
-1 
degree cm
2
 g
-1
.  
High resolution mass spectra (HRMS) data were obtained with the help of Dr Lijang 
Song and Mr Philip Aston on a Bruker micro-TOF ESI spectrometer.  
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Typical procedure for the synthesis of gem-dichloro-
diphenyl/triphenylcyclopropanes  
 
cis-1,1-Dichloro-2,3-diphenylcylcopropane (1) 
 
To a solution of cis-stilbene (0.42 g, 2.3 mmol, 1.0 equiv.) in chloroform (4.7 mL, 58 
mmol, 25 equiv.) cooled on an ice bath was added benzyltrimethylammonium 
bromide (12 mg, 52 µmol, ~2 mol%) with stirring. A solution of 50% aqueous 
NaOH (2.3 mL, 29 mmol, 12.5 equiv.) was then added dropwise under rapid stirring. 
The reaction mixture was further stirred at room temperature overnight before the 
solvent was removed in vacuo and water was added. The aqueous layer was 
extracted with diethyl ether (3 x 15 mL), dried over MgSO4, filtered and concentrated 
to give an oil. The product was purified by standard silica chromatography (eluent: 
9:1 hexane:CH2Cl2) to give 0.54 g (88%) of 1 as a very pale-yellow oil which 
solidified upon storage at 0 ºC, mp 49 – 51 ºC (lit.,75 mp 51 – 52 ºC);  IR (neat) 
υmax/cm
-1
 3061-3031 (C-H), 1603 (C=C), 1497, 805, 752, 695 (Ar-H); 
1
H NMR (400 
MHz, CDCl3) δ ppm 7.35-7.13 (6H, m, Ar-H), 7.05-7.00 (4H, m, Ar-H), 3.30 (2H, s, 
CHCCl2); 
13
C NMR (101 MHz, CDCl3) δ ppm 132.1 (ipso Ar-C), 131.0, 127.9, 
127.4 (Ar-C), 65.3 (CCl2), 39.4 (CHCCl2). Mass spectrometric data were not 
obtainable via ESI mass spectrometry. 
This compound is known and has previously been reported with 
1
H NMR 
spectroscopic data consistent with those reported here.
75
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(±)-cis-1,1-Dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane (2) 
 
Prepared in a similar manner to compound 1, the reaction of cis-4-methoxystilbene 
(0.51 g, 2.4 mmol, 1.0 equiv.) with CHCl3 (4.9 mL, 60 mmol, 25 equiv.) and a 
solution of 50% aqueous NaOH (2.4 mL, 30 mmol, 12.5 equiv.) in the presence of 
benzyltrimethylammonium bromide (13 mg, 56 µmol, 2 mol%) gave 0.39 g (55%) of 
2 as a yellow oil which solidified upon storage at 0 ºC, mp 56 – 58 ºC (lit.,220 mp 59 
– 60 ºC); IR (neat) υmax/cm
-1
 3032 – 2836 (C-H), 1611 (C=C), 1512, 802, 739, 697 
(Ar-H), 1246 (C-O); 
1
H NMR (400 MHz, CDCl3) δ ppm 7.29-7.16 (3H, m, Ar-H), 
7.08-6.98 (2H, m, Ar-H), 6.96-6.89 (2H, m, Ar-H) , 6.79-6.73 (2H, m, Ar-H), 3.75 
(3H, s, OCH3), 3.24 (2H, s, CHCCl2); 
13
C NMR (101 MHz, CDCl3) δ ppm 158.9 
(ArCOMe), 132.1, 123.9 (ipso Ar-C), 132.0, 131.0, 128.0, 127.3, 113.4, (Ar-CH), 
65.5 (CCl2), 55.3 (OCH3), 39.2, 38.9 (CHCCl2). 
This compound is known and has previously been reported with 
1
H NMR 
spectroscopic data consistent with those reported here.
220
  
 
 (±)-trans-1,1-Dichloro-2,3-diphenylcylcopropane (3) 
 
 
Prepared in a similar manner to compound 1, the reaction of trans-stilbene (0.32 g, 
1.8 mmol, 1.0 equiv.) with CHCl3 (3.6 mL, 45 mmol, 25 equiv.) and a solution of 
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50% aqueous NaOH (1.8 mL, 23 mmol, 12.5 equiv.) in the presence of 
benzyltrimethylammonium bromide (9 mg, 39 µmol, ~2 mol%) gave 0.39 g (69%) 
of 3 as a yellow oil which solidified upon standing for overnight, mp 38 – 40 ºC, 
(lit.,
221
 mp 39 – 40 ºC); IR (neat) υmax/cm
-1 
3062-3031 (C-H), 1497 (Ar); 
1
H NMR 
(400 MHz, CDCl3) δ ppm 7.43-7.26 (10H, m, Ar-H), 3.25 (2H, s, CHCCl2); 
13
C 
NMR (101 MHz, CDCl3) δ ppm 134.6 (ipso Ar-C), 129.0, 128.6, 127.9 (Ar-CH), 
65.4 (CCl2), 39.8 (CHCCl2). Mass spectrometric data were not obtainable via ESI 
mass spectrometry. 
These data were consistent with those previously reported.
221
  
 
 (±)-1,1-Dichloro-2,2-diphenyl-3-phenylcylcopropane (4) 
 
 
Prepared in a similar manner to compound 1, the reaction of triphenylethylene (0.51 
g, 2.0 mmol, 1.0 equiv.) with CHCl3 (4.0 mL, 40 mmol, 25 equiv.) and a solution of 
50% aqueous NaOH (2.0 mL, 25 mmol, 12.5 equiv.) in the presence of 
benzyltrimethylammonium bromide (9 mg, 39 µmol, 2 mol%) gave 0.55 g (81%)  of 
4 as a pale-yellow solid, mp 102 - 103 ºC, (lit.,
222
 mp 105 – 107 ºC); IR (neat) 
υmax/cm
-1 
3062-3030 (C-H), 1601 (C=C), 1493, 784-746, 694 (Ar-H); 
1
H NMR (400 
MHz, CDCl3) δ ppm 7.45-7.43 (2H, m, Ar-H), 7.24-7.09 (11H, m, Ar-H), 6.92-6.90 
(2H, m, Ar-H), 3.48 (1H, s, CHCCl2); 
13
C NMR (101 MHz, CDCl3) δ ppm 143.6, 
136.5, 133.4 (ipso, Ar-C) 131.3, 130.9, 128.8, 128.8, 128.3, 127.8, 127.5, 127.3 (Ar-
CH), 69.9 (CCl2), 49.2 (Ph2CCCl2CH), 46.0 (Ph2CCCl2CH).  
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Mass spectrometric data were not obtainable via ESI mass spectrometry. 
This compound is known and has previously been reported with 
1
H NMR 
spectroscopic data consistent with those reported here.
222
  
cis-β-Bromosytrene (6) 
 
Cinnamic acid (7.53 g, 50 mmol, 1.0 equiv.) was dissolved in chloroform (70 mL), 
and a solution of bromine (3.0 mL, 0.59 mmol, 1.2 equiv.) in chloroform (5 mL) was 
added dropwise with stirring. The reaction mixture was stirred overnight before the 
solvent was evaporated to dryness. To the residues, acetone (90 mL) and K2CO3 
(10.83 g, 78 mmol, 1.5 equiv.) were added and the reaction mixture was heated at 
reflux for four hours. After cooling to room temperature, the solvent was removed in 
vacuo and water (30 mL) was added. The product was extracted with diethyl ether (3 
x 20 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material 
was purified by standard silica chromatography using hexane to give 6.57 g (71%) of 
6 as a pale-yellow oil; IR (neat) υmax/cm
-1
 3025 (C-H), 1613 (C=C), 1490, 690 (Ar-
H), 678 (C-Br); 
1
H NMR (400 MHz, CDCl3) δ ppm 7.65 (2H, d, J = 7.0, ortho Ar-
H), 7.35-7.27 (3H, m, meta, para Ar-H), 6.99 (1H, d, J = 8.0, CH=CH), 6.36 (1H, d, 
J = 8.0, CH=CH); 
13
C NMR (75 MHz, CDCl3) δ ppm 135.1 (ipso Ar-C), 132.6 
(CH=CHBr), 129.2, 128.5, 128.4 (Ar-CH), 106.6 (CH=CHBr);  
Mass spectrometric data were not obtainable via ESI mass spectrometry. 
These data were  consistent with those previously reported.
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 cis-4-Methoxystilbene (7) 
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cis-β-Bromosytrene (6) (1.15 g, 6.3 mmol, 1.0 equiv.) and KOH aq. (3.0 M, 6.3 mL, 
19 mmol, 3.0 equiv.) was introduced to a two neck round bottom flask and the 
solution was degassed for 15 minutes before 4-methoxybenzene boronic acid (1.23 
g, 8.1 mmol, 1.3 equiv.) and Pd(Ph3)4 (0.42 g, 0.36 mmol, 6 mol%) were 
subsequently added under a nitrogen atmosphere. The reaction mixture was heated at 
100 °C for 36 hours in the dark. The solvent was evaporated before the reaction 
mixture was diluted with water (20 mL). The aqueous layer was extracted with 
CH2Cl2 (3 x 10 mL), dried over MgSO4 and concentrated to give a brownish residue. 
The residue was purified by standard silica chromatography using 99:1 
hexane:EtOAc to give 0.64 g (49%) of 7 as a light orange oil; IR (neat) υmax/cm
-1 
3006 (C-H), 1605 (C=C); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.40 - 7.15 (7H, m, 
Ar-H), 6.94 – 6.70 (2H, m, Ar-H), 6.56 (2H, s, CH=CH), 3.80 (3H, s, OCH3);
 13C 
NMR (75 MHz, CDCl3) δ ppm 158.2 (COMe), 137.1 (ipso Ar-C), 129.6, 129.2, (Ar-
C or CH=CH) 129.1 (ipso Ar-C), 128.3, 128.2, 127.7, 126.4, 113.0 (Ar-C or 
CH=CH), 54.6 (OCH3); HRMS (+ESI) m/z for (C15H15O) [M + H] calculated 
211.1117 found 211.1115. 
These data were  consistent with those previously reported.
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(±)-trans-4-Phenyl-3-buten-2-ol (12) 
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trans-4-Phenyl-3-buten-2-one (1.49 g, 10 mmol, 10 eq,) and cerium (III) chloride 
heptahydrate (0.38 g, 1 mmol, 1 equiv.) were dissolved in methanol (10 mL) cooled 
in an ice bath and NaBH4 (0.57 g, 1.5 mmol, 15 equiv.) was added portionwise with 
stirring. The reaction mixture was further stirred at 0 ºC for 2 hours. After that, the 
solvent was evaporated and water (30 mL) was added. The aqueous layer was 
extracted with ethyl acetate (3 x 20 mL), dried over MgSO4, filtered and 
concentrated to give 1.24 g (83%) of 12 as a pale-yellow oil; IR (neat) υmax/cm
-1
 
3334 (O-H), 3084-3027 (C-H), 1598, (C=C), 1493, 745.61, 691 (Ar-H); 
1
H NMR 
(400 MHz, CDCl3) δ ppm 7.31-7.15 (5H, m, Ar-H), 6.48 (1 H, d, J = 16.0, CH-Ar), 
6.19 (1 H, dd, J = 16.0, 6.5, CHCHOHCH3), 4.40 (1 H, qd, J = 6.5, 1.0, CHOHCH3), 
3.32 (1 H, s, OH ), 1.31 (3 H, d, J = 6.5, CH3); 
13
C NMR (101 MHz, CDCl3) δ ppm 
136.7 (ipso Ar-C), 133.6, 129.0, 128.5, 127.4, 126.4 (Ar-CH and HC=CH), 68.5 
(COHCH3), 23.3 (CH3); HRMS (+ESI) m/z for (C10H12NaO) [M+Na
+
] calculated 
171.0780 found 171.0780. 
These data were consistent with those previously reported.
225
  
 
(1S, 1’S, 3’S)-(±)-1-2,2-Dichloro-3-phenylcyclopropylethanol (13) 
 
 
To a solution of trans-4-phenyl-3-buten-2-ol (12) (0.21 g, 1.4 mmol, 1.0 equiv.) in 
chloroform (2.8 mL, 34.7 mmol, 25 equiv.) cooled on an ice bath was added 
benzyltrimethylammonium bromide (7 mg, 50 µmol, 2 mol%) with rapid stirring. A 
solution of 50% aqueous NaOH (1.4 mL, 26.7 mmol, 19.1 equiv.) was then added 
dropwise over a period of 10 minutes. The reaction mixture was further stirred for 2 
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hours before being diluted with water and extracted 3 times with diethyl ether. The 
combined organic extracts were dried over MgSO4 and concentrated to give a 
residue. The residue contained a mixture of diastereoisomers with a dr of ~5:1 as 
determined by 
1
H NMR spectroscopy. The major diastereoisomer was successfully 
isolated by standard silica chromatography using 99:1 hexane: ethyl acetate to give 
0.16 g (49%) of 13 as a pale-yellow oil; IR (neat) υmax/cm
-1
 3330 (O-H), 3028 (C-H), 
1601 (C=C), 1493, 746, 694 (Ar-H), 1076 (C-O);
 1
H NMR (400 MHz, CDCl3) δ ppm 
7.40 – 7.27 (3H, m, meta and para Ar-H), 7.23 (2H, d, J = 7.5, ortho Ar-H), 3.83 
(1H, dq, J = 8.5, 6.5 CHOH), 2.61 (1H, d, J = 8.5, Ar-CHCCl2 or OH), 2.59 (1H, d, J 
= 8.5, Ar-CHCCl2 or OH), 2.10 (1H, t, J = 8.5, CHCHOHCH3), 1.44 (3H, d, J = 6.5 
CH3);
 13
C NMR (101 MHz, CDCl3) δ ppm 134.1 (ipso Ar-C), 129.0, 128.7, 128.1 
(Ar-CH), 70.0 (C-OH), 64.8 (CCl2), 42.1, 39.6 (CHCHCCl2), 21.8 (CH3); HRMS 
(+ESI) m/z for (C11H12Cl2NaO) [M+Na
+
], calculated 253.0157 found 253.0159.  
 
 (±)-cis-4-Phenyl-3-buten-2-ol (15) 
 
A round bottom flask was charged with hexane (1 mL), 4-phenyl-3-butyn-2-ol (0.5 
g, 3.4 mmol), ~5% palladium on calcium carbonate (0.017 g) and quinoline (3 
drops). The air inside the round bottom was evacuated and hydrogen was admitted 
via a balloon. The reaction mixture was stirred at room temperature for 3 hours 
before filtered through a pad of celite and concentrated to give a residue. The crude 
material was purified by silica chromatograph to give 0.23 g (44%) of 15 as a 
colourless oil; IR (neat) υmax/cm
-1 
3332 (O-H), 3057-2928 (C-H) 1600 (C=C), 1494, 
767, 697 (aromatic C-H), 1049 (C-O), 1050 (C-O); 
1
H NMR (400 MHz, CDCl3) δ 
ppm 7.39-7.31 (2H, m, Ar-H), 7.31-7.23 (3H, m, Ar-H), 6.50 (1H, d, J = 11.5 Ar-
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CH=CH), 5.69 (1H, dd, J = 11.5, 9.0 Ar-CH=CH), 4.79 (1H, dq, J = 9.0, 6.0, 
CHOH), 1.57 (1H, s, OH), 1.36 (3H, d, J = 6.0, CH3); 
13
C NMR (101 MHz, CDCl3) 
δ ppm 136.9 (ipso Ar-C), 136.1, 129.8, 129.0, 128.5, 127.3 (Ar-CH and Ar-
CH=CH), 64.2 (CHOHCH3), 23.7 (CH3); HRMS (+ESI) m/z for (C10H12NaO) 
[M+Na
+
], calculated 171.0780 found 171.0776.  
These data were consistent with those previously reported. 
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(1R, 1’R, 3’S)-(±)-1-2,2-Dichloro-3-phenylcyclopropylethanol (16) 
 
Prepared in a similar manner to compound 13. 
Method A: (±)-cis-4-Phenyl-3-buten-2-ol (15) (0.52 g, 3.5 mmol, 1.0 equiv.) was 
allowed to react with chloroform (7.0 mL, 87.1 mmol, 25 equiv.) and a solution of 
50% aqueous NaOH (3.49 mL, 50 mmol, 19.1 equiv.) for 2 hours to give a residue 
that seemed to only contain one diastereoisomer (>95:5) as determined by 
1
H NMR 
spectroscopy. The crude product was purified by silica chromatograph (eluent: 98:2 
hexane:EtOAc) to give 0.22 g (28%) of 16 as a very pale-yellow oil; IR (neat) 
υmax/cm
-1
 3397 (O-H), 2978 (C-H), 1603 (C=C), 1497, 730, 694 (Ar-H), 1075 (C-O);
 
1
H NMR (400 MHz, CDCl3) δ ppm 7.33 – 7.15 (5H, m, Ar-H), 3.62 (1H, dq, J = 10, 
6.0, CHOH), 2.95 (1H, d, J = 11.5, Ar-CHCCl2), 2.12 (1H, s, OH), 2.06 (1H, dd, J = 
11.5, 10, CHCHOHCH3), 1.37 (3H, d, J = 6.0, CH3); 
13
C NMR (101 MHz, CDCl3) δ 
ppm 132.9 (ipso Ar-C),  123.0, 128.7, 127.8 (Ar-CH), 66.2 (C-OH), 63.7 (C-OH), 
42.3 (CHCHOH), 38.2 (Ar-CHCCl2), 22.4 (CH3); HRMS (+ESI) m/z for 
(C11H12Cl2NaO) [M+Na
+
], calculated 253.0157 found 253.0158.  
148 
 
Method B: cis-4-Phenyl-3-buten-2-ol (15) (0.3 g, 2.0 mmol, 1.0 equiv.) was 
protected with dihyropyran (0.28 mL, 3 mmol, 1.5 equiv.) by stirring with a little 
toluene p-toluenesulfonic acid in diethyl ether (4 mL) at room temperature for 
overnight. The solvent was evaporated in vacuo and the reaction mixture was 
washed with NaHCO3 (15 mL).  The residue was dissolved in chloroform (4.0 mL, 
50.0 mmol, 25.0 equiv.) and benzyltrimethyl ammonium bromide (10 mg, 40 µmol, 
2 mol%.) were added with rapid stirring, followed by adding a solution of 50% 
aqueous NaOH (2.0 mL, 25.0 mmol, 12.5 equiv.) dropwise over a period of 10 
minutes. The reaction mixture was further stirred at room temperature for 2 days 
before diluted with water (15 mL) and extracted with diethyl ether (3 x 10 mL), dried 
over MgSO4 and concentrated to afford an oil. The oil was dissolved in a solution 
containing a little of p-toluenesulfonic acid in methanol (4 mL) and stirred for 
overnight. After that, the reaction mixture was treated with sat. NaHCO3 (10 mL) 
and the solvent was evaporated in vacuo before water was added (20 mL). The 
organic material was extracted with diethyl ether (3 x 15 mL), dried over Na2SO4 
and filtered to afford a crude oil which contained a mixture of diastereoisomers with 
dr of ~1.5:1 as determined by 
1
H NMR spectroscopy. The two diastereoisomers was 
subsequently separated by silica chromatograph to give 0.13 g (29%) yield of the 
major isomer and 0.05 g (12%) of the minor isomer, with a combined yield of 41%. 
The spectrometry of the major diastereoisomer is consistent to the data of the 
product isolated using method A.  
Minor isomer: IR (neat) υmax/cm
-1
 3369 (O-H), 3061-2929 (C-H), 1604, 1498, 730, 
698 (aromatic C-H), 1075 (C-O); 
1
H NMR (400 MHz, CDCl3) δ ppm 7.50 – 7.40 
(2H, m, ortho Ar-H), 7.31 – 7.10 (3H, m, meta, para Ar-H), 3.48 (2H, ddq, J = 10.0, 
6.0, 5.0, CHOH), 2.92 (1H, d, J = 11.0, Ar-CHCCl2), 1.94 (1H, dd, J = 11.0, 10.0, 
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CCl2CHCHOH), 1.58 (1H, d, J = 5.0, OH), 1.38 (3H, d,  J = 6.0, CH3); 
13
C NMR 
(101 MHz, CDCl3) δ ppm 133.0 (ipso Ar-C), 130.5, 128.6, 127.6 (Ar-C), 65.8 (C-
OH), 62.1 (CCl2), 41.1, 37.5 (CHCHCCl2), 23.4 (CH3); HRMS (+ESI) m/z for 
(C11H12Cl2NaO) [M+Na
+
], calculated 253.0157 found 253.0159.  
 
 (1S, 3S)-(±)-2,2-Dichloro-3-phenylcyclopropylmethanol (23) 
 
Prepared in a similar manner to compound 13 using method B, cinnamyl alcohol 
(0.98 g 7.3 mmol 1.0 equiv.) protected with 3,4-dihydro-2H-pyran (1 mL, 11 mmol, 
1.5 equiv.) by stirring with a little (+) camphorsulfonic acid in diethyl ether (15 mL) 
at room temperature for overnight. The solvent was removed in vacuo and the 
reaction mixture was washed with NaHCO3 (20 mL).  The residue was dissolved in 
chloroform (15 mL, 125 mmol, 17.0 equiv.) and benzyltrimethyl ammonium 
bromide (84 mg, 0.36 mmol, 5 mol%.) were added with rapid stirring, followed by 
adding a solution of 50% aqueous NaOH (5.8 mL, 75 mmol, 10 equiv.) dropwise 
over a period of 10 minutes. The reaction mixture was further stirred at room 
temperature for 2 days before diluted with water (50 mL) and extracted with CH2Cl2 
(3 x 25 mL). The organic extracts were combined, washed with water (2 x 25 mL) 
and brine (1 x 20 mL), dried over MgSO4 and concentrated to afford a pale-yellow 
oil. The oil was dissolved in a solution containing a little of p-toluenesulfonic acid in 
methanol (15 mL) and stirred for overnight. After that, the reaction mixture was 
treated with sat. NaHCO3 (10 mL) and the solvent was evaporated in vacuo before 
water was added (20 mL). The organic material was extracted with diethyl ether (3 x 
10 mL), dried over MgSO4, filtered and concentrated to give a crude oil. The product 
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was purified by standard silica chromatography using 95:5 hexane:EtOAc to give 
0.50 g (32%) of 21 as a very pale-yellow oil; IR (neat) υmax/cm
-1
 3330 (O-H), 3032 
(C-H), 1603 (C=C), 1047 (C-O); 
1
H NMR (400 MHz, CDCl3) δ ppm 7.39 – 7.27 
(3H, m, meta, para Ar-H), 7.28-7.20 (2H, m, ortho Ar-H), 4.06 (1H, dd, J = 12.0, 
5.5, CH2OH), 3.85 (1H, dd, J = 12.0, 8.5, CH2OH), 2.66 (1H, d, J = 8.5,  Ar-
CHCCl2), 2.28 (1H, td, J = 8.5, 5.5, CHCH2OH), 2.17 (1H, s, OH); 
13
C NMR (101 
MHz, CDCl3) δ ppm 134.1 (ipso Ar-C), 129.0, 128.6, 128.0 (Ar-CH), 64.7 (CCl2), 
63.0 (CH2OH), 39.2, 36.4 (CHCHCCl2); HRMS (+ESI) m/z for (C10H12Cl2NaO) 
[M+Na
+
], calculated 239.0001 found 238.9997.  
 
 (±)-trans-1,3‐Diphenylprop‐2‐en‐1‐ol (27) 
 
Prepared in a similar manner to compound 12, trans-chalcone (10.41 g, 50 mmol, 
1.0 equiv.) and cerium (III) chloride heptahydrate (1.87 g, 5 mmol, 1 equiv.) were 
dissolved in methanol (100 mL) cooled in an ice bath and NaBH4 (2.85 g, 75 mmol, 
15 equiv.) was added portionwise with stirring. After the reaction was completed, the 
solvent was evaporated in vacuo and water (100 mL) was added. The aqueous layer 
was extracted with ethyl acetate (3 x 50 mL), dried over MgSO4, filtered and 
concentrated to give a solid. The crude product was purified by silica chromatograph 
to give 10.41 g (69%) of 27 as a white solid.  mp 55 – 56 ºC, (lit.,227 mp 58 - 59 ºC); 
IR (neat)  υmax/cm
-1 
3342 (br OH) 3027 (C-H),  1598 (C=H), 1491, 1447, 964, 743 
(Ar-H), 1011 (O-H); 
1
H NMR (400 MHz, CDCl3) δ ppm 7.57 – 7.28 (10H, m, Ar-
H), 6.74 (1H, d, J = 16, Ar-CH=CH), 6.45 (1H, dd, J = 16, 6.5 Ar-CH=CH), 5.42 
(1H, dd, J = 6.5, 3.5, CHOH), 2.52 (1H, d, J = 3.5 CHOH); 
13
C NMR (101 MHz, 
151 
 
CDCl3) δ ppm 143.1, 136.8 (ipso Ar-C), 131.8, 130.8, 128.9, 128.8, 128.1, 126.9, 
126.7 (Ar-CH and CH=CH), 75.3 (CHOH); HRMS (+ESI) m/z for (C15H14NaO) 
[M+Na
+
] calculated 233.0937 found 233.0942.  
These data were consistent with those previously reported.
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(1R, 1’S, 3’S)-(±)-1-(2,2-Dichloro-3-phenylcyclopropylbenzenemethanol (28) 
 
Prepared in a similar manner to compound 13 using method A, the reaction of trans-
1,3-diphenyl-2-propen-1-ol with CCl2 derived from CHCl3/NaOH gave a mixture of 
diastereoisomers with a dr of ~6.1 : 1. The major diastereoisomer was successfully 
isolated by standard silica chromatography using 1:99 EtOAc:hexane as eluent to 
give 28 as a pale-yellow oil (0.12 g, 39% yield). Upon standing, the product 
solidified, mp 94 - 95 ºC; IR (neat) υmax/cm
-1
 3296 (O-H), 2995-2925 (C-H), 1600 
(C=C), 1050 (C-O); 
1
H NMR (400 MHz, CDCl3) δ ppm 7.51 (2H, d, J = 7.0, Ar-H), 
7.47-7.26 (6H, m, Ar-H), 7.14-7.05 (2H, m, Ar-H), 4.74 (1 H, dd, J = 9.0, 3.0, 
CHOH), 2.86 (1H, d, J = 8.5, Ar-CH), 2.54 (1H, d, J = 3.0, OH), 2.42 (1H, t, J = 9.0, 
CHCHOH); 
13
C NMR (101 MHz, CDCl3) δ ppm 141.3, 133.8 (ipso, Ar-C), 129.0, 
128.9, 128.5, 128.5, 127.9, 126.1 (Ar-C), 75.8 (CHOH), 42.1, 39.8 (CHCCl2); 
HRMS (+ESI) m/z for (C16H14Cl2NaO) [M+Na
+
] calculated 315.0310 found 
315.0314.  
1,2:5,6-Diisopropylidene-D-mannitol (31) 
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2,2-Dimethoxypropane (56 mL, 455 mmol, 2.1 equiv.) was added to a suspension of 
D-mannitol (40.0 g, 219 mmol, 1.0 equiv.) in dry DMF (200 mL). The mixture was 
stirred well before p-toluene-sulfonic acid monohydrate (0.52 g, 2.6 mmol, ~0.6 
mol%) was added and the slurry was stirred overnight at room temperature. The 
reaction mixture was quenched with triethylamine (1.68 mL) and then diluted with 
EtOAc (1.5 L). The organic layer was washed repeatedly with water (8 x 100 mL). 
The organic layer was dried over MgSO4 and concentrated to give a residue. Upon 
standing, a white solid was formed. The solid was suspended in hexane (200 mL) 
and stirred well for 1 h. The suspension was filtered, the white solid collected and 
dried to give 25 g (44%) of 31 mp 116-118 ºC, (lit.,
228
 mp 58 - 59 ºC); [α]
28
D = + 8.3 
(c = 1.03, CHCl3); IR (neat) υmax/cm
-1
 3307 (O-H), 2982 (C-H), 1203 (C-O ether), 
1062 (C-O alcohol); 
1
H NMR (300 MHz, CDCl3) δ ppm 4.09-4.21 (4H, m, 
CH2CHOR and CH2CHOR), 3.92-3.97 (2H, m, CH2CHOR), 3.74 (2H, t, J = 6.5, 
CHOH), 2.68 (2H, d, J = 7.0, OH), 1.41 (6H, s, CH3) 1.35 (6H, s, CH3); 
13
C NMR 
(75 MHz, CDCl3) δ ppm 109.5 (CMe2), 76.4 (CH2CHOR, 71.3 (CHOH), 66.9 
(CH2CHOR), 26.9, 25.3 (CH3); HRMS (+ESI) m/z for (C12H22NaO6) [M+Na
+
] 
calculated 285.1309 found 285.1315. 
These data were consistent with those previously reported.
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 (R)-(+)-2,2-Dimethyl-1,3-dioxolane-4-carboxaldehyde (32) 
 
To a solution containing 1,2:5,6-diisopropylidene-D-mannitol (1.4 g, 5.3 mmol, 1.0 
equiv.) in CH2Cl2 (10 mL) was added sat. NaHCO3 (0.85 mL), NaIO4 (2.25 g, 10.5 
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mmol, 2.0 equiv.) was then added portion wise over a period of 30 minutes. The 
resulting suspension was stirred vigorously for 3 hours before MgSO4 was added, 
and the reaction mixture was filtered and concentrated to give 32 as a colorless 
which was not purified and used immediately for the next step.  
 
(4S)-(-)-2,2-Dimethyl-4-[(Z)-phenylethenyl]-1,3-dioxolane (33) 
 
n-BuLi (2.5 M in hexane, 4.3 mL, 10.5 mmol, 2.0 equiv.) was added dropwise at 0 
ºC to a white suspension of the benzyltriphenylphosphonium bromide (4.63 g, 10.5 
mmol, 2.0 equiv.) in dry THF (10 mL); the resulting mixture immediately became 
orange. The temperature was allowed to rise to room temperature over a period of 30 
minutes and then all of (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-carboxaldehyde (32) 
from the previous step was added. The reaction mixture was further stirred until TLC 
analysis indicated the reaction was complete (approx. 2 hours).  The solvent was 
removed and the reaction mixture was diluted with water and extracted 3 times with 
EtOAc, dried over MgSO4 and concentrated to give a crude oil. The cis and trans 
geometric ratio was about 72:28 as determined by 
1
H NMR spectroscopy.  The crude 
material was purified by standard silica chromatography using a 1:9 diethyl ether: 
40-60 hexane as eluent to give 0.659 g (60% overall yield from 1,2:5,6-di-O-
isopropylidene-D-mannitol) of 33 as a colorless oil; [α]
28
D = -42.1 (c = 1.28, CHCl3); 
IR (neat) υmax/cm
-1
 2985-2867 (C-H), 1498 (C=C), 1055 (C-O); 
1
H NMR (300 MHz, 
CDCl3) δ ppm 7.42-7.30 (5H, m, Ar-H), 6.76 (1H, d, J = 11.5, HC=CHAr), 5.75 
(1H, dd, J = 11.5, 9.0, HC=CHAr), 4.95 (1H, ddd J = 9.0, 8.0, 6.0, CHHCOR), 4.20 
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(1H, dd, J = 8.0, 6.0, CHHCHOR), 3.72 (1H, t, J = 8.0, CH2CHOR), 1.53 (3H, s, 
CH3) 1.44 (1H, s, CH3); 
13
C NMR (101 MHz, CDCl3) δ ppm 136.3 (ipso Ar-C), 
134.0, 129.3, 128.8, 128.4, 127.6 (Ar-C and CH=CH), 109.5 (CMe2), 72.5 (CHOR), 
69.8 (CH2CHOR), 27.0, 26.0 (CH3); HRMS (+ESI) m/z for (C13H16NaO2) [M+Na
+
] 
calculated 227.1043 found 227.1046. 
These data were consistent with those previously reported.
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(4S)-(-)-(6’,6’-dichloro-7’-phenylcyclopropyl)-2,2-dimethyl-1,3-dioxolane (34) 
 
Prepared in a similar manner to compound 13, (4S)-2,2-dimethyl-4-[(Z)-
phenylethenyl]-1,3-dioxolane (33) (2.0 g 9.8 mmol, 1.0 equiv.) was treated with 
CHCl3 (7.0 mL, 87.1 mmol, 25 equiv.) and a solution of 50% aqueous NaOH (3.49 
mL, 50 mmol, 19.1 equiv.) for 3 days to give a mixture with dr ~ 6:1 as determined 
by 
1
H NMR spectroscopy. The two diastereoisomers were separated by standard 
silica chromatography to give 1.71 g (61%) of the major isomer as a pale-yellow oil 
and 0.23 g (8%) of the minor isomer as a white solid.  
 
Major isomer: [α]
28
D = -5.3 (c = 1.075, CHCl3); IR (neat) υmax/cm
-1
 2987-2873 (C-
H), 1604, 1499 (C=C), 1064 (C-O); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.44-7.42 
(2H, m, Ar-H), 7.32-7.18 (3H, m, Ar-H), 4.12 (1H, dd, J = 8.5, 6.5, CHHCHOR), 
3.87 (1H, dd, J = 8.5, 6.5, CHHCHOR), 3.69 (1H, dt, J = 9.5, 6.5, CH2CHOR), 3.02 
(1H, d, J = 11.0, ArCHCCl2), 2.10 (1H, dd, J = 11.0, 9.5, CHOCHCCl2), 1.46 (3H, s, 
CH3), 1.26 (3H, s, CH3); 
13
C NMR (101 MHz, CDCl3) δ ppm 132.2 (ipso Ar-C), 
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130.8, 128.6, 127.8 (Ar-C), 109.6 (CMe2), 73.4 (CH2CHO), 68.7 (CH2CHO), 61.1 
(CCl2), 37.8, 37.2 (CHCHCCl2 and CHCHCCl2), 27.0, 25.6 (CH3);  HRMS (ESI) m/z 
for (C14H16
35
Cl2NaO2) [M+Na
+
] calculated 309.0420 found 309.0419. 
 
Minor isomer: mp 74 – 75 ºC; [α]
28
D = -15.8 ( c = 1.14, CHCl3); IR (neat) υmax/cm
-1
 
2991-2938 (C-H), 1601, 1499 (C=C), 1021 (C-O); 
1
H NMR (300 MHz, CDCl3) δ 
ppm 7.32-7.14 (5H, m, Ar-H), 4.08 (1H, dd, J = 8.0, 6.0, CH2CHOR), 3.90 (1H, dd, 
J = 8.0, 6.0, CH2CHOR), 3.78 (1H, dt, J = 10.0, 6.0, CH2CHOR), 2.95 (1H, d, J = 
11.5, ArCHCCl2), 2.10 (1H, dd, J = 11.0, 10.0, CHORCHCCl2), 1.46 (3H, s, CH3), 
1.24 (3H, s, CH3); 
13
C NMR (101 MHz, CDCl3) δ ppm 132.6 (ipso Ar-C), 129.9, 
128.7, 127.8 (Ar-C), 109.8 (CMe2), 74.4 (CH2CHO), 68.3 (CH2CHO), 62.7 (CCl2), 
37.8, 37.3 (CHCHCCl2 and CHCHCCl2), 27.2, 25.5 (CH3); HRMS (+ESI) m/z for 
(C14H16Cl2NaO2) [M+Na
+
] calculated 309.0420 found 309.0420.  
 
General procedure for microwave assisted difluorocyclopropanation of 
stilbenes: 
NaI (1.25 mmol, 2.5 equiv.) and TMSCF3 (1.25 mmol, 2.5 equiv.) were added to a 
microwave reaction tube containing the alkene (0.5 mmol, 1.0 equiv.) in 1 mL of 
CH3CN. The reaction tube was sealed and the reaction mixture was heated with 
stirring at 80 ºC for 20 minutes in a microwave reactor. The solvent was removed in 
vacuo before water was added and the aqueous solution was extracted 3 times with 
ethyl acetate. The organic extracts were combined, dried over MgSO4 and 
evaporated under vacuum to give a dark-brown mixture which was not purified and 
directly used for the next step.  
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General procedure for the oxidative cleavage of stilbenes and isolation of 
diphenyldifluorocyclopropanes: 
Oxone (4 equiv.) was added to potassium osmate(VI) dihydrate (0.01 equiv.) in 
DMF (0.2 M based on olefin) and the resulting mixture was stirred for 30 minutes, 
followed by addition of the olefin and difluorocyclopropane mixture in DMF (1 ~ 2 
mL). The stirring was continued for overnight, after which Na2SO3 (4.2 equiv.) was 
added and stirred for an additional hour. The resultant mixture was diluted with ethyl 
acetate and stirred for 10 minutes. The solid was filtered and the filter cake was 
washed with ethyl acetate. The organic exact was washed 3 times with 1 M HCl and 
twice with diluted NaHCO3 solution, dried over MgSO4 and concentrated under 
vacuum to give an oil. The crude material was purified by standard silica 
chromatography to give diphenyldifluorocyclopropanes as a white solids. 
 
cis-1,1- Difluoro-2,3-diphenylcyclopropane (52) 
 
cis-Stilbene (0.9 g, 5 mmol, 1.0) was allowed to react with TMSCF3 (1.85 mL, 12.5 
mmol, 2.5 equiv.) and NaI (1.87 g, 12.5 mmol, 2.5 equiv.) in CH3CN (10 mL) using 
the microwave-assisted difluorocyclopropanation method, isolated by the oxidative 
cleavage described above and purified by standard silica chromatography using 
hexane as eluent to give 52 (0.21 g, 18%) as a mixture of cis- and trans-isomers with 
a ratio of 96:4, mp 64 - 66 ºC; IR (neat) υmax/cm
-1
 3050 (C-H), 1496 (Ar), 1140 (C-
F); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.29 – 7.16 (6H, m, Ph-H), 7.10 – 7.01 (4H, 
m, Ph-H), 3.22 (2H, dd, J = 14.5, 2.5, CHCF2); 
13
C NMR (75 MHz, CDCl3) δ ppm 
130.8 (ipso Ph-C), 130.1, 128.2, 127.1 (Ph-C), 114.0 (dd, 
1
JC-F = 291.5, 288.0, CF2), 
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32.2 (dd, 
2
JC-F = 12.0, 9.5, CHCF2); 
19
F NMR (282 MHz, CDCl3) δ ppm -117.0 (dt, 
2
JF-F = 157.0, 
3
JH-F = 14.0), -146.6 (d, 
2
JF-F  = 157.0).  
This compound is known and has previously been reported with 
19
F NMR 
spectroscopic data consistent with those reported here.
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trans -(±)-1,1- Difluoro-2,3-diphenylcyclopropane (53) 
 
trans-Stilbene (0.9 g, 5 mmol, 1.0) was allowed to react with TMSCF3 (1.85 mL, 
12.5 mmol, 2.5 equiv.) and NaI (1.87 g, 12.5 mmol, 2.5 equiv.) in CH3CN3 (10 mL) 
using the microwave-assisted difluorocyclopropanation method, isolated by the 
oxidative cleavage described previously and purified by standard silica 
chromatography using hexane as eluent to give 53 (0.22 g, 19%) as a mixture of cis-  
and trans-isomers with a ratio of 4:96, mp 50 - 51 ºC, (lit.,
230
 mp 43 ºC); IR (neat) 
υmax/cm
-1
 3050 (C-H), 1498 (Ar), 1270 (C-F); 
1
H NMR (300 MHz, CDCl3) δ ppm 
7.34 – 7.13 (10H, m, Ph-H), 2.93 (2H, t, J = 7.5, CHCF2); 
13
C NMR (75 MHz, 
CDCl3) δ ppm 132.9 (ipso Ph-C), 128.1, 127.5, 126.8 (Ph-C), 112.2 (t, 
1
JC-F = 292, 
CF2), 33.9 (t, 
2
JC-F = 10.5, CHCF2); 
19
F NMR (282 MHz, CDCl3) δ ppm -134.6 (t, 
3
JH-F = 7.5).  
Mass spectrometric data were not obtainable via ESI mass spectrometry. 
This compound is known and has previously been reported with 
1
H and 
19
F NMR 
spectroscopic data only which were consistent with those reported here.
126, 230
  
 
1,1-Difluoro-2,3-diphenylcyclopropene (58) 
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This compound was synthesized according to Hu’s et al. method. Diphenylacetylene 
(0.18 g, 1 mmol, 1.0 equiv.), TMSCF3 (0.3 mL, 2 mmol, 2.0 equiv.), NaI (0.33 g, 2.2 
mmol, 2.2 equiv.) and THF (3 mL) were added to a pressure tube equipped with a 
magnetic stirrer and the tube was sealed. The resulting mixture was heated on an oil 
bath at 80 ºC for 2 hours. The solvent was evaporated and the crude product was 
purified by standard silica chromatography using hexane as elute to give 58 (0.19 g, 
83%) as a white solid; mp 57 - 59 ºC; (lit.,
128
 mp 58 - 59 ºC); IR (neat) υmax/cm
-1
 
3001 (C-H), 1263 (C-F);  
1
H NMR (400 MHz, CDCl3) δ ppm 7.84 – 7.76 (4H, m, 
Ar-H), 7.61 – 7.41 (6H. m, Ar-H); 19F NMR (282 MHz, CDCl3) δ ppm -112.4. Mass 
spectrometric data were not obtainable via ESI mass spectrometry. 
These data were consistent with those previously reported.
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General procedure for Horner-Wadsworth-Emmons reaction: 
A few trans-diarylethenes was prepared according to the procedure of Lion et al.
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Briefly, NaBH4 (0.5 equiv.) was added slowly to a solution of substituted 
benzaldehyde (1.0 equiv.) in isopropyl alcohol. The resulting mixture was stirred at 
room temperature for 15 minutes followed by heating at reflux for 10 minutes. After 
the addition of dilute aqueous HCl (10%) until the solution was slightly acidic, the 
solvent was evaporated under vacuum. Water was added and the solution was 
extracted with CH2Cl2. The organic extracts were combined and washed with a 
solution of 5% aqueous NaHCO3, dried over MgSO4 to give the substituted aryl 
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alcohol as a viscous oil. The crude material was used directly for the next step 
without any purification.  
 
To a solution of mono- or dimethoxy substituted aryl alcohol (1.0 equiv.) in CH2Cl2 
(10 mL/mol) phosphorus tribromide (1.2 equiv.) was added slowly at 0 ºC, and 
stirring was continued overnight. Dilute sodium dicarbonate solution was added 
cautiously, followed by extraction of the organic material with CH2Cl2. The organic 
extracts were combined, dried over MgSO4 and the solvent was evaporated under 
vacuum to give substituted aryl bromide as a colorless which was used without 
purification for the next transformation.   
 
Mono- or dimethoxy substituted benzyl bromide (1.0 equiv.) was heated with 
triethylphosphite (1.5 equiv.) at 140 ºC until completed dissolution occurred and the 
evolution of bromoethane had ceased.  The excess triethylphosphite was 
subsequently removed by concentration of the reaction mixture under vacuum to 
afford the substituted phosphonic acid diethyl ester as a viscous oil which was used 
for the next step without any purification.  
 
To a solution of mono- or dimethoxy substituted phosphonic acid diethyl ester (1.0 
equiv.) in dry DMF was added sodium methoxide (2.0 equiv.) and 18-crown-6 ether 
(0.2 equiv.). The resulting mixture was stirred at room temperature for 5 minutes 
before benzaldehyde (1.5 equiv.) in dry DMF was added dropwise at 0 ºC. The 
stirring was continued for an hour followed by heating to 120 ºC for 5 hours. After 
cooling to room temperature, water was added to quench the reaction and the organic 
material was exacted with ethyl acetate. The organic solvent was evaporated under 
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vacuum to give a residue which was then redissolved in CH2Cl2 and acethydrazide 
trimethylammonium chloride (0.6 equiv.) was added. The reaction mixture was 
stirred for 2 hours before water was added and the layers were separated. The 
organic layer was collected, washed successively with brine and aqueous Na2CO3, 
dried over MgSO4, and evaporated under vacuum to give the crude product as a solid 
which was purified either by recrystallization or silica chromatography.  
 
trans-3-Methoxystilbene (63) 
 
63 was synthesized from 3-methoxy benzyl bromide (6.0 g, 30 mmol) using Horner-
Wadsworth-Emmons reaction and purified by standard silica chromatography using 
hexane as eluent to give the title compound (6.03 g, 96%) as a pale-yellow solid, mp 
34 – 35 ºC, (lit.,232 mp 34 – 35 ºC); IR (neat) υmax/cm
-1
 ~3013 (C-H), 1584 (C=C); 
1
H 
NMR (300 MHz, CDCl3) δ ppm 7.66 (2H, m, Ar-H or CH=CH), 7.55 – 7.45 (2H, m, 
Ar-H or CH=CH), 7.45 – 7.35 (2H, m, Ar-H or CH=CH), 7.31 – 7.15 (4H, m, Ar-H 
or CH=CH), 6.97 (1H, ddd, J = 8.0, 2.5, 1.0, CHCHCHMe or CHOMe), 3.94 (3H, s, 
OCH3); 
13
C NMR (75 MHz, CDCl3) δ ppm 160.1 (COMe), 138.9, 137.4 (ipso Ar-C), 
129.8, 129.1, 128.9, 128.8, 127.9, 126.8, 119.4, 113.4, 112.0 (Ar-C or CH=CH), 55.3 
(OCH3); HRMS (+ESI) m/z for (C15H15O) [M + H] calculated 211.1117 found 
211.1119.  
These data were consistent with those previously reported.
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trans-4-Methoxystilbene (64) 
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64 was synthesized from 4-methoxybenzaldehyde (5.46 g 20 mmol) using Horner-
Wadsworth-Emmons reaction and purified by recrystallization to give the title 
compound (3.52 g, 56%) as a pale-yellow solid, mp 136 - 137 ºC (MeOH), (lit.,
232
 
mp 135 – 136 ºC); IR (neat) υmax/cm
-1
 1666 (C=C); 
1
H NMR (300 MHz, CDCl3) δ 
ppm 7.30 – 7.18 (4H, m, Ar-H), 7.17 – 7.07 (2H, m, Ar-H), 7.05 – 6.96 (1H, m, para 
Ar-H), 6.84 (1H, d, J = 16.5, CH=CH), 6.74 (1H, d, J = 16.5, CH=CH), 6.70 – 6.63 
(2H, m, Ar-H), 3.59 (3H, s, OCH3); 
13
C NMR (75 MHz, CDCl3) δ ppm 158.8 
(COMe), 137.1 (ipso Ar-C), 129.6, 128.1, 127.7, 127.2, 126.7, 126.0, 125.7, 113.6 
(Ar-C or CH=CH), 54.7 (OCH3); HRMS (+ESI) m/z for (C15H15O) [M + H] 
calculated 211.1117 found 211.1115. 
These data were consistent with those previously reported.
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 trans-3,4-Dimethoxystilbene (65) 
 
65 was synthesized from 3,4-dimethoxybenzaldehyde (5.0 g, 30 mmol) using 
Horner-Wadsworth-Emmons reaction and purified by recrystallization to give the 
title compound (4.10 g, 57% ) as a pale-yellow solid, mp 109 - 110 ºC (MeOH), 
(lit.,
235
 mp 108 - 109 ºC); IR (neat) υmax/cm
-1
 2963 (C-H), 1590 (C=C); 
1
H NMR 
(300 MHz, CDCl3) δ ppm 7.49 (2H, d, J = 7.5, ortho Ph-H), 7.34 (2H, J = 7.5, meta 
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Ph-H), 7.24 (1H, m, para Ph-H), 7.13 – 7.01 (3H, m, CH=CH and ortho Ar-H), 6.96 
(1H, d, J = 16.5, CH=CH), 6.85 (1H, d, J = 8.0, CHCHCOMe), 3.94 (3H, s, OCH3), 
3.89 (3H, s, OCH3); 
13
C NMR (75 MHz, CDCl3) δ ppm 148.5, 148.3 (COMe), 136.9, 
129.8 (ipso Ar-C), 128.1, 127.9, 126.7, 126.2, 125.7, 119.3 (Ar-CH and CH=CH), 
110.6 (CHCHCOMe), 108.1 (CHCOMe), 55.3, 55.3 (OCH3); HRMS (+ESI) m/z for 
(C16H17O2) [M + H] calculated 241.1223 found 241.1227. 
These data were consistent with those previously reported.
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trans-3,5-Dimethoxystilbene (66) 
 
66 was synthesized from 3,5-dimethoxybenzaldehyde (2.0 g, 11 mmol) using 
Horner-Wadsworth-Emmons reaction and purified by standard silica 
chromatography using hexane as eluent to give the title compound (1.28 g, 48%) as a 
pale-yellow solid, mp 55 - 56 ºC, (lit.,
233
 mp 53 - 55 ºC); IR (neat) υmax/cm
-1
 2954 
(C-H), 1590 (C=C); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.44 – 7.33 (2H, m, Ar-H), 
7.30 – 7.19 (2H, m, Ar-H), 7.19 – 7.08 (1H, m, Ar-H), 6.98 (1H, d, J = 16.5, 
CH=CH), 6.91 (1H, d, J = 16.5, CH=CH), 6.57 (2H, d, J = 2.5, COMeCHCOMe), 
6.29 (1H, t, J = 2.0, CHCOMe), 3.70 (6H, s, OCH3); 
13
C NMR (75 MHz, CDCl3) δ 
ppm 161.0 (COMe), 139.4, 137.2 (ipso Ar-C), 129.2 (CH=CH), 128.8 (2 x Ar-CH), 
127.8, 126.7 (CH=CH and Ar-CH), 104.6 (CHCOMe), 100.0 (COMeCHCOMe), 
55.4 (OCH3); HRMS (+ESI) m/z for (C16H17O2) [M + H] calculated 241.1223 found 
241.1229.  
These data were consistent with those previously reported.
233
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General procedure for the preparation of substituted diphenylpropenoic acid:  
trans-[(4-Fluorophenyl)methylene]phenylacetic acid (67) 
 
A stirred mixture of phenylacetic acid (5.45 g, 40 mmol, 1.0 equiv.) and 4-
fluorobenzaldehyde (4.96 g, 40 mmol, 1.0 equiv.) in triethylamine (4 mL, 29 mmol, 
0.7 equiv.) and acetic anhydride (8 mL, 85 mmol, 2.1 equiv.) were heated at reflux 
for 5 hours. To the cooled reaction mixture, concentrated HCl (9 mL) and water (40 
mL) were added. The precipitate was filtered and washed with cold water (2 x 20 
mL). The filter cake was mixed with water (50 mL) and extracted with CH2Cl2 (3 x 
50 mL). The combined organic layers were extracted with 1 M aqueous NaOH 
solution (3 x 50 mL) and the alkaline solutions were acidified to pH 2 with 1 M 
hydrochloric acid. After that, the aqueous solution was extracted with CH2Cl2 (3 x 
50 mL) and the organic extracts were combined, dried over MgSO4 and concentrated 
under vacuum to give a crude mixture. The crude mixture was purified by 
recrystallization to give 67 (5.40 g, 56%) as an intense yellow needle-like crystal, mp 
187 - 188 ºC (CH3CN), (lit.,
237
 mp 192 – 195 ºC); IR (neat) υmax/cm
-1
 2795 (br OH), 
1668 (C=O), 1157 (C-F); 
1
H NMR (300 MHz, d6-DMSO) δ ppm 12.77 (1H, br, s, 
COOH), 7.78 (1H, s, CHCCO2H), 7.45 – 7.29 (3H, m, Ar-H), 7.22 – 7.14 (2H, m, 
Ar-H), 7.14 – 6.96 (4H, m, Ar-H); 13C NMR (75 MHz, d6-DMSO) δ ppm 168.3 
(COOH), 162.1 (d, 
1
JC-F = 248.0, CF), 137.8 (CHCCO2H), 136.1, 133.1 (ipso Ar-C 
or CHCCO2H), 132.3 (d, 
3
JC-F = 8.5, CHCHCF), 131.0 (d, 
4
JC-F = 3.0, ipso Ar-C), 
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129.4, 128.6, 127.6 (Ar-CH), 115.3 (d, 
2
JC-F = 21.5, CHCF); HRMS (-ESI) m/z for 
(C15H10FO2) [M-H] calculated 241.0670 found 241.0672.  
These data were consistent with those previously reported.
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trans-[(4-Chlorophenyl)methylene]phenylacetic acid (68) 
 
Prepared in a similar manner to compound 67, 4-chlorobenzaldehyde (5.62 g, 40 
mmol, 1.0 equiv.) was reacted with phenylacetic acid (5.45 g, 40 mmol, 1.0 equiv.) 
in triethylamine (4.0 mL, 29 mmol, 0.7 equiv.) and acetic anhydride (8.0 mL, 85 
mmol, 2.1 equiv.) to give a crude material. The crude product was purified by 
recrystallization to give 68 (7.0 g, 68%) as a pale-yellow needle-like crystal, mp 
>300 ºC (CH3CN), (lit.,
238
 mp 323 – 326 ºC); IR (neat) υmax/cm
-1
 3340 (br OH), 1653 
(C=O), 1632 (C=C), 774 (C-Cl); 
1
H NMR (300 MHz, d6-DMSO) δ ppm 7.47 (1H, s, 
CHCCO2H), 7.34 – 7.16 (3H, m, Ar-H), 7.16 – 7.07 (4H, m, Ar-H), 6.97 – 6.89 (2H, 
m, Ar-H); 
13
C NMR (75 MHz, d6-DMSO) δ ppm 171.2 (COOH), 143.1, 139.8, 
135.8, 131.3 (ipso Ar-C, CCl or CHCCO2H), 130.9, 130.6, 129.3, 127.8, 127.7, 
126.1 (Ar-CH and CHCHCHCOMe); HRMS (-ESI) m/z for (C15H10
35
ClO2) [M-H] 
calculated 257.0375 found 257.0379. 
This compound is known, but no spectroscopic data were reported.
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trans-[(3-Methoxyphenyl)methylene]phenylacetic acid (69) 
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Prepared in a similar manner to compound 67, 3-anisaldehyde (2.72 g, 20 mmol, 1.0 
equiv.) was reacted with phenylacetic acid (2.72 g, 20 mmol, 1.0 equiv.) in 
triethylamine (2.0 mL, 14 mmol, 0.7 equiv.) and acetic anhydride (3.8 mL, 40 mmol, 
2.0 equiv.) to give a crude material. The crude product was purified by 
recrystallization to give 69 (2.0 g, 39%) as a pale-yellow needle-like crystal, mp 189 
- 190 ºC (CH3CN), (lit.,
240
 mp 191 - 192 ºC); IR (neat) υmax/cm
-1
 3057 (C-H), 2832 
(O-CH3), 1660 (C=O), 1609 (C=C); 
1
H NMR (300 MHz, d6-DMSO) δ ppm 12.77 
(1H, s, CO2H), 7.77 (1H, s, CHCCO2H), 7.46 – 7.30 (3H, m, Ar-H), 7.24 – 7.16 (2H, 
m, Ar-H), 7.12 (1H, t, J = 8.0, CHCHCHCOMe), 6.80 (1H, dd, J = 8.0, 2.5, 
CHCOMe or CHCHCHCOMe), 6.73 (1H, d, J = 8.0, 1H, CHCOMe or 
CHCHCHCOMe), 6.54 (1H, s, MeOCCHCCHCCO2H), 3.46 (3H, s, OCH3); 
13
C 
NMR (75 MHz, d6-DMSO) δ ppm 168.2 (COOH), 158.7 (COMe), 138.9 
(CHCCO2H), 136.4, 135.6, 133.5 (ipso Ar-C or CHCCO2H), 129.4, 129.3, 128.5, 
127.5, 123.2 (Ar-CH and CHCHCHCOMe), 116.5 (CHCOMe or CHCHCHCOMe), 
114.5 (MeOCCHCCHCCO2H), 54.4 (OCH3); HRMS (-ESI) m/z for (C16H13O3) [M-
H] calculated 253.0870 found 253.0864.  
These data were consistent with those previously reported.
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trans-[(4-Methoxyphenyl)methylene]phenylacetic acid (70) 
 
Prepared in a similar manner to compound 67, 4-anisaldehyde (2.72 g, 20 mmol, 1.0 
equiv.) was reacted with phenylacetic acid (2.72 g, 20 mmol, 1.0 equiv.) in 
triethylamine (2.0 mL, 14 mmol, 0.7 equiv.) and acetic anhydride (4.0 mL, 42 mmol, 
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2.1 equiv.) to give a crude material. The crude product was purified by 
recrystallization to give 70 (2.20 g, 43%) as a pale-yellow needle-like crystal, mp 188 
- 189 ºC (CH3CN), (lit.,
237
 mp 188 - 189 ºC); IR (neat) υmax/cm
-1
: 2940 (C-H), 2842 
(O-CH3), 1666 (C=O), 1600 (C=C); 
1
H NMR (300 MHz, d6-DMSO) δ ppm 12.56 
(1H, s, CO2H), 7.74 (1H, s, CHCCO2H), 7.52 – 7.25 (3H, m, Ar-H), 7.18 (2H, m, 
Ar-H), 7.00 (2H, d, J = 9.0, CHCHCOMe), 6.75 (2H, d, J = 9.0, CHCOMe), 3.69 
(3H, s, OCH3); 
13
C NMR (75 MHz, d6-DMSO) δ ppm 168.5 (COOH), 159.9 
(COMe), 138.8 (CHCCO2H), 136.8 (ipso Ar-C or CHCCO2H), 132.0 
(CHCHCOMe), 130.7 (ipso Ar-C or CHCCO2H), 129.5, 128.6, 127.4 (Ar-CH), 
126.7 (ipso Ar-C or CHCCO2H), 113.8 (CHCOMe), 55.1 (OCH3); HRMS (-ESI) m/z 
for (C16H13O3) [M-H] calculated 253.0870 found 253.0873. 
These data were consistent with those previously reported.
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trans-[(2,3-Dimethoxyphenyl)methylene]phenylacetic acid (71) 
 
Prepared in a similar manner to compound 67, 2,3-dimethoxybenzaldehyde (6.65 g, 
40 mmol, 1.0 equiv.) was reacted with phenylacetic acid (5.45 g, 40 mmol, 1.0 
equiv.) in triethylamine (4.0 mL, 29 mmol, 0.7 equiv.) and acetic anhydride (8.0 mL, 
85 mmol, 2.1 equiv.) to give a crude material. The crude product was purified by 
recrystallization to give 71 (7.98 g, 70%) as a pale-yellow needle-like crystal, mp 
156 - 157 ºC (CH3CN), (lit.,
242
 mp 154 - 155 ºC); IR (neat) υmax/cm
-1
 2923 (C-H), 
2824 (O-CH3), 1667 (C=O), 1572 (C=C); 
1
H NMR (300 MHz, d6-DMSO) δ ppm 
7.97 (1H, s, CHCCO2H), 7.40 – 7.20 (3H, m, Ar-H), 7.23 – 7.04 (2H, m, Ar-H), 6.91 
(1H, dd, J = 8.0, 1.0, CHCOMe or CHCHCHCOMe), 6.74 – 6.63 (1H, t, J = 8.0, 
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CHCHCOMe), 6.16 (1H, dd, J = 8.0, 1.0, CHCOMe or CHCHCHCOMe), 3.80 (3H, 
s, OCH3), 3.78 (3H, s, OCH3); 
13
C NMR (75 MHz, d6-DMSO) δ ppm 168.3 
(COOH), 152.3, 147.9 (COMe), 136.0 (ipso Ar-C), 134.0 (CHCCO2H), 133.8 
(CHCCO2H), 129.7 (ortho Ph-CH), 128.5 (ipso Ar-C), 128.1, 127.4 (meta and para 
Ph-CH), 123.3 (CHCHCHCOMe), 121.3 (CHCHCOMe), 113.3 (CHCOMe), 60.6, 
55.6 (OCH3); HRMS (-ESI) m/z for (C17H15O3) [M-H] calculated 283.1009 found 
283.0981. 
These data were consistent with those previously reported.
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trans-[(3,4-Dimethoxyphenyl)methylene]phenylacetic acid (72) 
 
Prepared in a similar manner to compound 67, 3,4-dimethoxybenzaldehyde (3.32 g, 
20 mmol, 1.0 equiv.) was reacted with phenylacetic acid (2.72 g, 20 mmol, 1.0 
equiv.) in triethylamine (2.0 mL, 14 mmol, 0.7 equiv.) and acetic anhydride (3.8 mL, 
40 mmol, 2.0 equiv.) to give a crude material. The crude product was purified by 
recrystallization to give 72 (2.13 g, 38%) as a pale-yellow needle-like crystal, mp 
224 - 225 ºC (CH3CN), (lit.,
242
 mp 231 – 232 ºC); IR (neat) υmax/cm
-1
 2935 (C-H), 
2800 (O-CH3), 1664 (C=O), 1574 (C=C); 
1
H NMR (300 MHz, d6-DMSO) δ ppm 
12.55 (1H, s, CO2H), 7.72 (1H, s, CHCCO2H), 7.48 – 7.30 (3H, m, Ar-H), 7.28 – 
7.15 (2H, m, Ar -H), 6.87 – 6.77 (2H, m, CHCOMeCOMe and CHCHCOMe), 6.46 
(1H, s, CCHCOMe), 3.73 (3H, s, OCH3), 3.29 (3H, s, OCH3); 
13
C NMR (75 MHz, 
d6-DMSO) δ ppm 168.5 (COOH), 149.7, 147.8 (COMe), 139.2 (CHCCO2H), 136.9 
(ipso Ar-C), 130.6 (CHCCO2H), 129.6, 128.6, 127.4 (Ar-CH), 126.8 (ipso Ar-C), 
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124.8 (CHCHCOMe), 112.5 (CCHCOMe), 111.1 (CHCHCOMe), 55.3, 54.5 
(OCH3); HRMS (-ESI) m/z for (C17H15O3) [M-H] calculated 283.0976 found 
283.0975. 
These data were consistent with those previously reported.
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trans-[(3,5-Dimethoxyphenyl)methylene]phenylacetic acid (73) 
 
Prepared in a similar manner to compound 67, 3,5-dimethoxybenzaldehyde (3.32 g, 
20 mmol, 1.0 equiv.) was reacted with phenylacetic acid (2.72 g, 20 mmol, 1.0 
equiv.) in triethylamine (2.0 mL, 14 mmol, 0.7 equiv.) and acetic anhydride (3.8 mL, 
40 mmol, 2.0 equiv.) to give a crude material. The crude product was purified by 
recrystallization to give 73 (3.41 g, 60%) as a pale-yellow needle-like crystal, mp 
206 - 207 ºC (CH3CN), (lit.,
242
 mp 204 – 206 ºC); IR (neat) υmax/cm
-1
 2944 (C-H), 
2832 (O-CH3), 1668 (C=O), 1583 (C=C); 
1
H NMR (300 MHz, d6-DMSO) δ ppm 
12.78 (1H, s, CO2H), 7.74 (1H, s, CHCCO2H), 7.54 – 7.29 (3H, m, Ar-H), 7.29 – 
7.10 (2H, m, Ar-H), 6.40 (1H, t, J = 2.0, COMeCHCOMe), 6.27 (2H, d, J = 2.0, 
CHOMe), 3.52 (6H, s, OCH3); 
13
C NMR (75 MHz, d6-DMSO) δ ppm 168.2 
(COOH), 159.9 (COMe), 139.0 (CHCCO2H), 136.5, 136.0 (ipso Ar-C), 133.7 
(CHCCO2H), 129.4, 128.5, 127.5 (Ar-CH), 108.2 (CHCOMe), 101.4 
(COMeCHCOMe), 54.8 (OCH3); HRMS (-ESI) m/z for (C17H15O3) [M-H] calculated 
283.0976 found 283.0980. 
These data were consistent with those previously reported.
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trans-[(2,4,5-Trimethoxyphenyl)methylene]phenylacetic acid (74) 
 
Prepared in a similar manner to compound 67, 2,4,5-trimethoxybenzaldehyde (7.85 
g, 40 mmol, 1.0 equiv.) was reacted with phenylacetic acid (5.45 g, 40 mmol, 1.0 
equiv.) in triethylamine (4.0 mL, 29 mmol, 0.7 equiv.) and acetic anhydride (8.0 mL, 
85 mmol, 2.1 equiv.) to give a crude material. The crude product was purified by 
recrystallization to 74 (5.40 g, 48%) as a pale-yellow needle-like crystal, mp 219 - 
220 ºC (CH3CN), (lit.,
243
 mp 220 ºC); IR (neat) υmax/cm
-1
 2945 (C-H), 2850 (O-CH3), 
1666 (C=O), 1581 (C=C); 
1
H NMR (300 MHz, d6-DMSO) δ ppm 12.47 (1H, br, s, 
COOH), 8.04 (1H, s, CHCCO2H), 7.49 – 7.24 (3H, m, Ph-H), 7.24 – 7.13 (2H, m, 
Ph-H), 6.65 (1H, s, CHCOMe), 6.11 (1H, s, CHCOMe), 3.86 (3H, s, OCH3), 3.78 
(3H, s, OCH3), 3.04 (3H, s, OCH3); 
13
C NMR (75 MHz, d6-DMSO) δ ppm 168.6 
(COOH), 153.5, 150.9, 141.5, 137.1 (COMe or ipso Ar-C or CHCCO2H), 133.2 
(CHCCO2H), 129.8 (Ph-C), 129.7 (COMe or ipso Ar-C or CHCCO2H), 128.5, 127.2 
(Ph-C), 113.5 (COMe or ipso Ar-C or CHCCO2H), 112.5, 97.2 (CHCOMe), 56.3, 
55.6, 54.6 (OCH3); HRMS (-ESI) m/z for (C18H17O3) [M-H] calculated 313.1081 
found 313.1079. 
This is a known compound and NMR spectroscopic data have previously been 
reported in CDCl3.
244
   
trans-[(3,4,5-Trimethoxyphenyl)methylene]phenylacetic acid (75) 
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Prepared in a similar manner to compound 67, 3,4,5-trimethoxybenzaldehyde (7.85 
g, 40 mmol, 1.0 equiv.) was reacted with phenylacetic acid (5.45 g, 40 mmol, 1.0 
equiv.) in triethylamine (4.0 mL, 29 mmol, 0.7 equiv.) and acetic anhydride (8.0 mL, 
85 mmol, 2.1 equiv.) to give a crude material. The crude product was purified by 
recrystallization to give 75 (7.81 g, 63%) as a pale-yellow needle-like crystal, mp 
185 - 186 ºC (CH3CN), (lit.,
245
 mp 186 - 187 ºC); IR (neat) υmax/cm
-1
 2940 (C-H), 
2830 (O-CH3), 1666 (C=O), 1579 (C=C), 1505 (Ar); 
1
H NMR (300 MHz, d6-
DMSO) δ ppm 12.67 (1H, br, s, COOH), 7.73 (1H, s, CHCCO2H), 7.52 – 7.30 (3H, 
m, Ar-H), 7.26 – 7.16 (2H, m, Ar-H), 6.40 (2H, s, CHCOMe), 3.61 (3H, s, para 
OCH3), 3.45 (6H, s, meta OCH3); 
13
C NMR (75 MHz, d6-DMSO) δ ppm 168.3 
(COOH), 152.2 (ipso Ar-C or COMe or CHCCOOH), 139.1 (CHCCOOH), 138.2, 
136.7, 132.3 (ipso Ar-C or COMe or CHCCOOH), 129.5, 128.6, 127.4 (Ar-C), 108.0 
(CHCOMe), 59.9 (para OCH3), 55.2 (meta OCH3); HRMS (-ESI) m/z for 
(C18H17O3) [M-H] calculated 313.1081 found 313.1091.               
This is a known compound and NMR spectroscopic data have previously been 
reported in CDCl3.
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General procedure for decarboxylation of diarylpropenoic acid: 
cis-3-Methoxystilbene (76) 
 
To a solution of trans-[(3-methoxyphenyl)methylene]phenylacetic acid (69) (1.4 g, 
5.5 mmol, 1.0 equiv.) in quinoline (7.2 mL, 61 mmol, 11 equiv.) was added copper 
chromite (0.11 g, 0.71 mmol, 0.12 equiv.). The resulting mixture was stirred and 
heated to reflux at 230 - 240 ºC for 2 h. After cooling to room temperature, the 
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reaction mixture was filtered through Celite and washed with ethyl acetate. The 
organic layer was repeatedly washed with 2 M HCl, dried over MgSO4 and 
concentrated under vacuum to give a mixture of cis- and trans-isomers. Careful 
separation of the two stereoisomers on silica chromatography using hexane as eluent 
allowed 76 (0.84 g, 73%) to be isolated as a pale-yellow oil; IR (neat) υmax/cm
-1
 3008 
(C-H), 1576 (C=C); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.47 – 7.05 (6H, m, Ar-H), 
6.99 – 6.82 (2H, m, Ar-H), 6.82 – 6.71 (1H, m, Ar-H),  6.60 (1H, d, J = 12.5, 
CH=CH), 6.54 (1H, d, J = 12.5, CH=CH), 3.63 (3H, s, OCH3); 
13
C NMR (75 MHz, 
CDCl3) δ ppm 158.9 (COMe), 138.0, 136.8 (ipso Ar-C), 130.0, 129.7, 128.8, 128.4, 
127.7, 126.7, 121.0, 113.3, 112.8 (Ar-CH or CH=CH), 54.5 (OCH3); HRMS (+ESI) 
m/z for (C15H15O) [M + H] calculated 211.1117 found 211.1120. 
These data were consistent with those previously reported.
246
 
 
 cis-4-Methoxystilbene (77) 
 
Prepared in a similar manner to compound 76, the decarboxylation of trans-[(4-
methoxyphenyl)methylene]-phenylacetic acid (70) (1.8 g, 7.0 mmol, 1.0 equiv.) was 
achieved using quinoline (9.2 mL, 78 mmol, 11 equiv.) and copper chromite (0.12 g, 
0.78 mmol, 0.11 equiv.) to give a mixture of cis- and trans-isomers. Careful 
separation of the two stereoisomers on silica chromatography using hexane as eluent 
allowed 77 (1.16 g, 78%) to be isolated as a pale-yellow oil; IR (neat) υmax/cm
-1
 3006 
(C-H), 1605 (C=C); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.40 - 7.15 (7H, m, Ar-H), 
6.94 – 6.70 (2H, m, Ar-H), 6.60 (1H, d, J = 12, CH=CH), 6.55 (1H, J = 12, 
CH=CH), 3.80 (3H, s, OCH3);
 13C NMR (75 MHz, CDCl3) δ ppm 158.1 (COMe), 
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137.1 (ipso Ar-C), 129.6, 129.3, (Ar-CH or CH=CH) 129.1 (ipso Ar-C), 128.3, 
128.2, 127.7, 126.4, 113.0 (Ar-C or CH=CH), 54.6 (OCH3); HRMS (+ESI) m/z for 
(C15H15O) [M + H] calculated 211.1117 found 211.1115. 
These data were consistent with those previously reported.
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cis-3,4-Dimethoxystilbene (78) 
 
Prepared in a similar manner to compound 76,  the decarboxylation of trans-[(3,4-
dimethoxyphenyl)methylene]phenylacetic acid (72) (1.0 g, 3.5 mmol, 1.0 equiv.) 
was achieved using quinoline (4.5 mL, 38 mmol, 11 equiv.) and copper chromite 
(0.06 g, 0.39 mmol, 0.11 equiv.) to give a mixture of cis- and trans-isomers. Careful 
separation of the two stereoisomers on silica chromatography using hexane as eluent 
allowed 78 (0.67 g, 80%) to be isolated as a pale-yellow oil; IR (neat) υmax/cm
-1
 2954 
(C-H), 1599 (C=C); 
1
H NMR (300 MHz, CDCl3) 
1
H NMR (300 MHz, CDCl3) δ 
ppm 7.39 - 7.11 (5H, m, Ph-H), 6.84 (1H, dd, J = 8.0, 2.0, Ar-H), 6.85 – 6.75 (2H, 
m, Ar-H), 6.57 (1H, d, J = 12.5, CH=CH), 6.52 (1H, d, J = 12.5, CH=CH), 3.84 (3H, 
s, OCH3), 3.57 (3H, s, OCH3); 
13
C NMR (75 MHz, CDCl3) δ ppm 148.3, 148.2 
(COMe), 137.7 (ipso Ar-C), 130.0 (Ar-CH or CH=CH), 129.8 (ipso Ar-C), 128.9, 
128.3, 127.0, 126.9, 121.9 (Ar-CH or CH=CH), 111.7, 110.8 (CHCOMe), 55.8, 55.4 
(OCH3); HRMS (ESI) m/z for (C16H17O2) [M + H] calculated 241.1223 found 
241.1224.  
These data were consistent with those previously reported.
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cis-3,5-Dimethoxystilbene (79) 
173 
 
 
Prepared in a similar manner to compound 76,  the decarboxylation of trans-[(3,5-
dimethoxyphenyl)methylene]phenylacetic acid (73) (1.7 g, 6 mmol, 1.0 equiv.) was 
achieved using quinoline (7.9 mL, 66 mmol, 11 equiv.) and copper chromite (0.11 g, 
0.71 mmol, 0.11 equiv.) to give a mixture of cis- and trans-isomers. Careful 
separation of the two stereoisomers on silica chromatography using hexane as eluent 
allowed 79 (0.81 g, 56%) to be isolated as a pale-yellow oil; IR (neat) υmax/cm
-1
 2955 
(C-H), 1586 (C=C); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.33 - 7.12 (5H, m, Ar-H), 
6.62 (1H, d, J = 12.0, CH=CH), 6.53 (1H, d, J = 12.0, CH=CH), 6.41 (2H, d, J = 2.5, 
CCHCOMe), 6.32 (1H, t, J = 2.5, COMeCHCOMe), 3.63 (6H, s, OCH3); 
13
C NMR 
(75 MHz, CDCl3) δ ppm 159.9 (COMe), 138.5, 136.7 (ipso Ar-C), 130.1, 129.7, 
128.8, 127.6, 126.6 (Ar-CH and CH=CH), 106.1 (COMeCHCOMe), 99.3 
(CHCOMe), 54.6 (OCH3); HRMS (+ESI) m/z for (C16H17O2) [M + H] calculated 
241.1223 found 241.1226. 
These data were consistent with those previously reported.
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cis-2,3-Dimethoxystilbene (80) 
 
Prepared in a similar manner to compound 76, the decarboxylation of trans-[(2,3-
dimethoxyphenyl)methylene]phenylacetic acid (71) (9.3 g, 33 mmol, 1.0 equiv.) was 
achieved using quinoline (43 mL, 0.36 mol, 11 equiv.) and copper chromite (0.56 g, 
3.6 mmol, 0.11 equiv.) to give a mixture of cis- and trans-isomers. Careful 
separation of the two stereoisomers on silica chromatography using hexane as eluent 
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allowed 80 (2.1 g, 26%) to be isolated as a pale-yellow oil which solidified upon 
storage at 0 ºC, mp 47 - 48 ºC; IR (neat) υmax/cm
-1
 2956 (C-H), 1575 (C=C); 
1
H 
NMR (300 MHz, CDCl3) δ ppm 7.33 - 7.09 (5H, m, Ar-H), 6.88 – 6.75 (3H, m, Ar-
H), 6.75 (1H, d, J = 12.5, CH=CH), 6.66 (1H, d, J = 12.5, CH=CH), 3.89 (3H, s, 
OCH3), 3.87 (3H, s, OCH3); 
13
C NMR (75 MHz, CDCl3) δ ppm 152.2, 146.5 
(COMe), 136.5, 131.2 (ipso Ar-C), 130.2, 128.4, 127.5, 126.5, 125.1, 123.0, 121.4, 
110.7 (CH=CH or Ar-C), 55.2 (2 x OCH3); HRMS (+ESI) m/z for (C16H16NaO2) [M 
+ Na] calculated 263.1043 found 263.1042. 
 
cis-3,4,5-Timethoxystilbene (81) 
 
Prepared in a similar manner to compound 76,  the decarboxylation of trans-[(3,4,5-
trimethoxyphenyl)methylene]phenylacetic acid (75) (6.28 g, 20 mmol, 1.0 equiv.) 
was achieved using quinoline (26 mL, 0.22 mol, 11 equiv.) and copper chromite 
(0.34 g, 2.2 mmol, 0.11 equiv.) to give a mixture of cis- and trans-isomers. Careful 
separation of the two stereoisomers on silica chromatography using hexane as eluent 
allowed 81 (3.48 g, 64%) to be isolated as a pale-yellow oil; IR (neat) υmax/cm
-1
 2937 
(C-H), 1579 (C=C); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.31 - 7.07 (5H, m, Ar-H), 
6.56 (1H, d, J = 12.0, CH=CH), 6.45 (1H, d, J = 12.0, CH=CH), 6.42 (2H, s, 
CHCOMe), 3.79 (3H, s, para OCH3), 3.60 (6H, s, meta OCH3); 
13
C NMR (75 MHz, 
CDCl3) δ ppm 152.2, 136.9 (COMe), 136.5, 131.8 (ipso Ar-C), 129.5, 129.4, 128.3, 
127.6, 126.5, (Ar-CH and CH=CH), 105.5 (CHCOMe), 60.2, 55.2 (OCH3);  HRMS 
(+ESI) m/z for (C17H18NaO3) [M + Na] calculated 293.1148 found 293.1151.  
These data were consistent with those previously reported.
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General procedure for iodine-catalysed isomerisation of cis- to trans-
diarylthene: 
Iodine (one crystal) was added to a solution of the Z/E mixture of diarylethene (5 
mmol) in hexane (50 mL), the resulting solution was heated at reflux at 70 ºC for 2 
days. After cooling to room temperature, the reaction mixture was diluted with ethyl 
acetate (50 mL) and washed with saturated aqueous sodium bisulfate. The organic 
layer was dried over MgSO4 and concentrated under vacuum to give predominated 
the corresponding E isomer which was purified by recrystallization or silica 
chromatography.  
  
trans-4-Fluorostilbene (82) 
 
 82 (1.47 g, 37%) was isolated as a white solid, mp 125 - 126 ºC (MeOH), (lit.,
249
 mp 
125 ºC); IR (neat) υmax/cm
-1
 3000 (C-H), 1590 (C=C); 
1
H NMR (300 MHz, CDCl3) δ 
ppm 7.30 - 7.16 (4H, m, Ar-H or CH=CH), 7.16 – 7.07 (2H, m, Ar-H or CH=CH), 
7.06 – 6.96 (1H, m, Ar-H or CH=CH), 6.87 – 6.72 (4H, m, Ar-H or CH=CH); 13C 
NMR (75 MHz, CDCl3) δ ppm 161.7 (d, 
1
JCF = 247.0, CF), 137.3 (ipso Ph-C), 133.6 
(d, 
4
JCF = 3.0, CCHCHCF), 128.9 (CH=CH or Ar-CH), 128.6 (d, 
5
JCF = 2.0, 
CHC6H4F), 127.4 (d, 
3
JCF = 8.0, CHCF), 127.8, 127.6, 126.6, (CH=CH or Ar-CH), 
115.8 (d, 
2
JCF = 21.50, CHCF);
 19
F NMR (282 MHz, CDCl3) δ ppm -114.8.  
These data were consistent with those previously reported.
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trans-4-Chlorostilbene (83) 
 
83 (1.58 g, 37%) was isolated as a white solid, mp 131 - 132 ºC (MeOH), (lit.,
250
 mp 
130 - 132 ºC); IR (neat) υmax/cm
-1
 2950 (C-H), 1576 (C=C); 
1
H NMR (300 MHz, 
CDCl3) δ ppm 7.41 – 7.52 (2H, m, Ar-C), 7.37 – 7.31 (2H, m, Ar-C), 7.31 – 7.13 
(5H, m, Ar-C), 7.00 (1H, d, J = 16.5, CH=CH), 6.94 (1H, d, J = 16.5, CH=CH); 
13
C 
NMR (75 MHz, CDCl3) δ ppm 137.0, 135.9, 133.1 (ipso Ar-C or CCl), 129.3, 128.9, 
128.8, 127.9, 127.7, 127.4, 126.6 (Ar-CH or CH=CH).  
These data were consistent with those previously reported.
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trans-2,3-Dimethoxystilbene (84) 
 
84 (3.12 g, 38%) was purified by standard silica chromatography using 20:80 
EtOAc:hexane to give a waxy solid, mp 39 - 40 ºC, (lit.,
235
 mp 37 - 39 ºC); IR (neat) 
υmax/cm
-1
 2934 (C-H), 1598 (C=C); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.45 (2H, d, 
J = 7.5, ortho Ph-H), 7.37 (1H, d, J = 16.5, CH=CH), 7.31 – 7.20 (2H, m, meta Ph-
H), 7.20 – 7.10 (2H, m, CHCHCHCOMe and para Ph-H), 7.02 (d, J = 16.5, 
CH=CH), 6.95 (1H, t, J = 8.0, CHCHCOMe), 6.73 (dd, J = 8.1, 1.3, CHCOMe), 3.75 
(3H, s, OCH3), 3.73 (3H, s, OCH3); 
13
C NMR (75 MHz, CDCl3) δ ppm 152.5, 146.4 
(COMe), 137.1, 131.0 (ipso Ar-C), 129.3, (para Ph-CH), 128.1 (meta Ph-CH), 127.1 
(CH=CH), 126.1 (ortho Ph-CH), 123.5 (CH=CH), 122.3 (CHCHCOMe), 117.3 
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(CHCHCHCOMe), 110.8 (CHCOMe), 60.3, 55.4 (OCH3); HRMS (+ESI) m/z for 
(C16H17O2) [M + H] calculated 241.1223 found 241.1222. 
These data were consistent with those previously reported.
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trans-3,4,5-Trimethoxystilbene (85) 
 
85 (1.54 g, 29%) was isolated as a white solid.  mp 107 - 108 ºC (MeOH), (lit.,
235, 248
 
mp 107 – 108 ºC); IR (neat) υmax/cm
-1
 2966 (C-H), 1583 (C=C); 
1
H NMR (300 MHz, 
CDCl3) δ ppm 7.48 – 7.31 (2H, m, Ar-H), 7.29 – 7.18 (2H, m, Ar-H), 7.14 (1H, m, 
Ar-H), 6.94 (1H, d, J = 16.5, CH=CH), 6.88 (1H, d, J = 16.5, CH=CH), 6.62 (2H, s, 
CHCOMe), 3.79 (6H, s, meta OCH3), 3.76 (3H, s, para OCH3); 13C NMR (75 MHz, 
CDCl3) δ ppm 153.7, 138.2 (COMe), 137.5, 133.3 (ipso Ar-C), 129.0, 128.9, 128.4, 
127.9, 126.7, 103.8, (CHCOMe and Ar-CH), 60.6, 56.4 (OCH3); HRMS (+ESI) m/z 
for (C17H18NaO3) [M + Na] calculated 293.1148 found 293.1149. 
These data were consistent with those previously reported.
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Typical reaction conditions for room temperature difluorocyclopropanation:  
NaI (5.0 equiv.) and TMSCF3 (5.0 equiv.) were added to a pressure tube containing 
the alkene (1.0 equiv.) in CH3CN (1 mL per 1.25 mmol of TMSCF3 and NaI). The 
pressure tube was tightly sealed and the reaction mixture was stirred at room 
temperature for 14 days. The reaction mixture was filtered and the solid washed with 
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twice with CH3CN (10 mL). The filtrate and washings were reduced under vacuum 
to give a crude product which was not purified and directly used for the next step.  
 
General procedure for the oxidative cleavage of olefins and isolation of 
diphenyldifluorocyclopropanes: 
Oxone (4 equiv.) was added to potassium osmate(VI) dihydrate (0.01 equiv.) in 
DMF (0.2 M based on olefin) and the resulting mixture was stirred for 30 minutes, 
followed by addition of the olefin and difluorocyclopropane mixture in DMF (1 ~ 2 
mL). The stirring was continued for overnight, after which Na2SO3 (4.2 equiv.) was 
added and stirred for an additional hour. The resultant mixture was diluted with ethyl 
acetate and stirred for 10 minutes. The solid was filtered and the filter cake was 
washed with EtOAc. The organic exacts were washed 3 times with 1 M HCl and 
twice with diluted NaHCO3 solution, dried over MgSO4 and concentrated under 
vacuum to give an oil. The crude material was purified by standard silica 
chromatography to give diaryldifluorocyclopropanes most of the time as a white 
solid.  
 
(±)-cis-1,1-Difluoro-2-(3-methoxyphenyl)-3-phenylcyclopropane (86) 
 
The reaction of cis-3-methoxystilbene (76) (0.42, 2 mmol, 1.0 equiv.) with TMSCF3 
(1.48 mL, 10 mmol, 5.0 equiv.) and NaI (1.50 g, 10 mmol, 5.0 equiv.)  in CH3CN (8 
mL) gave a dark-brown crude product. The crude product was purified by standard 
silica chromatography using hexane as eluent to give 86 (0.23 g, 44%) a pale-yellow 
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oil with cis- and trans-isomeric ratio of ~98:2; IR (neat) υmax/cm
-1
 3029 (C-H), 1602 
(C=C), 1257 (C-F), 1142 (C-O); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.33 – 7.21 
(3H, Ar-H), 7.22 – 7.04 (3H, Ar-H), 6.80 (1H, m, Ar-H), 6.70 (1H, m, Ar-H), 6.52 
(1H, s, CHCOMeCH), 3.63 (3H, s, OCH3), 3.33 – 3.13 (2H, m, CHCF2); 
13
C NMR 
(75 MHz, CDCl3) δ ppm 159.5 (CHCOCH3), 132.5, 131.0 (ipso Ar-C), 130.4, 129.3, 
128.4, 127.4, 122.8, 115.3 (Ar-CH), 114.1 (dd, 
1
JC-F = 291.5, 288.5, CF2), 113.4 
(CHCOMe), 55.3 (OCH3), 32.6 (d, 
2
JC-F = 10, CHCF2), 32.3 (d, 
2
JC-F = 10, CHCF2); 
19
F NMR (282 MHz, CDCl3) δ ppm -117.6 (ddd, 
2
JF-F = 156.5,
 3
JH-F = 14.0, 5.5), -
147.2 (d, 
2
JF-F = 157.0); HRMS (+ESI) m/z for (C16H14F2NaO) [M+Na] calculated 
283.0905 found 283.0908. 
 
(±)-cis-1,1-Difluoro-2-(4-methoxyphenyl)-3-phenylcyclopropane (87) 
 
The reaction of cis-4-methoxystilbene (77) (0.84, 4 mmol, 1.0 equiv.) with TMSCF3 
(2.96 mL, 20 mmol, 5.0 equiv.) and NaI (3.0 g, 20 mmol, 5.0 equiv.)  in CH3CN (16 
mL) gave a dark-brown crude product. The crude product was purified by standard 
silica chromatography using hexane as eluent to give 87 (0.62 g, 60%) as a pale-
yellow solid with cis- and trans-isomeric ratio of 89:11, mp 37 - 39 ºC; IR (neat) 
υmax/cm
-1
 3036 (C-H), 1514 (C=C), 1250 (C-F), 1149 (C-O); 
1
H NMR (300 MHz, 
CDCl3) δ ppm 7.23 – 7.13 (3H, m, Ar-H), 7.05 – 6.87 (4H, m, Ar-H), 6.78 – 6.68 
(2H, m, CHCOMe), 3.74 (3H, s, OCH3), 3.12 (2H, dd, 
3
JH-F = 14.5, 2.0, CHCF2); 
13
C 
NMR (75 MHz, CDCl3) δ ppm 159.0 (CHCOCH3), 131.5 (Ar-CH), 131.3 (ipso Ar-
C), 130.3, 128.4, 127.2 (Ar-CH), 122.8 (ipso Ar-C), 114.3 (dd, 
1
JC-F = 291.5, 288.0, 
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CF2), 113.9 (CHCOCH3), 55.4 (OCH3), 32.3 (dd, 
2
JC-F = 12.0, 9.5, CHCF2), 31.8 
(dd, 
2
JC-F = 12.0, 9.5, CHCF2); 
19
F NMR (282 MHz, CDCl3) δ ppm -117.5 (dt, 
2
JF-F = 
156.5, 
3
JH-F = 14.5), -147.5 (d, 
2
JF-F  = 156.5); HRMS (+ESI) m/z for (C16H14F2NaO) 
[M+Na] calculated 283.0905 found 283.0906.  
 
(±)-cis-1,1-Difluoro-2-(2,3-dimethoxyphenyl)-3-phenylcyclopropane (88) 
 
The reaction of cis-2,3-dimethoxystilbene (80) (0.48, 2 mmol, 1.0 equiv.) with 
TMSCF3 (1.48 mL, 10 mmol, 5.0 equiv.) and NaI (1.50 g, 10 mmol, 5.0 equiv.)  in 
CH3CN (8 mL) gave a dark-brown crude material. The crude product was purified 
by standard silica chromatography using 20:80 EtOAc:hexane as eluent to give 88 
(0.33 g, 57%) as a pale-yellow oil with cis- and trans-isomeric ratio of ~95:5; IR 
(neat) υmax/cm
-1
: 3001 (C-H), 1442, 1476 (C=C), 1278 (C-F), 1143 (C-O); 
1
H NMR 
(300 MHz, CDCl3) δ ppm 7.23 – 7.11 (3H, m, Ar-H), 7.04 (2H, m, Ar-H), 6.89 – 
6.72 (2H, m, Ar-H), 6.57 – 6.43 (1H, m, Ar-H), 3.81 (3H, s, OCH3), 3.70 (3H, s, 
OCH3), 3.44 – 3.12 (2H, m, CHCF2); 
13
C NMR (75 MHz, CDCl3) δ ppm 152.7, 
148.9 (COMe), 131.6 (ipso Ar-C), 130.0, 128.3, 127.2 (Ar-H), 125.2 (ipso Ar-C), 
123.5, 122.1 (d, 
3
JC-F = 12.5, 8.5, ipso Ar-C), 114.7 (dd, 
1
JC-F = 291.5, 288.5, CF2), 
111.9 (CHCOMe), 55.9 (2 x OCH3), 32.4 (dd, 
2
JC-F = 11.5, 9.5, CHCF2), 27.7 (dd, 
2
JC-F = 12.5, 8.5, CHCF2). δ ppm -117.1 (dt, 
2
JF-F = 157.0, 
3
JH-F = 14.0), -147.4 (d, 
2
JF-F  = 156.5); HRMS (+ESI) m/z for (C17H16F2NaO2) [M+Na] calculated 131.1011 
found 313.1011. 
 
(±)-cis-1,1-Difluoro-2-(3,4-dimethoxyphenyl)-3-phenylcyclopropane (89) 
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The reaction of cis-3,4-dimethoxystilbene (78) (0.48, 2 mmol, 1.0 equiv.) with 
TMSCF3 (1.48 mL, 10 mmol, 5.0 equiv.) and NaI (1.50 g, 10 mmol, 5.0 equiv.)  in 
CH3CN (8 mL) gave a dark-brown crude product. The crude product was purified by 
standard silica chromatography using 20:80 EtOAc:hexane as eluent to give 89 (0.35 
g, 60%) as a waxy solid with cis- and trans-isomeric ratio of 83:17, mp 33 - 36 ºC; 
IR (neat) υmax/cm
-1
 3004 (C-H), 1516 (C=C), 1252 (C-F), 1135 (C-O); 
1
H NMR (300 
MHz, CDCl3) δ ppm 7.22 – 7.12 (3H, m, Ar-CH), 7.01 (2H, m, Ar-CH), 6.74 – 6.60 
(2H, m, Ar-CH), 6.26 (1H, s CHCOMeCOMe), 3.80 (3H, s, OCH3), 3.51 (3H, s, 
OCH3), 3.16 – 3.07 (2H, m, CHCF2); 
13
C NMR (75 MHz, CDCl3) δ ppm 148.5, 
148.3 (CHCOMe), 131.2 (ipso Ar-C), 130.4, 128.4, 127.3 (Ar-CH), 123.3 (ipso Ar-
C), 122.9 (Ar-CH), 114.2 (dd, 
1
JC-F = 291.5, 288.5, CF2), 113.1 (Ar-CH), 111.0 
(COMeCHCOMe), 56.0, 55.8 (OCH3), 32.5 – 31.9 (m, 2 x CHCF2); 
19
F NMR (282 
MHz, CDCl3) δ ppm -117.8 (dt, 
2
JF-F = 157.0, 
3
JH-F = 14.0), -147.4 (d, 
2
JF-F  = 156.5); 
HRMS (+ESI) m/z for (C17H16F2NaO2) [M+Na] calculated 131.1011 found 
313.1015. 
(±)- cis-1,1-Difluoro-2-(3,5-dimethoxyphenyl)-3-phenylcyclopropane (90) 
 
The reaction of cis-3,5-dimethoxystilbene (79) (0.48, 2 mmol, 1.0 equiv.) with 
TMSCF3 (1.48 mL, 10 mmol, 5.0 equiv.) and NaI (1.50 g, 10 mmol, 5.0 equiv.)  in 
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CH3CN (8 mL) gave a dark-brown crude product. The crude product was purified by 
standard silica chromatography using 20:80 EtOAc:hexane as eluent to give 90 (0.19 
g, 37%) as a pale-yellow solid with cis- and trans-isomeric ratio of 95:5, mp 37 - 39 
ºC; IR (neat) υmax/cm
-1
 3021 (C-H), 1608 (C=C), 1204 (C-F), 1146 (C-O); 
1
H NMR 
(300 MHz, CDCl3) δ ppm 7.34 – 7.20 (3H, m, Ar-CH), 7.20 – 7.03 (2H, m, Ar-CH), 
6.36 (1H, t, J = 2.5, COMeCHCOMe), 6.17 (2H, d, J = 2.0, CHCCHCOMe), 3.63 
(6H, s, OCH3), 3.33 – 3.08 (2H, m, CHCF2); 
13
C NMR (75 MHz, CDCl3) δ ppm 
160.5 (COMe), 133.1, 131.0 (ipso Ar-C), 130.4, 128.5, 127.4 (Ar-CH), 114.1 (dd, 
1
JC-F = 291.5, 288.5, CF2), 108.2 (CHCOMeCHCOMe), 99.9 (COMeCHCOMe), 
55.4 (2 x OCH3), 32.7 (dd, 
2
JC-F = 12.0, 9.5, CHCF2), 32.3 (dd, 
2
JC-F = 12.0, 9.5, 
CHCF2);
 19F NMR (282 MHz, CDCl3) δ ppm -117.5 (dt, 
2
JF-F = 157.0, 
3
JH-F = 14.0), -
147.0 (d, 
2
JF-F = 157.0); HRMS (+ESI) m/z for (C17H16F2NaO2) [M+Na] calculated 
131.1011 found 313.1013. 
 
(±)-cis-1,1-Difluoro-2-(3,4,5-trimethoxyphenyl)-3-phenylcyclopropane (91) 
 
The reaction of cis-3,4,5-trimethoxystilbene (81) (1.35, 5 mmol, 1.0 equiv.) with 
TMSCF3 (3.70 mL, 25 mmol, 5.0 equiv.) and NaI (3.75 g, 25 mmol, 5.0 equiv.) in 
CH3CN (20 mL) gave a dark-brown crude product. The crude product was purified 
by standard silica chromatography using 20:80 EtOAc:hexane as eluent to give 91 
(0.57 g, 36%) as a pale-yellow solid with ci- and trans-isomeric ratio of 96:4, mp 71 
- 73 ºC; IR (neat) υmax/cm
-1
 3007 (C-H), 1586, 1415 (C=C), 1238 (C-F), 1122 (C-O); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.37 – 7.21 (3H, m, Ar-H), 7.20 – 7.06 (2H, m, 
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Ar-H), 6.18 (2H, s, CHOMe), 3.85 (3H, s, para OCH3), 3.64 (6H, s, meta OCH3), 
3.33 – 3.07 (2H, m, CHCF2); 
13
C NMR (75 MHz, CDCl3) δ ppm 152.8, 137.2 (para 
and meta COMe), 130.7 (ipso Ar-C), 130.3, 128.4, 127.3 (Ar-CH), 126.3 (ipso Ar-
C), 114.0 (dd, 
1
JC-F = 292.0, 288.0, CF2), 107.3 (CHCOMe), 55.9 (2 x OCH3), 32.5 
(dd, 
2
JC-F = 12.0, 9.5, CHCF2), 32.1 (dd, 
2
JC-F = 12.0, 9.5, CHCF2);
 19
F NMR (282 
MHz, CDCl3) δ ppm -117.6 (dt, 
2
JF-F = 157.0, 
3
JH-F = 14.0), -147.2 (d, 
2
JF-F = 157.0); 
HRMS (+ESI) m/z for (C18H18F2NaO3) [M+H] calculated 343.1120 found 343.1123. 
 
trans-(±)-1,1-Difluoro-2-(3-methoxyphenyl)-3-phenylcyclopropane (92) 
 
The reaction of trans-3-methoxystilbene (63) (0.53, 2.5 mmol, 1.0 equiv.) with 
TMSCF3 (1.85 mL, 12.5 mmol, 5.0 equiv.) and NaI (1.87 g, 12.5 mmol, 5.0 equiv.)  
in CH3CN (5 mL) gave a dark-brown crude product. The crude product was purified 
by standard silica chromatography using hexane as eluent to give 92 (0.41 g, 64%) as 
a pale-yellow oil; IR (neat) υmax/cm
-1
 3029 (C-H), 1602 (C=C), 1274 (C-F), 1154 (C-
O); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.37 – 7.11 (6H, m, Ar-H), 6.89 – 6.70 (3H, 
m, Ar-H), 3.70 (3H, s, OCH3), 2.92 (2H, t, 
3
JH-F = 7.5, CHCF2).
 13C NMR (75 MHz, 
CDCl3) δ ppm 160.1 (COMe), 135.3, 133.7 (ipso Ar-C), 130.0, 129.0, 128.4, 127.7, 
120.7, 114.3 (Ar-CH), 113.1 (t, 
1
JC-F = 291.5, CF2), 113.1 (CHCOMe), 55.5 (OCH3), 
34.8 (t, 
2
JC-F = 10.5, CHCF2); 
19
F NMR (282 MHz, CDCl3) δ ppm -134.4 (t, 
3
JH-F = 
7.5); HRMS (+ESI) m/z for (C16H14F2NaO) [M+Na] calculated 283.0905 found 
283.0909. 
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trans-(±)-1,1-Difluoro-2-(3,4-dimethoxyphenyl)-3-phenylcyclopropane (93) 
 
The reaction of trans-3,4-dimethoxystilbene (65) (0.60, 2.5 mmol, 1.0 equiv.) with 
TMSCF3 (1.85 mL, 12.5 mmol, 5.0 equiv.) and NaI (1.87 g, 12.5 mmol, 5.0 equiv.)  
in CH3CN (5 mL) gave a dark-brown crude product. The crude product was purified 
by standard silica chromatography using 20:80 EtOAc:hexane as eluent to give 93 
(0.31 g, 43%) as a pale-yellow oil; IR (neat) υmax/cm
-1 
3004 (C-H), 1517 (C=C), 
1256 (C-F), 1157 (C-O); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.48 – 7.04 (5H, m, Ar-
CH), 6.97 – 6.59 (3H, m, Ar-CH), 3.80 (3H, s, OCH3), 3.79 (3H, s, OCH3), 2.98 – 
2.83 (2H, m, CHCF2); 
13
C NMR (75 MHz, CDCl3) δ ppm 149.3, 148.8 (COMe), 
133.8 (ipso Ar-C), 128.9, 128.4, 127.7 (Ar-CH), 126.1 (ipso Ar-C), 120.6 (Ar-CH), 
113.2 (t, 
1
JC-F = 291.5, CF2), 111.8, 111.5 (CHCOMe), 56.2 (2 x OCH3), 34.2 (t, 
2
JC-
F = 10.5, CHCF2); 
19
F NMR (282 MHz, CDCl3) δ ppm -134.3 (ddd, 
2
JF-F = 152.0, 
3
JH-F = 10.5, 4.5), -135.0 (ddd, 
2
JF-F = 151.5, 
3
JH-F = 10.5, 4.5); HRMS (+ESI) m/z for 
(C17H16F2NaO2) [M+Na] calculated 131.1011 found 313.1014.
 
 
(±)-trans-1,1-Dichloro-2-(3-methoxyphenyl)-3-phenylcyclopropane (94) 
 
Prepared in a similar manner to compound 1, the reaction of trans-3-methoxystilbene 
(63) (0.84 g, 4 mmol, 1.0 equiv.) with CHCl3 (8.0 mL, 99 mmol, 25 equiv.) and a 
solution of 50% aqueous NaOH (4.0 mL, 50 mmol, 12.5 equiv.) in the presence of 
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benzyltrimethylammonium bromide (20 mg, 86 µmol, ~2 mol%) gave a dark-brown 
crude product. The crude product was purified by standard silica chromatography 
using hexane as eluent to give 94 (1.06 g, 91%) as a pale-yellow oil; IR (neat) 
υmax/cm
-1
: 3060 (C-H), 1600 (C=C), 1040 (C-O), 691(C-Cl); 
1
H NMR (400 MHz, 
CDCl3) δ ppm 7.35 – 7.10 (6H, m, Ar-H), 6.89 – 6.83 (1H, m, Ar-H), 6.82 – 6.73 
(2H, m, CHCOMe), 3.71 (3H, s, OCH3), 3.10 (2H, s, CHCCl2); 
13
C NMR (101 MHz, 
CDCl3) δ ppm 160.0 (COMe), 136.4, 134.8 (ipso Ar-C), 129.8, 129.3, 128.8, 128.2, 
121.6 (Ar-CH) 115.1, 113.6 (CHCOMe), 65.6 (CCl2), 55.6 (OCH3), 40.1, 40.0 
(CHCCl2); HRMS (+ESI) m/z for (C16H14Cl2NaO) [M+Na] calculated 315.0315 
found 315.0311. 
 
(±)-trans-1,1-Dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane (95) 
 
Prepared in a similar manner to compound 1, the reaction of trans-4-methoxy 
stilbene (64) (0.84 g, 4 mmol, 1.0 equiv.) with CHCl3 (8.0 mL, 99 mmol, 25 equiv.) 
and a solution of 50% aqueous NaOH (4.0 mL, 50 mmol, 12.5 equiv.) in the 
presence of benzyltrimethylammonium bromide (20 mg, 87 µmol, ~2 mol%) gave a 
dark-brown crude product. The crude product was purified by standard silica 
chromatography using hexane as eluent to gave 95 (1.06 g, 91%) as a pale-yellow 
solid,  mp 53 – 55 ºC; IR (neat) υmax/cm
-1
: 3032 (C-H), 1517 (C=C), 1253 (C-O), 696 
(C-Cl); 
1
H NMR (400 MHz, CDCl3) δ ppm 7.44 – 7.23 (7H, m, Ar-H), 6.95 – 6.87 
(2H, m, CHCOMe), 3.80 (3H, s, OCH3), 3.15 (2H, s, CHCCl2); 
13
C NMR (101 MHz, 
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CDCl3) δ ppm 159.5 (COMe), 134.9 (ipso Ar-C), 130.3 129.2, 128.8, 128.1 (Ar-
CH), 126.9 (ipso Ar-C), 114.2 (CHCOMe), 65.9 (CCl2), 55.6 (OCH3), 40.1, 39.4 
(CHCCl2); HRMS (+ESI) m/z for (C16H14Cl2NaO) [M+Na] calculated 315.0315 
found 315.0313.  
 
 (±)-trans-1,1-Dichloro-2-(3,4-dimethoxyphenyl)-3-phenylcyclopropane (96) 
 
Prepared in a similar manner to compound 1 , the reaction of trans-3,4-dimethoxy 
stilbene (65) (0.38 g, 1.6 mmol, 1.0 equiv.) with CHCl3 (3.2 mL, 39 mmol, 25 
equiv.) and a solution of 50% aqueous NaOH (1.6 mL, 20 mmol, 12.5 equiv.) in the 
presence of benzyltrimethylammonium bromide (8 mg, 43 µmol, ~2 mol%) gave a 
dark-brown crude product. The crude product was purified by standard silica 
chromatography using hexane as eluent to gave 96 (0.45 g, 88%) as a pale-yellow 
solid, mp 93 - 94 ºC; IR (neat) υmax/cm
-1
 3059 (C-H), 1514 (C=C), 1137 (C-O), 702 
(C-Cl);
 1
H NMR (400 MHz, CDCl3) δ ppm 7.39 – 7.16 (5H, m, Ar-H), 6.85 – 6.68 
(3H, m, CHCOMe and Ar-H), 3.79 (3H, s, OCH3), 3.76 (3H, s, OCH3), 3.13 – 2.96 
(2H, m, CHCCl2); 
13
C NMR (101 MHz, CDCl3) δ ppm 149.1, 149.0 (COMe), 134.8 
(ipso Ar-C), 129.2, 128.7, 128.0 (Ar-CH), 127.2 (ipso Ar-C), 121.2 (Ar-CH), 112.5, 
111.2 (CHCOMe), 65.7 (CCl2), 56.2, 56.1 (OCH3), 40.1, 39.6 (CHCCl2); HRMS 
(+ESI) m/z for (C17H16Cl2NaO2) [M+Na
+
] calculated 345.0420 found 345.0423. 
 
(±)-1,1-Difluoro-2-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylcyclopropane 
(97) 
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A mixture of 2-chloro-N,N-dimethylethylamine hydrochloride (0.43 g, 3 mmol, 0.75 
equiv.), 101 (0.98 g, 4 mmol, 1.0 equiv.) and anhydrous K2CO3 (1.93 g, 14 mmol, 
3.5 equiv.) in acetone (50 mL) was heated at reflux overnight. After cooling to 
ambient temperature, the solid was filtered and the filtrate was concentrated in vacuo 
to give a crude material. The crude product was purified by standard silica 
chromatography using 20:80 acetone:hexane as eluent to give 97 (0.74 g, 77%) as a 
pale-yellow oil which solidified upon storage at 0 ºC, mp 62 – 64 ºC; IR (neat) 
υmax/cm
-1
 3012 (C-H), 2756 (N-CH2) 1608, 1512, 1474 (Ar-H), 1206 (C-F), 977, 
796, 696 (Ar-H); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.23 – 6.99 (7H, m, Ar-H), 
6.71 – 6.64 (2H, m, CH2OCCH), 3.83 (2H, t, J = 6.0, OCH2CH2), 2.50 (2H, t, J = 
6.0, OCH2CH2), 2.12 (6H, s, N(CH3)2), 1.91 – 1.78 (2H, m,CF2CH2);
 13
C NMR (126 
MHz, CDCl3) δ ppm 158.4 (CHCOCH2), 139.3, 131.2 (ipso Ar-C), 130.2, 129.0, 
128.9, 127.5 (Ar-CH), 115.0 (CHCOCH2), 113.4 (t, 
1
JC-F = 288.5, CF2), 66.2 
(OCH2CH2), 58.5 (OCH2CH2), 46.2 (N(CH3)3), 39.7 (t, 
2
JC-F = 10.5, CH2CCF2), 24.0 
(t, 
2
JC-F = 10.0, CH2CCF2);
 19
F NMR (282 MHz, CDCl3) δ ppm -130.6- -130.8 (m); 
HRMS (+ESI) m/z for (C19H22F2NO) [M+H] calculated 318.1664 found 318.1668. 
4-Methoxy-α-phenylstyrene (99) 
 
This synthesis of this compound was adopted from the method of Maike et al.
253
 A 
solution of acetophenone (2.4 g, 50 mmol, 1.0 equiv.) in THF (150 mL) was added 
dropwise to 4-(methoxyphenyl) magnesium bromide (prepared by adding 4-
bromoanisole (11.2 g, 60 mmol, 1.0 equiv.) in THF (30 mL) to magnesium turning 
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(1.54 g, 66 mmol, 3.1 equiv.) in THF (50 mL) with a few grains of I2 crystals] cooled 
on in ice bath. After the reaction was stirred for 1 hour and the reaction was 
completed as monitored by TLC. The reaction was quenched by water (100 mL) and 
neutralized with diluted 1 M HCl solution to pH 7 as determined by indicator paper. 
The organic material was extracted with diethyl ether (3 x 50 mL), dried over 
MgSO4 to afford an oil. The crude oil was purified by standard silica 
chromatography hexane to give 99 (2.56 g, 25%) as a white solid, mp 74 - 75 ºC, 
(lit.,
255
 mp 75.3 – 76.8 ºC); IR (neat) υmax/cm
-1 
3050 (C-H), 1496 (Ar-H), 1140 (C-F); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.33 – 7.10 (5H, m, Ar-H), 6.79 (2H, m, Ar-H), 
5.36 (1H,  d, J = 13.0, H2C=C),  5.30 (1H, d, J = 13.0, H2C=C), 3.82 – 3.67 (3H, s, 
OCH3); 
13
C NMR (75 MHz, CDCl3) δ ppm 159.7 (COMe), 149.8, 142.1, 134.3 (ipso 
Ar-C), 129.7, 128.6, 128.4, 128.0 (Ar-CH), 113.8 (CHCOMe), 113.3 (H2C=C), 55.6 
(OCH3); HRMS (+ESI) m/z for (C18H22NO) [M+H] calculated 268.1701 found 
268.1697.  
These data were consistent with those previously reported.
255
 
 
(±)-1,1-Difluoro-2-(4-methoxyphenyl)-2-phenylcyclopropane (101) 
 
To a 5 mL pressure tube containing 1-(4-methoxyphenyl)-1-phenylethylene (99) 
(0.21 g, 1 mmol, 1.0 equiv.) in CH3CN (2 mL) was added NaI (0.37 g, 2.5 mmol, 2.5 
equiv.) and TMSCF3 (0.39 mL, 2.5 mmol, 2.5 equiv.) and the pressure tube was 
securely sealed. The resulting mixture was heated at 80 ºC for 15 minutes. After that, 
the mixture was filtered and the solid washed with CH3CN (2 x 5 mL). The filtrate 
and washings were evaporated in vacuo to give a dark-brown residue. The crude 
189 
 
product was purified by standard silica chromatography using hexane as eluent to 
give 101 (0.22 g, 84%) as a pale-yellow solid, mp 58 – 59 ºC; IR (neat) υmax/cm
-1
 
3007 (C-H), 1610, 1511, 1443 (Ar-H), 1251 (C-F), 978, 795, 696 (Ar-H); 
1
H NMR 
(300 MHz, CDCl3) δ ppm 7.37 – 7.10 (7H, m, Ar-H), 6.86 – 6.69 (2H, m, 
CHCOMe), 3.64 (3H, s, OCH3), 2.05 – 1.85 (2H, m, CH2CF2);
 13C NMR (75 MHz, 
CDCl3) δ ppm 159.1 (CHCOCH3), 139.3, 131.1 (ipso Ar-C), 130.3, 129.0, 128.9, 
127.5 (Ar-CH), 114.3 (CHCOCH3), 113.5 (t, 
1
JC-F = 288.5, CF2), 55.4 (OCH3), 39.7 
(t, 
2
JC-F = 10.5, CH2CCF2), 24.0 (t, 
2
JC-F = 10.0, CH2CCF2); 
19
F NMR (282 MHz, 
CDCl3) δ ppm -131.2 - -129.8 (m);
 
HRMS (+ESI) m/z for (C16H14F2NaO) [M+H] 
calculated 283.0905 found 283.0917.  
(±)-1,1-Difluoro-2-(4-hydroxyphenyl)-2-phenylcyclopropane (102) 
 
To a 35 mL pressure tube containing 4-hydroxy-α-phenylstyrene (104) (1.05 g, 5 
mmol, 1.0 equiv.) in CH3CN (20 mL) was added NaI (3.75 g, 25 mmol, 5.0 equiv.) 
and TMSCF3 (3.7 mL, 25 mmol, 5.0 equiv.) and the pressure tube was securely 
sealed. The resulting mixture was heated at 80 ºC for 2 hours. After that, the mixture 
was filtered and the solid washed with CH3CN (2 x 10 mL). The filtrate and 
washings were evaporated in vacuo to give a dark-brown residue. The residue was 
re-dissolved in methanol (15 mL) followed by addition of N-bromosuccinimide (0.18 
g, 1 mmol, 0.2 equiv.). The resulting mixture was then stirred at room temperature 
for 2 hours. After that, the methanol was evaporated in vacuo to give a crude 
material. The crude product  was purified by standard silica chromatography using 
20:80 EtOAc:hexane as eluent to give 102 (0.82 g, 67%) as a pale-yellow oil which 
solidified on standing, mp 75 – 77 ºC; IR (neat) υmax/cm
-1
 ~3200 br (OH), 3026 (C-
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H), 1613, 1513, 1443 (Ar-H), 1205 (C-F),  976, 795, 696 (Ar-H); 
1
H NMR (300 
MHz, CDCl3) δ ppm 7.40-7.18 (7H, m, Ar-H), 6.77-6.72 (2H, m, HOCCH), 5.26 
(1H, br s, OH), 2.10-1.94 (2H, m, CH2); 
13
C NMR (126 MHz, CDCl3) δ ppm 154.8 
(CHCOCH2), 139.0, 131.1 (ipso Ar-C), 130.2, 128.7, 128.6, 127.3 (Ar-CH), 115.5 
(CHCOCH2), 113.1 (t, 
1
JC-F = 288.5, CF2), 39.4 ( t, 
2
JC-F = 10.5, CH2CCF2), 23.8 (t, 
2
JC-F = 10.0, CH2CCF2); 
19
F NMR (282 MHz, CDCl3) δ ppm -130.6 - -130.7 (m); 
HRMS (+ESI) m/z for (C15H12F2NaO) [M+H] calculated 269.0748 found 269.0748. 
This compound is known, but no synthesis has been reported and only 
1
H NMR 
spectroscopic data were recorded which were consistent with those reported here.
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4-Hydroxy-α-phenylstyrene (104) 
 
This compound was prepared according to the method of Maike et al.
253
 A solution 
of 4-hydroxyacetophenone (2.72 g, 20 mmol, 1.0 equiv.) in THF (150 mL) was 
added dropwise to PhMgBr (62 mmol, 3.1 equiv.) [prepared by adding PhBr (6.53 
mL, 62 mmol, 3.1 equiv.) in THF (30 mL) to Mg turning (1.60 g, 66 mmol, 3.3 
equiv.) in THF (30 mL) with a few grains of I2 crystals] cooled on in ice bath. After 
the reaction was stirred for 1 hour and the reaction was completed as monitored by 
TLC. The reaction was quenched by water (100 mL) and neutralized with diluted 1 
M HCl solution to pH 7 as determined by indicator paper. The organic material was 
exacted by diethyl ether (3 x 50 mL), dried over MgSO4 to give afford an oil. The 
crude oil was purified by standard silica chromatography using 20:80 EtOAc:hexane 
to give 104 (3.49 g, 89%) as a pale-yellow oil; 
1
H NMR (300 MHz, CDCl3): δ ppm 
7.30-7.21 (5H, m, Ar-H), 7.17−7.11 (2H, m, HOCCHCH), 6.75-6.67 (2H, m, 
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HOCCH), 6.20-5.80 (1H, m, OH), 5.35 (1H, d, J = 1.2, CH2), 5.31 (1H, d, J = 1.2, 
CH2); 
13
C NMR (75 MHz, CDCl3) δ ppm 155.8 (C-OH), 149.8, 142.1, 134.3 (ipso 
Ar-C and CCH2) 129.9, 128.6, 128.4, 128.0, 115.4 (Ar-CH), 113.2 (CH2);
 
HRMS 
(+ESI) m/z for (C14H13O) [M+H] calculated 197.0961 found 197.0961. 
These data were consistent with those previously reported.
254
  
 
1-Phenyl-1-(4-(2-(diethylamino)ethoxy)phenyl)-ethylene (105) 
 
105 was prepared by adapting the method of Sato et al.
256
 2-Chloro-N,N-
dimethylethylamine hydrochloride (1.30 g, 9 mmol, 1.8 equiv.) and K2CO3 (7.15 g, 
51 mmol, 10.0 equiv.)  were stirred in acetone/H2O (80 mL/9 mL) at 0 ºC for 30 
minutes, then 4-hydroxy-α-phenylstyrene (104) (1.0 g, 5.1 mmol, 1.0 equiv.) and 
K2CO3 (1.95 g, 14 mmol, 2.8 equiv.) were added, and the resulting mixture was 
heated at reflux for 24 h. After cooling to ambient temperature, the inorganic 
materials were filtered and the filtrate was evaporated in vacuo. The residue was 
purified by standard silica chromatography using 20:80 acetone:hexane as eluent to 
give 105 (1.1 g, 81%) as a pale-yellow solid, mp 47 – 48 ºC, (lit.,257 mp 47 - 48 ºC); 
IR (neat) υmax/cm
-1
 2930 (C-H), 2763 (N-CH2) 1602, 1506, 1442, 1032, 842, 700 
(Ar-H); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.40 – 7.04 (7H, m, Ar-H), 6.94 – 6.58 
(2H, m, CHCOCH2), 5.29 (1H, d, J = 15.0, PhCCH2Ar), 5.27 (1H, d, J = 15.0, 
PhCCH2Ar), 3.98 (2H, t, J = 5.5, OCH2CH2), 2.64 (2H, t, J = 5.5, OCH2CH2), 2.25 
(6H, s, N(CH3)2); 
13
C NMR (75 MHz, CDCl3) δ ppm 158.8 (CHCOCH2), 149.7, 
142.0, 134.2 (ipso Ar-C and Ar2C) 129.6, 128.5, 128.3, 127.9 (Ar-CH), 114.4 
(CHOCH2CH2), 113.1 (PhCCH2Ar), 66.2 (OCH2CH2), 58.5 (OCH2CH2), 46.1 
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(N(CH3)2); HRMS (+ESI) m/z for (C18H22NO) [M+H] calculated 268.1696 found 
268.1697.  
This compound is known and has previously been reported with 
13
C NMR 
spectroscopic data consistent with those reported here.
258
  
 
 [2-(4-Benzyl-phenoxy)-ethyl]-diethyl-amine hydrochloride (111) 
 
The synthesis of this compound was adopted from the method of Poirot et al.
260
 2-
Chloro-N,N-dimethylethylamine hydrochloride (0.72 g, 5 mmol, 1.0 equiv.) was 
added to a solution of 4-benzylphenol (0.92 g, 5 mmol, 1.0 equiv.) and anhydrous 
K2CO3 (2.07 g, 15 mmol, 3.0 equiv.) in 1:1 DMF:acetone (30 mL). The reaction 
mixture was heated at 60 ºC for overnight. After cooling to ambient temperature, the 
solid was filtered and the filtrate was poured into water (100 mL). The organic 
material was extracted twice with diethyl ether (2 x 100 mL). The organic extracts 
were combined and washed with 0.1 N sodium hydroxide solution (3 x 15 mL) and 
then with brine (3 x 15 mL). After that, the organic layer was extracted with a 
solution of 12 N hydrochloric acid (5 mL). The aqueous layer was collected and 
evaporated in vacuo to give a crude solid. The crude product was recrystallized to 
give 111 (1.17 g, 80%) as a white solid, mp 175 – 176 ºC (3:1 isopropnaol:acetone), 
(lit.,
260
 mp 178 - 180 ºC); IR (neat) υmax/cm
-1 
3010 (C-H), 2463 (R3N-H) 1606, 1509, 
1464, 993, 767, 694 (Ar-H); 
1
H NMR (300 MHz, D2O) δ ppm 7.03 – 6.71 (7H, m, 
Ar-H), 6.67 – 6.53 (2H, m,CHCOCH2CH2), 3.87 (2H, t, J = 5, OCH2CH2), 3.47 (2H, 
s, PhCH2Ar), 3.21 (2H, t, J = 5, OCH2CH2), 2.65 (6H, s, N(CH3)3); 
13
C NMR (75 
MHz, D2O) δ ppm 155.6 (CHCOCH2), 141.7, 134.6 (ipso Ar-C), 129.8, 128.6, 
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128.5, 126.0 (Ar-CH), 114.7 (CHCOCH2), 61.5 (OCH2CH2), 56.0 (OCH2CH2), 42.7 
(N(CH3)3), 40.4 (PhCH2Ar); HRMS (ESI) m/z for (C17H22NO) [M-Cl] calculated 
256.1696 found 256.1697.  
This compound is known, but only 
1
H NMR spectroscopic data were recorded in d6-
DMSO and CD3OD.
191, 213
 
 
[2-(4-Phenoxy-phenoxy)-ethyl]dimethyl-amine hydrochloride (112) 
 
Prepared in a similar manner to 111, 2-chloro-N,N-dimethylethylamine 
hydrochloride (0.72 g, 5 mmol, 1.0 equiv.) was reacted with 4-phenoxyphenol (0.93 
g, 5 mmol, 1.0 equiv.) in the presence of anhydrous K2CO3 (2.07 g, 15 mmol, 3.0 
equiv.) to give a crude solid. The crude product was recrystallized to give 112 (1.11 
g, 75%) as a white solid, mp 136 – 138 ºC (3:1 isopropnaol:acetone), (lit., mp 163 - 
164 ºC); IR (neat) υmax/cm
-1
 3000 (C-H), 2456 (R3N-H), 1584, 1479, 1396, 992, 750, 
691 (Ar-H); 
1
H NMR (300 MHz, D2O) δ ppm 7.20 (2H, t, J = 8.0, Ar-H), 7.02 – 6.81 
(7H, m, Ar-H), 4.21 (2H, t, J = 5, OCH2CH2), 3.5 (2H, t, J = 5, OCH2CH2), 2.90 
(6H, s, N(CH3)3); 
13
C NMR (75 MHz, D2O) δ ppm 157.6 (COCH2CH2), 153.6, 150.6 
(ipso Ar-C), 129.8, 123.0, 120.6, 117.7, 115.9 (Ar-CH), 62.0 (OCH2CH2), 56.1 
(OCH2CH2), 42.7 (N(CH3)3); HRMS (ESI) m/z for (C16H20NO2) [M-Cl] calculated 
258.1489 found 258.1490.  
This compound is known, but no spectra data were recorded.
261
 
 
N,N-Diethyl-2-(4-benzylphenoxy)ethanamine (113) 
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A mixture of 2-chloro-N,N-dimethylethylamine hydrochloride (0.52 g, 3 mmol, 0.75 
equiv.), 4-benzylphenol (0.74 g, 4 mmol, 1.0 equiv.) and anhydrous K2CO3 (1.93 g, 
14 mmol, 3.5 equiv.) in acetone (50 mL) was heated at reflux overnight. After 
cooling to ambient temperature, the solid was filtered and the filtrate was 
concentrated in vacuo to give a crude residue. The crude product was purified by 
standard silica chromatography 20:80 acetone:hexane to give 113 (0.70 g, 82%) as a 
pale-yellow oil; IR (neat) υmax/cm
-1
 2968 (C-H), 2808 (N-CH2), 1611, 1509, 1453, 
1030, 796, 696 (Ar-H);
 1
H NMR (400 MHz, CDCl3) δ ppm 7.38 – 7.32 (2H, m, 
ortho Ar-H), 7.30 – 7.21 (3H, m, meta, para Ar-H), 7.17 (2H, m, ortho Ar-H), 6.91 
(2H, m, CHCOCH2), 4.10 (2H, t, J = 6.5, OCH2CH2), 4.00 (2H, s, Ph-CH2-Ar), 2.95 
(2H, t, J = 6.5, OCH2CH2), 2.72 (4H, q, J = 7.0, NCH2CH3), 1.15 (6H, t, J = 7.0, 
NCH2CH3); 
13
C NMR (101 MHz, CDCl3) δ ppm 157.5 (CHCOCH2), 141.8, 133.5 
(ipso Ar-C), 130.1, 129.1, 128.7, 126.2 (Ar-CH), 114.7 (CHCHCOCH2), 66.7 
(OCH2CH2), 52.0 (OCH2CH2), 48.0 (NCH2CH3), 41.3 (Ph-CH2-Ar), 12.0 
(NCH2CH3); HRMS (+ESI) m/z for (C19H26NO) [M+H] calculated 284.2009 found 
284.2008. 
The hydrochloride salt form of this compound is known,
191, 213
 but the free amine 
form has never been reported. 
 
4-(2-(Pyrrolidin-1-yl)ethoxy)benzylbenzene (114) 
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Prepared in a similar manner to 113, 1-(2-chloroethyl)pyrrolidine hydrochloride 
(0.51 g, 3 mmol, 0.75 equiv.) was reacted with 4-benzylphenol (0.74 g, 4 mmol, 1.0 
equiv.) in the presence of anhydrous K2CO3 (1.93 g, 14 mmol, 3.5 equiv.)  to give a 
crude material. The crude product was purified by silica chromatography using 20:80 
acetone:hexane as eluent to give 114 (0.70 g, 83%)  ; IR (neat) υmax/cm
-1
 2961 (C-H), 
2779 (N-CH2), 1611, 1509, 1453, 1031, 796, 696 (Ar-H); 
1
H NMR (300 MHz, 
CDCl3) δ ppm 7.48 – 7.17 (7H, m, Ar-H), 7.09 – 6.89 (2H, m, CHCOCH2), 4.21 
(2H, t, J = 6.0, OCH2CH2), 4.05 (2H, s, PhCH2Ar), 3.02 (2H, t, J = 6.0, OCH2CH2), 
2.78 – 2.70 (4H, m, N(CH2CH2)2), 1.93 (4H, m, N(CH2CH2)2); 
13
C NMR (75 MHz, 
CDCl3) δ ppm 157.5 (CHCOCH2CH2), 141.8, 133.5 (ipso Ar-C) 130.0, 129.0, 128.6, 
126.2 (Ar-CH), 114.8 (CHCOCH2CH2), 67.3 (OCH2CH2), 55.3 (OCH2CH2), 54.9 
(N(CH2CH2)2), 41.3 (Ph-CH2-Ar), 23.7 (N(CH2CH2)2); HRMS (+ESI) m/z for 
(C19H24NO) [M+H] calculated 282.1852 found 282.1853. 
This compound is known and has previously been reported with 
1
H NMR 
spectroscopic data consistent with those reported here.
213
 
 
4-(2-(Piperidin-1-yl)ethoxy)benzylbenzene (115) 
 
Prepared in a similar manner to 113, 1-(2-chloroethyl)piperidine hydrochloride (3.59 
g, 19.5 mmol, 3.63 equiv.) was reacted with 4-benzylphenol (1.0 g, 5.4 mmol, 1.0 
equiv.) in the presence of K2CO3 (19.6 g, 0.14 mol, 26.0 equiv.) to give a crude 
material. The crude product was purified by silica chromatography using 20:80 
acetone:hexane as eluent to give 115 (0.74 g, 46%) as a pale-yellow oil; IR (neat) 
υmax/cm
-1
 2931 (C-H), 2782 (N-CH2), 1611, 1509, 1441, 1036, 794, 696 (Ar-H); 
1
H 
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NMR (300 MHz, CDCl3) δ ppm 7.41 – 7.11 (7H, m, Ar-H), 6.95 – 6.87 (2H, m, 
CHOCH2CH2), 4.15 (2H, t, J = 6.0, OCH2CH2), 3.99 (2H, s, Ph-CH2-Ar), 2.83 (2H, 
t, J = 6.0, OCH2CH2), 2.69 – 2.46 (4H, m, CH2NCH2CH2CH2), 1.74 – 1.62 (4H, m, 
CH2NCH2CH2CH2), 1.51 (2H, m, CH2NCH2CH2CH2); 
13
C NMR (75 MHz, CDCl3) 
δ ppm 157.4 (CHCOCH2CH2), 141.8, 133.5 (ipso Ar-C), 130.1, 129.0, 128.6, 126.2 
(Ar-CH), 114.8 (CHCHCOCH2), 66.1 (OCH2CH2), 58.2 (OCH2CH2), 55.3 
(CH2NCH2CH2CH2), 41.3 (Ph-CH2-Ar) 26.2 (CH2NCH2CH2CH2), 24.5 (CH2NCH-
2CH2CH2); HRMS (+ESI) m/z for (C20H26NO) [M+H] calculated 296.2009 found 
296.2007. 
The hydrochloride salt form of this compound is known,
213
 but the free amine form 
has never been reported. 
 
4-[(2-(4-Benzyl-phenoxy)-ethyl]-morpholin hydrochloride (116) 
 
Prepared in a similar manner to 113, 4-(2-chloroethyl)morpholine hydrochloride 
(1.86 g, 10 mmol, 3.6 equiv.) was reacted with 4-benzylphenol (0.51 g, 2.8 mmol, 
1.0 equiv.) in the presence of anhydrous K2CO3 (10.0 g, 72 mmol, 26 equiv.) give a 
crude oil. The crude oil was purified by standard silica chromatography 20:80 
acetone:hexane before a solution of 3N HCl (2 mL) was added and the solvent was 
evaporated in vacuo. The residue was recrystallized to give 116 (0.45 g, 49%) as a 
white solid, mp 193 – 195 ºC (acetone), (lit.,191 mp 185 - 186 ºC); IR (neat) υmax/cm
-1
 
2945 (C-H), 2448 (R3N-H), 1608 1510, 1450, 1020, 856, 728 (Ar-H); 
1
H NMR (400 
MHz, D2O) δ ppm 8.71 – 8.61 (2H, m, Ar-H), 8.61 – 8.52 (5H, m, Ar-H), 8.40 – 
8.31 (2H, m, CHOCH2CH2), 5.79 (2H, t, J = 5.0, ArOCH2CH2), 5.55 – 5.18 (6H, m, 
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Ar-CH2-Ph and N(CH2CH2)2O or N(CH2CH2)2O), 5.09 – 4.59 (6H, m, ArOCH2CH2 
and N(CH2CH2)2O or N(CH2CH2)2O); 
13
C NMR (101 MHz, D2O) δ ppm 157.5 
(CHCOCH2CH2), 143.0, 136.4 (ipso Ar-C), 131.1, 129.8, 129.5, 127.1 (Ar-CH), 
115.8 (CHCHCOCH2), 64.9 (NCH2CH2O or NCH2CH2O), 63.1 (ArOCH2CH2), 57.5 
(ArOCH2CH2), 53.7 (N(CH2CH2)2O or N(CH2CH2)2O), 41.9 (Ar-CH2-Ph); HRMS 
(+ESI) m/z for (C19H24NO2) [M+H] calculated 298.1802 found 298.1805.  
This compound is known, but only 
1
H NMR spectroscopic data were recorded in d6-
DMSO and CD3OD.
191, 213
 
 
N,N-Diethyl-2-(4-phenoxyphenoxy)ethanamine (117) 
 
 
Prepared in a similar manner to 113, 2-chloro-N,N-diethylethylamine hydrochloride 
(0.51 g, 3 mmol, 0.75 equiv.) was reacted with 4-phenoxyphenol (0.74 g, 4 mmol, 
1.0 equiv.) in the presence of anhydrous K2CO3 (1.93 g, 14 mmol, 3.5 equiv.) to give 
a crude material. The crude product was purified by silica chromatography using 
20:80 acetone:hexane as eluent to give 117 (0.66 g, 77%) as a pale-yellow oil; IR 
(neat) υmax/cm
-1
 2968 (C-H), 2807 (N-CH2), 1589, 1503, 1487, 1008, 840, 690 (Ar-
H); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.29 – 7.16 (2H, m, Ar-H), 7.05 – 6.78 (7H, 
m, CHCOCH2), 3.98 (2H, t, J = 6.5, OCH2CH2), 2.83 (2H, t, J = 6.5, OCH2CH2), 
2.60 (4H, q, J = 7.0, NCH2CH3), 1.03 (6H, t, J = 7.0, NCH2CH3); 
13
C NMR (75 
MHz, CDCl3) δ ppm 158.8 (CHCOCH2), 155.5, 150.4 (ipso Ar-C), 129.9, 122.7, 
121.1, 117.9 (Ar-CH), 115.8 (CHCHCOCH2), 67.3 (OCH2CH2), 52.1 (OCH2CH2), 
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48.1 (NCH2CH3), 12.2 (NCH2CH3); HRMS (+ESI) m/z for (C18H24NO2) [M+H] 
calculated 286.1802 found 286.1798.  
 
4-(2-(Pyrrolidin-1-yl)ethoxy)phenoxybenzene (118) 
 
Prepared in a similar manner to 113, 1-(2-chloroethyl)pyrrolidine hydrochloride 
(0.51 g, 3 mmol, 0.75 equiv.) was reacted with 4-phenoxyphenol (0.74 g, 4 mmol, 
1.0 equiv.) in the presence of anhydrous K2CO3 (1.93 g, 14 mmol, 3.5 equiv.) to give 
a crude material. The crude product was purified by silica chromatography using 
20:80 acetone:hexane as eluent to give 118 (0.78 g, 92%) as a pale-yellow oil; IR 
(neat) υmax/cm
-1
 2960 (C-H), 2781 (N-CH2), 1589, 1503, 1036, 840, 690 (Ar-H); 
1
H 
NMR (300 MHz, CDCl3) δ ppm 7.30 – 7.16 (7H, m, Ar-H), 7.11 – 6.75 (2H, m, 
CHCOCH2), 4.03 (2H, t, J = 5.5, OCH2CH2), 2.84 (2H, t, J = 5.5, OCH2CH2), 2.73 – 
2.41 (4H, m, N(CH2CH2)2), 1.90 – 1.59 (4H, m, N(CH2CH2)2);
 13C NMR (75 MHz, 
CDCl3) δ ppm 158.6 (CHCOCH2), 155.4, 150.4 (ipso Ar-C), 129.8, 122.6, 121.0, 
117.8 (Ar-CH), 115.8 (CHCHCOCH2), 67.7 (OCH2CH2), 55.3 (OCH2CH2), 54.9 
(N(CH2CH2)2), 23.7 (N(CH2CH2)2); HRMS (+ESI) m/z for (C18H22NO2) [M+H] 
calculated 284.1645 found 284.1645. 
This compound is known, but only 
1
H NMR spectroscopic data were recorded in d6-
DMSO.
262
  
 
4-(2-(Piperidin-1-yl)ethoxy)phenoxybenzene (119) 
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1-(2-chloroethyl)piperidine hydrochloride (3.59 g, 19.5 mmol, 3.63 equiv.) and 
K2CO3 (15.4 g, 0.11 mol, 20.7 equiv.)  were stirred in acetone/H2O (180 mL/ 20 
mL) at 0 ºC for 30 minutes, then 4-phenoxyphenol (1.0 g, 5.4 mmol, 1.0 equiv.) and 
K2CO3 (4.2 g, 30 mmol, 5.6 equiv.) were added, and the resulting mixture was 
heated at reflux for overnight. After cooling to ambient temperature, the inorganic 
materials were filtered and the filtrate was concentrated in vacuo to give a crude 
residue. The crude residue was purified by standard silica chromatography using 
20:80 acetone:hexane to give 119 (0.93 g, 59%) as a pale-yellow oil; IR (neat) 
υmax/cm
-1
 2947 (C-H), 2800 (N-CH2), 1583, 1502, 1475, 1003, 758, 694 (Ar-H); 
1
H 
NMR (300 MHz, CDCl3) δ ppm 7.29 – 7.18 (7H, m, Ar-H), 7.04 – 6.79 (2H, m, 
CHOCH2CH2), 4.04 (2H, t, J = 6.0, OCH2CH2), 2.76 – 2.68 (2H, t, J = 6.0, 
OCH2CH2), 2.51 – 2.39 (4H, m, CH2NCH2CH2CH2), 1.66 – 1.49 (4H, m, CH2NCH-
2CH2CH2), 1.50 – 1.31 (2H, m, CH2NCH2CH2CH2);
 13C NMR (75 MHz, CDCl3) δ 
ppm 158.8 (CHCOCH2), 155.4, 150.4 (ipso Ar-C), 129.9, 122.7, 121.0, 117.9 (Ar-
CH), 115.9 (CHCHCOCH2), 66.7 (OCH2CH2), 58.3 (OCH2CH2), 55.4 (CH2NCH-
2CH2CH2), 26.1 (CH2NCH2CH2CH2), 24.5 (CH2NCH2CH2CH2); HRMS (+ESI) m/z 
for (C19H24NO2) [M+H] calculated 298.1802 found 298.1803. 
 
1-[2-(4-Phenoxy-phenoxy)-ethyl]-morpholine hydrochloride  (120) 
 
Prepared in a similar manner to 113, 4-(2-chloroethyl)morpholine hydrochloride 
(1.86 g, 10 mmol, 3.6 equiv.) was reacted with  4-phenoxyphenol (0.51 g, 2.8 mmol, 
1.0 equiv.) in the presence of anhydrous K2CO3 (10.0 g, 72 mmol, 26 equiv.) to give 
a crude oil. The crude oil was purified by standard silica chromatography using 
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20:80 acetone:hexane as eluent before a solution of 3N HCl (2 mL) was added and 
the solvent was evaporated in vacuo to give a crude residue. The crude residue was 
purified by recrystallization to give 120 (0.42 g, 46%) as a white solid, mp 177 - 178 
ºC (acetone), (lit.,
191
 mp 170 - 172 ºC); IR (neat) υmax/cm
-1
 2961 (C-H), 2470 (R3N-
H), 1611, 1509, 1453, 1031, 796, 696 (Ar-H); 
1
H NMR (400 MHz, d6-DMSO) δ 
ppm 7.43 – 7.35 (2H, m, Ar-H), 7.15 – 7.02 (5H, m, Ar-H), 7.01 – 6.93 (2H, m, 
CHOCH2CH2), 4.50 (2H, t, J = 4.5, ArOCH2CH2), 4.09 – 3.81 (4H, m, 
N(CH2CH2)2O or N(CH2CH2)2O), 3.55 (4H, m, ArOCH2CH2 and N(CH2CH2)2O or 
N(CH2CH2)2O), 3.36 – 3.14 (2H, m, N(CH2CH2)2O or N(CH2CH2)2O);
 13C NMR 
(101 MHz, d6-DMSO) δ ppm 158.8 (CHCOCH2CH2), 154.7, 151.0 (ipso Ar-C), 
130.8, 123.6, 121.6 (Ar-CH), 118.3 (CHCHCOCH2), 117.0 (Ar-CH), 64.0 
(NCH2CH2O or NCH2CH2O), 63.7 (ArOCH2CH2), 55.7 (ArOCH2CH2), 52.5 
(N(CH2CH2)2O or N(CH2CH2)2O); HRMS (ESI) m/z for (C18H22NO3) [M-Cl] 
calculated 300.1594 found 300.1594. 
This compound is known and has been previously reported with 
1
H NMR 
spectroscopic data consistent with reported here.
191
  
 
(±)-1,1-Difluoro-2-(4-(2-(diethylamino)ethoxy)phenyl)-2-phenylcyclopropane 
(121) 
 
Prepared in a similar manner to 113, 2-chloro-N,N-diethylethylamine hydrochloride 
(0.52 g, 3 mmol, 0.75 equiv.) was reacted with 104 (0.98 g, 4 mmol, 1.0 equiv.) and 
anhydrous K2CO3 (1.93 g, 14 mmol, 3.5 equiv.) to give a crude oil. The crude oil 
was purified by standard silica chromatography using 20:80 acetone:hexane as eluent 
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to give 121 (0.71 g, 69%) as a pale-yellow oil; IR (neat) υmax/cm
-1
 2968 (R3C-H), 
2803 (N-CH2) 1610, 1511, 1454 (Ar-CH), 1211 (C-F),  975, 794, 698 (Ar-H);
 1H 
NMR (300 MHz, CDCl3) δ ppm 7.52 – 7.00 (7H, m, Ar-H), 6.81 (2H, m, 
CH2OCCH), 4.13 (2H, t, J = 5.5, OCH2CH2), 3.01 (2H, t, J = 5.5, OCH2CH2), 2.79 
(4H, q, J = 7.0, CH2CH3), 2.05 – 1.87 (2H, m, CF2CH2), 1.14 (6H, t, J = 7.0, 
CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ ppm 157.7 (CHCOCH2), 139.1, 131.5 (ipso 
Ar-C), 130.3, 128.9, 128.8, 127.5 (Ar-CH), 114.8 (CHCOCH2), 113.3 (t, 
1
JC-F = 
288.5, CF2), 65.3 (OCH2CH2), 51.4 (OCH2CH2), 47.7 (NCH2CH3), 39.5 (t, 
2
JC-F = 
10.5, CH2CCF2), 23.9 (t, 
2
JC-F = 10.0, CH2CCF2), 10.8 (CH2CH3); 
19
F NMR (282 
MHz, CDCl3) δ ppm -129.0 - -132.1 (m); 
 
HRMS (+ESI) m/z for (C21H26F2NO) 
[M+H] calculated 346.1977 found 346.1976. 
 
(±)-1,1-Difluoro-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2-phenylcyclopropane 
(122) 
 
Prepared in a similar manner to 113, 1-(2-chloroethyl)pyrrolidine hydrochloride 
(0.51 g, 3 mmol, 0.75 equiv.) was reacted with 104 (0.98 g, 4 mmol, 1.0 equiv.) and 
anhydrous K2CO3 (1.93 g, 14 mmol, 3.5 equiv.) to give a crude oil. The crude oil 
was purified by standard silica chromatography using 20:80 acetone:hexane as eluent 
to give 122 (0.78 g, 76%) as an oil which solidified upon storage at 0 ºC, mp 44 – 45 
ºC; IR (neat) υmax/cm
-1
 2959 (C-H), 2816 (N-CH2) 1610, 1512, 1444 (Ar-CH), 1205 
(C-F),  977, 790, 697 (Ar-H);  
1
H NMR (300 MHz, CDCl3) δ ppm 7.38 – 7.11  (7H, 
m, Ar-H), 6.85 – 6.76 (2H, m, CH2OCCH), 4.04 (2H, t, J = 6.0, OCH2CH2), 2.84 
(2H, t, J = 6.0, OCH2CH2), 2.67 – 2.45 (4H, m, N(CH2)2), 2.04 – 1.90 (2H, m, 
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CF2CH2), 1.82 – 1.68 (6H, m, NCH2CH3); 
13
C NMR (75 MHz, CDCl3) δ ppm 158.3 
(CHCOCH2), 139.2, 131.2 (ipso Ar-C), 130.2, 129.0, 128.8, 127.5 (Ar-CH), 114.9 
(CHCOCH2), 113.4 (t, 
1
JC-F = 288.5, CF2), 67.1 (OCH2CH2), 55.2 (OCH2CH2), 54.9 
(N(CH2CH2)2), 39.5 (t, 
2
JC-F = 10.5, CH2CCF2), 24.0 (t, 
2
JC-F = 10.0, CH2CCF2), 23.7 
(N(CH2CH2)2); 
19
F NMR (282 MHz, CDCl3) δ ppm -129.5 - -130.6 (m); HRMS 
(+ESI) m/z for (C21H24F2NO) [M+H] calculated 344.1820 found 344.1819. 
 
 (±)-1,1-Difluoro-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2-phenylcyclopropane 
(123)  
 
Prepared in a similar manner to 113, 1-(2-chloroethyl)piperidine hydrochloride (0.55 
g, 3 mmol, 0.75 equiv.) was reacted with 104 (0.98 g, 4 mmol, 1.0 equiv.) in the 
presence of anhydrous K2CO3 (1.93 g, 14 mmol, 3.5 equiv.) to give a crude material. 
The crude product was purified by standard silica chromatography using 20:80 
acetone:hexane as eluent to give 123 (0.70 g, 65%) as a pale-yellow solid, mp 80 – 
81 ºC; IR (neat) υmax/cm
-1
 2930 (C-H), 2828 (N-CH2), 1610, 1512, 1443 (Ar-CH), 
1232 (C-F),  977, 790, 698 (Ar-H); 
1
H NMR (300 MHz, CDCl3) δ ppm 7.42 – 7.08 
(7H, m, Ar-H), 6.88 – 6.71 (2H, m, CH2OCCH), 4.00 (2H, t, J = 6.0, OCH2CH2), 
2.69 (2H, t, J = 6.0, OCH2CH2), 2.51 – 2.31 (4H, m, NCH2CH2CH2), 2.06 – 1.86 
(2H, m, CF2CH2), 1.62 – 1.47 (4H, NCH2CH2CH2), 1.44 – 1.30 (2H, m, 
NCH2CH2CH2); 
13
C NMR (75 MHz, CDCl3) δ ppm 158.3 (CHCOCH2), 139.3, 
131.2 (ipso Ar-C), 130.2, 129.0, 128.9, 127.5 (Ar-CH), 114.9 (CHCOCH2), 113.4 (t, 
1
JC-F = 288.5, CF2), 66.1 (OCH2CH2), 58.1 (OCH2CH2), 55.3 (NCH2CH2CH2), 39.7 
(t, 
2
JC-F = 10.5, CH2CCF2), 26.2, 24.4 (NCH2CH2CH2 and NCH2CH2CH2), 24.0 (t, 
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2
JC-F = 10.0, CH2CCF2);
 19
F NMR (282 MHz, CDCl3) δ ppm -130.1 - -131.2 (m); 
HRMS (+ESI) m/z for (C22H26F2NO) [M+H] calculated 358.1977 found 358.1982. 
 
(±)-1,1-Difluoro-2-(4-(2-(morpholin-1-yl)ethoxy)phenyl)-2-phenylcyclopropane 
(124) 
 
Prepared in a similar manner to 113, 4-(2-Chloroethyl)morpholine hydrochloride 
(0.55 g, 3 mmol, 0.75 equiv.) was reacted with 104 (0.98 g, 4 mmol, 1.0 equiv.) in 
the presence of anhydrous K2CO3 (1.93 g, 14 mmol, 3.5 equiv.) to give a crude oil. 
The crude oil was purified by standard silica chromatography using 20:80 
acetone:hexane as eluent before a solution of 3N HCl (2 mL) was added and the 
solvent was evaporated in vacuo to give a crude material. The crude product was 
recrystallized to give 124 (0.52 g, 44%) as a white solid, mp 213 – 214 ºC (acetone); 
IR (neat) υmax/cm
-1
~3000 (C-H), 2383 (R3N-H), 1609, 1513, 1444 (Ar-CH), 1207 (C-
F), 978, 792, 701 (Ar-H); 
1
H NMR (400 MHz, CD2Cl2) δ ppm 7.48 – 7.04 (7H, m, 
Ar-H ), 6.82 (2H, m, CH2OCCH), 4.47 – 4.42 (2H, m, ArOCH2CH2), 4.26 – 3.70 
(4H, m, N(CH2CH2)2O), 3.57 – 3.16 (4H, m, ArOCH2CH2 and N(CH2CH2)2O), 2.98 
(2H, br s, N(CH2CH2)2O), 1.98 (2H, m, CH2CF2); 
13
C NMR (126 MHz, CD2Cl2) δ 
ppm 157.1 (CHCOCH2), 139.3, 132.7 (ipso Ar-C), 130.7, 129.2, 128.9, 127.9, 116.1 
(Ar-CH), 113.8 (t, 
1
JC-F = 288.5, CF2), 64.3 (N(CH2CH2)2O), 63.3 (Ar-OCH2CH2), 
56.9 (Ar-OCH2CH2), 53.1 (N(CH2CH2)2O), 40.0 (t, 
2
JC-F = 10.5, CH2CCF2), 24.0 (t, 
2
JC-F = 10.0, CH2CCF2); 
19
F NMR (282 MHz, CDCl3) δ ppm -129.2 - -132.0 (m); 
HRMS (ESI) m/z for (C21H24F2NO2) [M-Cl] calculated 360.1770 found 360.1769.  
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